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Summary
Introduction
Forced expiratory volume in 1 second (FEV1) is a predictor of mortality in the
general, as well as in the asthmatic population. Subjects with asthma have a
steeper decline in FEV1 over time than subjects without, and some patients with
severe asthma develop progressive airflow obstruction that is not fully reversible
with currently available therapy. Moreover, a FEV1 lower than predicted is a
marker of poor asthma control.
Aims
This thesis was aimed at shedding some light on the factors associated with
the decline in FEV1 in subjects with asthma, with particular attention paid to
investigating the potential preventative effect of the use of inhaled corticosteroids
(ICSs), as well as to the association of FEV1 decline with body mass index (BMI)
and change in body weight over time.
Methods
We analysed data from an international, population-based cohort of subjects
with asthma, identified in the European Community Respiratory Health Sur-
vey (ECRHS, 1991-1993) and followed up from 1999 to 2002. Spirometry was
performed on both occasions, and FEV1 decline was related to potential determi-
nants evaluated at baseline and during the follow-up by random intercept linear
regression models.
Results
• In asthmatic subjects with high (>100 kU/L) immunoglobulin E (IgE), the use
of ICSs for 4 years or more during the follow-up was associated with a
lower FEV1 decline (23 mL/y; 95% CI: 8-38 compared with non-users). This
association was not seen in asthmatic subjects with lower IgE.
• In asthmatic subjects who did not have airflow obstruction (FEV1/FVC<0.70) at
xi
baseline, obese subjects had the lowest level of FEV1 at baseline; a faster FEV1
decline was observed for subjects with intermediate BMI than for lean and
obese subjects; FEV1 decline was associated with weight gain independently
of baseline BMI, and this association was stronger in men (20, 95% CI: 10;
30, mL/year per kg gained) than in women (7, 95% CI: 2; 11, mL/year); these
figures were about 60% greater than the decline found in men and women
from the general population who took part in the ECRHS.
• In asthmatic subjects with airflow obstruction at baseline, the absence of allergen
sensitization and a low BMI at baseline were associated with a faster FEV1
decline, while weight gain was not associated with decline.
Conclusions and clinical implications
• Our findings confirm the beneficial association between long-term treatment
with ICSs and lung function decline in asthma. However, they suggest that
asthmatic subjects with high IgE could maximally benefit from prolonged
treatment with ICSs. As a consequence, it could be worth calibrating the
corticosteroid dose according to a patient’s level of total IgE, although further
studies are needed to clarify this.
• The detrimental effect of weight gain on FEV1 decline is particularly im-
portant in asthmatic subjects who still do not have an established airflow
obstruction. This effect could be greater in subjects with asthma than in
people from the general population. Accordingly, weight management in
asthma and weight loss in overweight or obese asthmatic individuals are
strongly recommended.
• Among asthmatic subjects with airflow obstruction at baseline, lean subjects
without sensitization to allergens deserve particular attention, because they
had the greatest decline in FEV1. Weight gain was not associated with de-
cline, suggesting that mechanisms that are typical of milder asthma could be
less important in severe asthma, while a serious long-lasting inflammation
may have a crucial role.
xii
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Chapter 1
Introduction
1.1 Asthma: a complex disease
Asthma is a problem worldwide, with an estimated 300 million affected individ-
uals.1,2 The global prevalence of asthma ranges from 1% to 18% of the population
in different countries.1 Worldwide, approximately 180,000 deaths annually are at-
tributable to asthma, although overall mortality rates have fallen since the 1980s.2
The Global Initiative for Asthma guidelines1 give a brief and comprehensive
definition of asthma: “Asthma is a chronic inflammatory disorder of the airways
in which many cells and cellular elements play a role. The chronic inflammation
is associated with airway hyperresponsiveness that leads to recurrent episodes
of wheezing, breathlessness, chest tightness, and coughing, particularly at night
or in the early morning. These episodes are usually associated with widespread,
but variable, airflow obstruction within the lung that is often reversible either
spontaneously or with treatment”.
Although a simple definition of asthma is appealing, asthma is unlikely to be a
single disease, but rather a series of complex, overlapping individual diseases or
phenotypes, each defined by its unique interaction between genetic and environ-
mental factors.3 These conditions include syndromes characterized by allergen-
exacerbated, nonallergic, and aspirin-exacerbated factors along with syndromes
best distinguished by their pathologic findings (eosinophilic, neutrophilic, pauci-
granulocytic), response to therapy (corticosteroid resistant), and natural history
(remodeling prone).3 Once considered to be a purely allergic disorder dominated
by T helper class 2 (Th2)-type lymphocytes, immunoglobulin E (IgE), mast cells,
eosinophils, macrophages, and cytokines, the disease also involves local epithe-
lial, mesenchymal, vascular and neurologic events that are involved in directing
the Th2 phenotype to the lung and through aberrant injury-repair mechanisms to
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remodeling of the airway wall.4
The presence of airway inflammation is a consistent feature of all the dif-
ferent asthma phenotypes. Acute inflammation is the response of vascularized
tissue to injury: the inflammatory reaction is designed to protect the host and
to restore tissue and its function to normal.5 The airway inflammation in asthma
is persistent even if symptoms are episodic, and the relationship between the
severity of asthma and the intensity of inflammation is not clearly established.6,7
The physiological effects of inflammation are most pronounced in medium-sized
bronchi. The pattern of inflammation in the airways appears to be similar in all
clinical forms of asthma, whether allergic, non-allergic or aspirin-induced, and at
all ages.1 The eosinophil is the most prominent inflammatory cell in the airways of
asthma, although mast cells, CD4+ T lymphocytes, macrophages, and neutrophils
are also higher in number.8 Prominent neutrophilic inflammation also occurs in
severe asthma. The number of neutrophils has been shown to be enhanced in the
airways of patients with severe steroid-dependent asthma or in patients who died
of asthma.9,10
Airway hyperresponsiveness is the excessive response of the airways to a
variety of stimuli. It is thought that its presence, at some time in the natural
history of this disorder, is essential for the diagnosis.11 However, in epidemio-
logical studies, airway hyperresponsiveness has been demonstrated to occur in
asymptomatic people,12 particularly atopic individuals, where its significance is
uncertain. The airway narrowing leads to variable airflow limitation and inter-
mittent symptoms. Airway hyperresponsiveness is linked to both inflammation
and repair of the airways and is partially reversible with therapy. Its mechanisms
are not fully understood.1,11 Abnormalities of the airway smooth muscle, airway
inflammation, airway remodelling, neural control, elaboration of mediators and
alteration in the elastic loads against which the airway smooth muscle contracts
have all been implicated, but none have given an entirely satisfactory explana-
tion of this phenomenon.11 Perhaps this is because there is no single underlying
mechanism or there are different mechanisms in different asthma phenotypes.
1.2 The lungs
The main function of the lungs is to provide continuous gas exchange between
inspired air and the blood in the pulmonary circulation, supplying oxygen and
removing carbon dioxide, which is then cleared from the lungs by subsequent
expiration. Survival is dependent upon this process being reliable, sustained and
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efficient, even when challenged by disease or an unfavourable environment.13
The respiratory tract extends from the mouth and nose to the alveoli. It
may be seen as a branching tree-like structure, with about 17 levels of branching
between the trachea and the respiratory bronchioles. As, on average, the number
of branches doubles at each level, there are about 130,000 respiratory bronchioles.
The part of the lung supplied by one of these first order respiratory bronchioles
is called a ”primary lobule”. Each primary lobule contains about two thousand
alveoli, and is about 3.5 mm in diameter. Branches within the primary lobule
give rise to alveolar ducts, which in turn give off alveoli.14 The alveoli provide an
enormous surface area for gas exchange with pulmonary blood (between 50-100
m2) with a thin membrane across which gases must diffuse. The solubility of
oxygen is such that its diffusion across the normal alveolar-capillary membrane
is an efficient and rapid process.
By convention, the upper airways are the extrathoracic ones (nasopharynx,
mouth, larynx and extrathoracic trachea). The function of the upper airways is
to filter airborne particles, humidify and warm the inspired gases. The lower
airways (the intrathoracic trachea followed by bifurcations into the bronchi and
bronchioli) are commonly divided into large and small airways. The small airways
have a diameter of <2 mm.
The right lung is divided into 3 lobes (upper, middle and lower) whereas the
left one has only 2 lobes (upper and lower), with further division into the broncho-
pulmonary segments (10 right, 9 left). In total there are up to 23 airway divisions
between trachea and alveoli. The pleura is a double layer surrounding the lungs,
the visceral pleura enveloping the lung itself and the parietal pleura lining the
thoracic cavity. Under normal circumstances the interpleural space between these
layers contains only a tiny amount of lubricating fluid. The lungs have a double
blood supply, the pulmonary circulation for gas exchange with the alveoli and the
bronchial circulation to supply the parenchyma (tissue) of the lung itself. Most of
the blood from the bronchial circulation drains into the left side of the heart via
the pulmonary veins and this deoxygenated blood makes up part of the normal
physiological shunt present in the body.13
The lungs move in response to external forces. During normal inspiration
these forces are the movement of the diaphragm, and movement of the chest wall
by the intercostal muscles.14 The various terms used to describe lung excursion
(movement) during quiet and maximal respiration are shown in figure 1.1. Tidal
volume (TV) is the lung volume representing the normal volume of air displaced
between normal inhalation and exhalation when extra effort is not applied. Func-
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tional residual capacity (FRC) is the volume of air in the lungs at the end of a
normal expiration. The point at which this occurs (and hence the FRC value) is
determined by a balance between the inward elastic forces of the lung and the
outward forces of the respiratory cage (mostly due to muscle tone). FRC falls with
obesity, pregnancy and anaesthesia, and when lying supine, though not with age.
In the absence of respiratory effort, the lung volume will be positioned at the FRC.
To move from this position and generate respiratory movement, two aspects need
to be considered which oppose lung expansion and airflow and therefore need to
be overcome by respiratory muscle activity. These are the airway resistance and
the compliance of the lung and chest wall.
Figure 1.1: Lung volumes (source: Wikipedia).
Resistance of the airways describes the obstruction to airflow provided by the
conducting airways (resulting largely from the larger airways down to division
6-7), plus a contribution from tissue resistance (produced by the friction gener-
ated when the tissues of the lung slide over each other during respiration. An
increase in resistance, resulting from airway narrowing such as bronchospasm,
leads to obstructive airways disease like asthma, bronchitis and chronic obstructive
pulmonary disease (COPD).
Compliance denotes distensibility (stretchiness). In a clinical setting it refers
to the lung and chest wall combined, and is defined as the volume change per
unit pressure change. When compliance is low, the lungs are stiffer and therefore
more effort is required to inflate the alveoli. Conditions that worsen compliance,
such as pulmonary fibrosis, produce restrictive lung disease. Compliance also
varies within the lung according to the degree of inflation. Poor compliance is
seen at low volumes (because of difficulty with initial lung inflation) and at high
volumes (because of the limit of chest wall expansion), with the best compliance
in the mid-expansion range. Of the two barriers that oppose respiration, airway
resistance and lung compliance, it is only the first of these that requires actual
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work to be done to overcome it. Airway resistance to flow is present during
both inspiration and expiration and the energy required to overcome it, which
represents the actual work of breathing, is dissipated as heat. Although energy
is required to overcome compliance in expanding the lung, it does not contribute
to the actual work of breathing as it is not dissipated but converted to potential
energy in the distended elastic tissues. Some of this stored energy is used for the
function of breathing during expiration.
1.3 Spirometry
Spirometry is a physiological test that measures how an individual inhales or
exhales volumes of air as a function of time. The primary signal measured in
spirometry may be volume or flow. Spirometry is invaluable as a screening
test of general respiratory health, in the same way that blood pressure provides
important information about general cardiovascular health.15 The most important
indexes measured by spirometry are the forced vital capacity (FVC), which is
the volume delivered during an expiration made as forcefully and completely
as possible starting from full inspiration, and the forced expiratory volume in
one second (FEV1), which is the volume delivered in the first second of an FVC
manoeuvre.15 Vital capacity (VC) (see figure 1.1) is the maximum volume of air
which can be exhaled or inspired during a slow manoeuvre. The %FEV1/FVC ratio
is the FEV1 expressed as a percentage of the FVC and gives a clinically useful index
of airflow obstruction.16 Spirometry can be undertaken with many different types
of equipment, and requires the cooperation between the subject and the examiner,
and the results obtained will depend on technical as well as personal factors.15
This is the reason why there is a strong need to perform spirometry following
standardized protocols, especially when it is used in epidemiological studies.
The lung function protocol followed in the ECRHS is shown in Appendix A.
1.4 Lung function in asthma and airway remodeling
Patients in particular may describe their current asthma status in terms of the
presence or absence of symptoms, quality of life or minimum use, if any, of
antiasthma medication. But, for the clinician, disease control is also characterized
by the best possible level of lung function and the absence of signs of poorly
controlled airway inflammation.17 Many studies have consistently shown that
lung function in patients with clinical asthma is less than predicted.17–19 This may
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reflect suboptimal treatment at the time of measurement, as well as (depending
on the age of the patient) any combination of at least four factors: slower growth
of lung-function; lower maximally attained level of lung function; earlier onset
of decline of lung function; and accelerated decline of lung function. Even if the
magnitude of the excess loss of lung function differs between studies, most studies
have reported an excess decline in FEV1 of 5-25 mL/yr in subjects with asthma,
when compared to subjects without asthma.17 Impaired pulmonary function is a
predictor of mortality in the general,20 as well as in the asthmatic population.21
Lung function decline may result in persistent airflow limitation for some of the
asthmatic individuals.
One of the factors contributing to the progressive loss of lung function in
asthma is airway remodeling.22 Airway remodeling includes an increase in over-
all wall thickness, an increase in airway fibrosis and smooth muscle mass, ab-
normalities in composition of the extracellular matrix, and an increase in vas-
cularity.23,24 Airway remodeling in asthma includes not only structural changes
but also fundamental changes in the relationships between and among various
airway constituents. Cell-cell interactions, the regulation of cells by extracellular
matrix, and the modulation of the composition of matrix by cells have all been
demonstrated to be altered.22
The process of remodeling per se is not necessarily abnormal. It is an alter-
ation in size, mass, or number of tissue structural components that occurs during
growth or in response to injury and/or inflammation. It may be ”appropriate”, as
in the case of normal lung development or what occurs during the acute reaction
to injury (e.g. wound healing); or ”inappropriate”, when it is chronic and associ-
ated with abnormally altered tissue structure and function, like, for example, in
asthma, COPD, or fibrosing alveolitis.5 In asthma, both inflammation and remod-
eling usually persist and the consequences are inappropriate for the maintenance
of normal airway function. The reasons for the persistence are unknown, but
they may be the result of repeated inhalation of allergens or exposure to high
concentrations of allergens, or infections, or a genetically influenced abnormal
host inflammatory response or defect in the repair process. The host responses in
asthma may of course differ due to differences in genetic makeup or consequent to
developmental abnormality or to the effects of perinatal environmental exposure.
It is generally believed that the accelerated decline in forced expiratory flow
over time in obstructive lung diseases (like COPD and asthma), is the direct result
of a switch from acute and episodic to chronic inflammation and to consequent
parenchymal and airway wall remodeling, respectively.7 However, as yet, there
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is no convincing evidence that the remodeling process is dependent on the prior
development of chronic inflammation.5 It is equally plausible that the processes
responsible for the development of chronic inflammation are distinct from those
responsible for remodeling. Alternatively, an intrisic abnormality of the airway
structure or function may drive inflammation.22
1.5 Asthma genetics
Burke et al.25 examined 33 studies from all geographic regions in the world. Most
of these studies used large population-based samples to assess if family case
history were a risk factor for asthma. Although there were many methodologic
differences, the picture that emerged was consistent. A family history of asthma is
a strong predictor of asthma risk. In fact, in most of the studies reviewed, the odds
ratios for asthma fell between 2 and 4 when a first-degree relative had asthma.
Studies in identical twins have convincingly demonstrated that at least 50%
of the susceptibility to asthma is determined by inherited predisposition.26 It
has also been clearly established that no single gene or even a small number
of genes exert a decisive influence in determining this susceptibility. Asthma is
essentially a polygenic disease in which many genetic variants determine small
changes in immune responses or in the manner in which the airways respond
to the environment.27,28 Linkage (and positional cloning) and association studies
have identified numerous candidate genes and chromosomal regions that may
contribute to asthma risk.28,29 Most of the genes currently known to modify asthma
and allergy susceptibility have been identified through hypothesis-driven studies
that sought to identify an association between variants such as single nucleotide
polymorphisms (SNPs) in the main pathways that influence allergic inflammation
and asthma or asthma-related (intermediate) phenotypes.30
On chromosome 1, A1 adenosine receptor (A1AR) and calcium-dependant
chloride channel 1 (CLCA1) genes are likely to be important in the pathogenesis
of asthma and other respiratory conditions. A1AR signaling may serve to regulate
the severity of pulmonary inflammation and remodeling in chronic lung disease
by controlling the levels of important mediators of inflammation and damage.29
Adenosine contributes to mucus hypersecretion by airway epithelial cells and
upregulates mucin expression. The pathway is initiated at the A1AR that trans-
duces signals through a Ca2+ activated Cl− channel and the epidermal growth
factor receptor (EGFR). CLCA1 gene polymorphisms have been associated with
childhood and adult asthma in the Japanese population.31 The CLCA1 channel
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may be responsible, in part, for the overproduction of mucus in asthmatic pa-
tients32, which is one of the reasons for fixed airflow obstruction in a subgroup of
subjects with asthma. White et al.33 reported their findings from a genome scan
for asthma using the GAIN (Genetics of Asthma International Network) families.
The study pinpointed a genetic locus on Chromosome 1q43 with subsequent fine
mapping identifying OPN3. The function of OPN3 is unknown. White et al.33,
however, showed that both the RNA and the protein of the gene are expressed in
lung bronchial epithelia and immune cells, whereas siRNA knockdown suggested
OPN3 might modulate T-cell responses.
On chromosome 2, studies have identified the IL-R1N gene as possibly being
responsible for some alterations in the pathogenesis of asthma.34,35 IL-1RN is a
gene encoding the IL-1 receptor antagonist protein, an anti-inflammatory cytokine
that plays an important role in maintaining the balance between inflammatory
and antiinflammatory cytokines. Another interesting gene in the region 2q14–32
is the dipeptidyl-peptidase 10 (DPP10) gene, discovered by positional cloning.35
The protein encoded by this gene is involved in cleavage of terminal dipeptides
from cytokines and chemokines.
The cytokine gene cluster on chromosome 5 (5q31–33) is another gene rich
region of the human genome.36 Two genes in this region, ADRB2 and IL4R, have
had many positive associations to asthma and asthma-related traits reported.30
ADRB2 encodes the β2-adrenergic receptor and contains several common genetic
variations that affect gene expression and receptor function in vitro.37 β2-agonists
are the most frequently prescribed form of medication in the treatment of the
bronchoconstriction that is seen in asthma.37 To date 55 single nucleotide poly-
morphisms (SNPs) for ADRB2 have been listed in public databases.38 A number
of these SNPs are nonsynonymous resulting in amino acid changes and functional
investigations have suggested that certain SNPs are of importance with regard
to the cellular response to β-agonists. IL4R is a key gene of the Th2 pathways
as are its ligands, interleukin (IL) 4 and IL13. These two cytokines are the only
known cytokines that are capable of inducing human IgE synthesis whereas IL13
is recognized to be the chief effector of the allergic immune response. The IL4R
gene contains many SNPs with the majority being contained in exon 12 of the gene
and coding for amino acid changes that have the potential to impact on receptor
signalling.36
The human major histocompatibility (MHC) genes and many other genes
that play an important role in the regulation of the immune system are found
on chromosome 6 (6p21).39 The 6p21 region has shown strong linkage to atopic
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phenotype and asthma in many studies40,41, and it is considered to be a major
locus influencing allergic diseases. One of the genes that is likely to be involved
in asthma and allergy is the TNF-α gene.42 Tumour necrosis factor (TNF) is a
proinflammatory cytokine that increases human airway tissue responsiveness.
Chromosome 7 seems to be involved in asthma through the alteration of the
IgE levels. The region involved is likely to be a 20cM region on chromosome
7p14-p15, which showed linkage for asthma and IgE.29 Particularly, the orphan
G protein-coupled receptor gene (GPRA, G-protein-coupled receptor for asthma
susceptibility) has been associated with elevated IgE.43,44
On chromosome 11, the glutatione-S-transferase (GST) genes and other genes
involved in the oxidation stress have been described to be involved in asthma
and atopy.45,46 Gene polymorphisms and differential expression levels of the GST
genes have been associated with asthma, atopy and lung function.47
Several studies have shown linkage of chromosome 12 (12q13-26) to asthma or
related phenotypes in different populations.48,49 The linkage shown spans a wide
region, suggesting that more than one asthma susceptibility gene may be located
on chromosome 12.50 Oxidative stress, with the formation of reactive oxygen
species, is a key component of inflammation. The nitric oxide synthase (NOS)
enzymes are involved in the synthesis of nitric oxide (NO) from arginine. NO
has been proposed to be a marker for airway inflammation in asthma. One of the
enzymes producing NO is the neuronal nNOS, which is located on chromosome
12q32. Another region of the chromosome 12 that seems to have a role in asthma
is the vitamin D receptor (VDR) gene.51 A recent study of experimental models
showed the importance of the vitamin D endocrine system in the generation of the
Th2-driven inflammation in the lung.52 IRAK-M was reported to be involved in the
pathogenesis of early onset persistent asthma. The gene (on Chromosome 12q14)
encodes a protein that is both a master regulator of NF-kB and inflammation, as
well as being a negative regulator of the Toll-like receptor/IL1-R pathways, and it
is expressed in the bronchial epithelium.53
On chromosome 13, there seem to be genes influencing IgE levels. Several
studies confirmed linkage of atopy and the related phenotype to chromosome
13q14.54 Plant homeodomain finger protein 11 (PHF11) is one of these genes, and
it was identified through linkage analysis followed by positional cloning.30 PHF11
is expressed in both T and B cells55, thus it is likely that this protein may regulate
the transcription of lymphocyte genes involved in allergic inflammation.
Linkage of chromosome 14 markers with asthma or related phenotypes has
been illustrated in several reports and some gene associations have been de-
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scribed.56,57 Mansur et al.58 reported the linkage and association of the D14S63
marker with total serum IgE levels in asthmatic families. Marker D14S63 is phys-
ically located 16 Mb from the prostaglandin D2 receptor (DP) gene (PTGDR).
PTGDR is present on mast cells and eosinophils, which generate the effector
molecules of the asthmatic diathesis.59
A disintegrin and metalloprotease (ADAM)33 gene on chromosome 20 (20p13)
has been recognized as a susceptibility gene for asthma through linkage studies
followed by positional cloning.30,60,61 ADAM33 consists of 22 exons that encode a
signal sequence, prodomain, catalytic domain, disintegrin domain, cysteine-rich
domain, EGF domain, transmembrane domain, and cytoplasmic domain with a
long 3’-untranslated region.60 From a functional standpoint, these different do-
mains translate into different functions of ADAM33, which include activation,
proteolysis, adhesion, fusion, and intracellular signaling.62 ADAM33 belongs to
a family of 40 ADAM proteins and, being a metalloprotease, the catalytic domain
has a zinc binding site. ADAM33 mRNA is preferentially expressed in smooth
muscle, fibroblasts, and myofibroblasts, but not in the bronchial epithelium or in
inflammatory or immune cells.60 Jongepier and colleagues investigated genetic
and environmental factors that may contribute to accelerated decline in lung func-
tion in 200 patients with chronic asthma studied annually for 25 yr.63 They showed
that the rare allele of the S 2 polymorphism was significantly associated with ex-
cess decline in FEV1 over time and concluded that this variant of ADAM33 was
not only important in the development of asthma but also in disease progression,
possibly related to enhanced airway remodeling. A further study by the same
group64 investigated whether polymorphic variation of ADAM33 could also pre-
dict an accelerated decline in baseline lung function at a population level. A total
of 1,390 subjects from a Dutch cohort were genotyped for eight asthma-associated
SNPs and these were analyzed in relation to baseline FEV1 measured every 3 yr
for 25 yr. Individuals homozygous for the minor alleles of SNPs S 2 and Q-1 and
heterozygous for the SNP S 1 had a significantly accelerated decline in FEV1 of 4.9,
9.6, and 3.6 ml/yr, respectively, when compared with the wild-type allele. A fur-
ther analysis demonstrated a higher prevalence of the SNPs F+1, S 1, S 2, and T 2
in subjects with COPD at GOLD (Global Initiative for Chronic Obstructive Lung
Disease) stage 2 or higher. Thus, in addition to asthma, it seems that polymorphic
variation in ADAM33 also influences the rate of decline of lung function at a pop-
ulation level and more specifically in COPD. The selective expression of ADAM33
in mesenchymal cells, and the stronger linkage and association observed when
conditioning asthma with bronchial hyperresponsiveness (BHR),60 strongly sug-
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gests that alterations in its activity may underlie abnormalities in the function
of airway smooth muscle cells and fibroblasts linked to airway remodelling and
BHR.65
Since completion of the human genome sequence, the toolkit available for
complex disease gene identification has grown substantially.36 Sequencing of the
human genome in itself was a remarkable achievement. It also opened up the
opportunity for comprehensive SNP identification and characterization of linkage
disequilibrium patterns across the genome for populations of differing ethnic
backgrounds. In hand with this has been the vast technological development in
platforms for SNP genotyping and advances in the study of genome-wide gene
expression. Consequently, it is now possible to genotype a single individual
for up to a million SNPs simultaneously. This has opened up the possibility of
conducting genome-wide association (GWA) studies. To date there have only
been two GWA studies for asthma.66,67
The first, published in 2007 for childhood asthma, involved 994 patients and
1,243 nonasthmatics that were genotyped for more than 317,000 SNPs.66 Seven
out of the 12 SNPs showing association above the 1% false discovery rate thresh-
old mapped to an interval on chromosome 17 (17q21). Further SNP typing was
conducted resulting in three SNPs jointly showing strong association to child-
hood asthma (P<10−12). By coupling their genetic findings with genome-wide
gene expression data from Epstein-Barr virus-transformed lymphoblastoid cells
from children in the genotyped family samples68, the authors showed that the
SNPs with the strongest association to asthma were consistently associated with
levels of ORMDL3 transcripts.66 Little is known about the protein that ORMDL3
encodes. ORMDL3 is a member of a conserved family of endoplasmic reticulum
membrane proteins and the gene is expressed in a large range of tissues. The pro-
tein contains four transmembrane regions and, therefore, has the potential to act
as a transporter. Several further publications69–72 have confirmed the associations
between asthma and the Chromosome 17q21 SNPs with one study highlighting
that the locus is a risk factor for asthma in ethnically diverse populations.70
In 2008, Ober et al.67 reported findings of a genetic influence on asthma and a
chitinase-like protein known as YKL-40, which is encoded by the chitinase 3–like 1
(CHI3L1) gene (chromosome 1, region 1q32.1). It had previously been established
that YKL-40 levels were increased in the lung and circulation of patients with se-
vere asthma.73 Using a carefully characterized founder population of European
descent, the Hutterites, 500,000 genomewide SNPs were genotyped. Following
further fine mapping, a promoter SNP in the CHI3L1 gene was found to be asso-
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ciated not only with elevated serum YKL-40 levels but also asthma and measures
of lung function. YKL-40 is produced at sites of inflammation in many cells and
is secreted from vascular smooth-muscle cells and macrophages.74 It is strongly
upregulated in the airway epithelium and alveolar macrophages of patients with
asthma.73 Although the real function of YKL-40 remains to be established, the
study of Ober et al.67 has identified not only a further susceptibility gene for
asthma that is of importance, but also an important biomarker that can be used
as a measure of asthma susceptibility.
1.6 Inhaled corticosteroids and lung function decline
Inhaled corticosteroids (ICSs) are the mainstay of asthma treatment,1 and are
generally effective for the control of symptoms. Several studies suggest that they
may also alter the natural history of the disease and have a role in the prevention
of the structural airway changes associated with asthma and the progressive lung
function decline that is characteristic of the disease.75 The first study to suggest
that ICSs may have an effect on lung function decline was one of the earlier
studies of budesonide use on growth and pulmonary function.76 In this controlled
prospective study, Agertoft et al. measured growth and pulmonary function
in children with asthma during long-term treatment with inhaled budesonide
and compared these findings with those obtained from children not treated with
corticosteroids. In the latter, an annual decrease in FEV1 % predicted of 1-3%
was seen. In contrast, FEV1 improved significantly with time during budesonide
treatment, both compared with the run-in period and with the control group
(p<0.01).
The Childhood Asthma Management Program (CAMP) study was a random-
ized controlled trial of older children (age five to 12 years) with established mild
to moderate asthma.77 It was designed to evaluate whether continuous long-term
treatment of budesonide 200 µg twice daily for a period of four to six years would
safely produce an improvement in lung growth as compared with treatment for
symptoms alone (placebo group: β2-agonist and prednisolone when needed). The
trial did not show a significant difference between either treatment and placebo
in the degree of change in the post-bronchidilator FEV1. However, compared
with the placebo control group, the children assigned to receive budesonide had
a significantly smaller decline in the ratio of pre-bronchodilator FEV1/FVC (0.2%
vs. 1.8%, p=0.001).
Virtually all short term studies (weeks to a few years) on adults have shown
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that ICSs benefit patients with chronic persistent asthma by decreasing airway
inflammation, improving lung function, and reducing symptoms and airway
hyperresponsiveness.78–81 The regular use of ICSs was found to be associated
with a decreased risk of fatal and near-fatal asthma,82,83 and with a decrease in
the risk of asthma hospitalisation.84 However, only recently observational studies
were performed to evaluate whether long-term treatment with ICSs also have
a beneficial effect on lung function decline.85,86 Lange et al.85 studied subjects
participating in the third and fourth examinations of the Copenhagen City Heart
Study. Compared to subjects who did not use ICSs, subjects who used ICSs
had a 18 mL/year significantly smaller decline in FEV1 (p=0.013). Dijkstra et al.86
reported that the use of ICSs was associated with a reduction in the annual decline
in lung function in men, but not in women. They also showed that the beneficial
effect of ICSs on lung function was dose-dependent, and that it was not present
in men with >5 pack-years smoking. Given the acknowledged benefits of ICSs
in asthma, randomized controlled trials that evaluate the effects of ICS use on
lung function decline will not be feasible, and long-term observational studies
will probably be the best available evidence.
1.7 Other determinants of lung function decline
The cross-sectional relationship existing between weight (or body mass index,
BMI) and lung function in healthy individuals was first revealed very long time
ago (1846),87 and later replicated.88 These papers showed that lung function, as
measured by the VC, increased with weight until a certain value (e.g. 107%
of average weight87), and decreased slightly with further increases in weight.
The explanation of this relationship between weight and lung function was that
the increase of lung function with weight may reflect increasing muscle force
(muscularity effect), while the decrease with further weight increase probably
reflects “the mere circumstance of fat preventing the mobility of the thoracic
boundaries”87 (obesity effect).88
Recently, the detrimental effect of weight gain on lung function decline has
been shown in the general population.89 Several mechanisms have been advocated
to explain the negative effect of obesity and weight gain on lung function.90,91 The
first of these possibilities rests on simple mechanical considerations, where both
static and dynamic factors come into play. Concerning static factors, increased ab-
dominal and chest wall mass in the obese causes lower than normal FRC. Because
lung volume is a major determinant of airway diameter, it is therefore likely that
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obesity-related changes in FRC unload the airway smooth muscle and thereby
allow it to shorten excessively when activated.92 Concerning dynamic factors,
the tidal action of spontaneous breathing imposes tidal strains on airway smooth
muscle, and these tidal strains happen to be the most potent of all known bron-
chodilating agencies.93 The obese individual breathes at higher frequencies but
substantially smaller tidal volume compared with the lean individual,94 and as a
result, this potent bronchodilating mechanism is compromised and predisposes
toward increased airway responsiveness compared with the lean individual. A
second possible explanation for the influence of obesity on airway smooth muscle
function concerns differences in the anatomy of the lungs and airways. For exam-
ple, in children the mechanical load of obesity might affect lung growth, leading
to reduced pulmonary function, a known risk factor for asthma. Obesity might
also lead to more accelerated airway remodeling with each asthma exacerbation.
Moreover, in obese individuals, even in the absence of an overt inflammatory in-
sult, there is chronic, low-grade systemic inflammation characterized by increased
circulating leukocytes and increased serum concentrations of cytokines, cytokine
receptors, chemokines, and acute-phase proteins.90,91,95 Despite the above con-
siderations, the relationship between weight (or weight gain) and lung function
decline has not been investigated thoroughly enough in the asthmatic population.
Smoking has been consistently shown to accelerate lung function decline in
the general population,19,89 and it is the main risk factor for COPD.16 Active
smoking is, therefore, likely to have a more deleterious effect on lung growth and
senescence in asthmatics than in nonasthmatics. However, in both children and
adults, an effect of smoking additional to the effect of asthma on longitudinal
changes in lung function has been difficult to demonstrate.17 In fact, although
many studies19,96,97 have found that asthmatic smokers have a steeper decline in
lung function than asthmatic non-smokers, and that smoking is a risk factor for
persistent airflow obstruction for subjects with asthma98, some studies could not
shown this association.18,99,100 It is possible that these studies have included insuf-
ficient numbers of smokers with asthma to draw conclusions about the impact of
cigarette smoking on outcome, perhaps because individuals with more suscepti-
ble airways, i.e. asthmatics, are less likely to take up smoking or quit at an early
stage (the healthy smoker effect). Although the evidence is scarce, it is difficult
not to assume that active smoking has a negative effect, additional to the effect
of asthma, on longitudinal changes in lung function in both children and adults
suffering from asthma.17
Passive exposure to cigarette smoke in childhood is a risk factor for wheezy
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bronchitis, airway hyperresponsiveness, and symptomatic asthma.101 In young
adults, passive smoking was found to be associated with respiratory symp-
toms, asthma, a small but significant impairment of lung function and increased
bronchial responsiveness.102,103
The duration of the disease seems to be associated with lung function decline
in a non-linear way. Both newly diagnosed asthma and long-standing asthma
appear to be associated with unfavourable longitudinal changes in lung func-
tion, possibly reflecting increased airway vulnerability initially, possibly owing
to unopposed inflammation, and progressive airway remodelling due to chronic
inflammation.17 In fact, several studies have found that adult asthmatics may
have an excessive annual decline in lung function prior to the time of diagnosis,
and also in the first years following the onset of asthma.104,105 However, in adult
asthmatics, the degree of lung function impairment seems to be related to the du-
ration of previous asthma. In other words, longer duration of the disease may be
associated with increasing decline in lung function.99,106 Accordingly, incomplete
reversibility of airflow obstruction may be found in some, most probably a mi-
nority, patients with long-standing disease.98,107 These observations suggest that
long-standing airway inflammation may lead to, perhaps nonreversible, struc-
tural changes in the airway wall.
Atopy, defined as a positive skin test reactivity to inhalant allergens, is found
in the majority of patients, especially children, with asthma, but the association
between atopy and the outcome of asthma is not straightforward.17 Allergic (also
called atopic, or extrinsic) asthma usually develops in the second decade of life
and frequently persists into adult years, but young patients with allergic asthma
often enjoy a transient or even a permanent remission. Asthma beginning af-
ter the fourth decade is usually non-allergic (also called non-atopic, or intrinsic)
and may include the aspirin triad. Its severity tends to increase with time.108
Only a few long-term longitudinal studies have focused on the possible impact
of atopy on longitudinal changes in lung function in patients with asthma. Ev-
idence from longitudinal population studies indicates that skin test-positivity is
associated with an accelerated decline in FEV1.109 However, results from studies
comparing subjects with atopic asthma and subjects with non-atopic asthma are
conflicting. Some studies indicate that atopy is not associated with lung func-
tion decline in subjects with asthma,18,110,111 although in one of these studies the
authors conclude that asthmatic patients with atopy and marked BHR should be
looked upon as patients with a risk of developing progressive airflow obstruc-
tion.111 Conversely, other papers report that non-atopic asthma is a more severe
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form of asthma than atopic asthma, and that it is associated with a steeper decline
in lung function.99,112,113 To explain these conflicting results, it can be observed that
the patients with nonatopic asthma recruited in these sudies were generally older
than the patients with atopic asthma, and as lung function decline accelerates with
age, the observed difference between atopic and nonatopic asthmatics might be, at
least partly, explained by the difference in age between the two groups. Atopy is a
known risk factor for symptomatic asthma, and in the nonasthmatic population it
may also be a risk factor for an accelerated decline in lung function. However, in
both children and adults with established asthma, according to Ulrik17 it appears
reasonable to conclude that atopy is not an independent determinant of prognosis
with regard to lung function, suggesting that inflammatory processes in the air-
ways of patients with asthma run their own courses irrespective of the subjects’
atopic status. However, another possible explanation of these conflicting results
on the association between atopy and lung function decline in asthma, could be
the complexity of asthma: there is likely to be heterogeneity of asthma phenotypes
even in the rather homogeneous atopic and non-atopic phenotypes.3
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Chapter 2
Aims
The aim of this thesis was to increase knowledge about factors associated with
lung function decline in asthma. We asked the following questions in a large,
international, population-based cohort of subjects with asthma, followed up for 9
years in the European Community Respiratory Health Survey (ECRHS):
• is prolonged use of inhaled steroids associated with a reduced long-term
decline in lung function?
• what are the main determinants of lung function decline in asthma? Do these
determinants vary among asthmatic subjects with and asthmatic subjects
without airflow obstruction?
17
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Chapter 3
Methods
3.1 Study design of the ECRHS
ECRHS stage I114 was an international postal questionnaire survey (see Ap-
pendix B), mainly carried out in 1990 and 1992, with randomly selected partici-
pants from the general population within administrative boundaries of 56 centres
in 25 countries (www.ecrhs.org). From those who responded, a 20% random sam-
ple was invited to undergo a more detailed clinical examination in 1992-94 (stage
2). In addition, a sample (called symptomatic sample) consisting of subjects not
already included in the random sample who reported asthma-like symptoms in
the last 12 months, or individuals who were using asthma medication in stage 1,
was also investigated. The ECRHS I aimed at describing variations in exposure
to risk factors and their association with asthma and allergy and in analysing the
variation in treatment practice in the international community. In ECRHS I stage 1
each centre invited about 1,500 men and 1,500 women for assessment of symptoms
(respiratory symptoms, nasal symptoms, asthma). In ECRHS I stage 2, at least 300
men and 300 women from each centre were invited to participate in a detailed clin-
ical examination. The main questionnaire in stage 2 (see Appendix C) included
factors known or hypothesised to be of importance for asthma and allergy (family
size, family history of the diseases, occupation, childhood and current exposure
to pets, exposure to tobacco smoke, dampness, ventilation, use of soft furnishings,
use of gas appliances) and use of health services and treatment for respiratory
diseases. The main questionnaire was based on the validated Bronchial Symp-
toms Questionnaire of the International Union Against Tuberculosis and Lung
Disease.114 In addition, in stage 2, blood was taken for measurement of specific
IgE to Der p1 (house dust mite), cat, Timothy grass, Cladosporium (mould), a lo-
cal allergen, and total IgE. Forced expiratory volume in one second (FEV1), forced
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vital capacity (FVC) and bronchial reactivity to metacholine were measured.
From 1998 to 2002, responders from 29 centres in 14 countries were invited to
a follow-up study, the ERCHS II.115 The ECRHS II stage 1 was a postal screening
questionnaire (see Appendix D), while the ECRHS II stage 2 included a detailed
clinical investigation (see Appendix E), additional questionnaires and a clinical
examination. Lung function measurements (see Appendix A), methacholine chal-
lenge tests and blood samples for measurement of serum specific IgE were also
performed. The present thesis includes longitudinal analyses using data from
both ECRHS I stage 2 and ECRHS II. A flow chart of the ECRHS is shown in
figure 3.1.
stage 1 - Postal questionnaire
Random sample of 3,000 
subjects (20-44 years) per centre
about 116,000 subjects
stage 2 - Clinical interview
and tests
20% random sample + 
“symptomatic” sample
about 18,000 subjects
ECRHS I (1990-94)
stage 1 - Postal questionnaire
stage 2 - Clinical interview
and tests
about 10,000 subjects
ECRHS II (1998-2002)
Figure 3.1: Flow-chart of the European Community Respiratory Health Survey.
3.2 Asthma definition and asthma phenotypes
Current asthma was defined in the ECRHS I as having reported asthma [EC1q13]∗
confirmed by a doctor [EC1q13.1] and having had:
∗the reference questions (q#) and questionnaires (EC1=ECRHS I main questionnaire,
EC2=ECRHS II main questionnaire) are indicated in squared brackets; e.g. ”EC1q1” is the first
question of the ECRHS I main questionnaire. See Appendix C for the ECRHS I main questionnaire
and Appendix E for the ECRHS II main questionnaire.
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• asthma-like symptoms (wheeze [EC1q1], nocturnal chest tightness [EC1q2],
attacks of breathlessness following activity [EC1q4], at rest [EC1q3] or at
night time [EC1q5], asthma attacks [EC1q13.5]) and/or
• having used inhaled [EC1q60] /oral [EC1q61] medicines because of breathing
problems during the last 12 months.
In the paper on the determinants of lung function decline in asthma (paper II),
two distinct phenotypes of asthma were separately investigated:
1. asthmatic subjects without airflow obstruction at baseline (milder asthma)
2. asthmatic subjects with airflow obstruction at baseline (more severe asthma)
Baseline airflow obstruction was defined as FEV1/FVC<0.7016 at the first visit
(ECRHS I). As a bronchodilator challenge test was not part of the ECRHS core pro-
tocol, the follow-up spirometry was used to confirm baseline airflow obstruction.
Accordingly, 29 subjects with baseline airflow obstruction who had FEV1/FVC≥
0.70 at follow-up were excluded from the analyses, in order to reduce the number
of ”false positives”.116
3.3 Outcome
The maximum FEV1 and FVC of at least two and as many as five technically
acceptable maneuvers were recorded, according to the American Thoracic Soci-
ety criteria for reproducibility.117 FEV1 % predicted and FVC % predicted were
calculated on the basis of the equations by Quanjer et al.118 The average decline
in FEV1 (or FVC) during the follow-up was computed as the difference between
FEV1 (or FVC) measured in the ECRHS I and II, divided by the duration of the
follow-up (expressed in mL/year). %FEV1/FVC decline was also computed as the
difference between %FEV1/FVC in the ECRHS I and II, divided by the duration of
the follow-up (expressed in %/year).
3.4 Use of inhaled steroids
In both surveys, the participants were asked whether they had used ICSs in the
last 12 months, and the type/brand of steroid was recorded [EC1q60.4, EC2q76.5
and nested questions]. In the ECRHS II, quantitative information was collected
about ICS use during the follow-up (how many months per year, how many years
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since the last survey a subject had been on ICSs [EC2q78 and nested questions]).
The data on ICSs were combined to calculate the cumulative time of treatment
during the follow-up. Subjects with asthma were stratified according to the time
of steroid use into:
1. non-users,
2. people who had used ICSs for <8.7 months (1st tertile of time of ICS use
distribution among users),
3. ≥ 8.7 months but <48 months (2nd tertile),
4. ≥ 48 months.
3.5 Other covariates considered in the analyses
The following covariates were considered in the analyses as potential determi-
nants of FEV1 decline or as potential confounding factors:
• baseline covariates:
– sex;
– age;
– height (m);
– Body Mass Index (BMI, kg/m2), the subject’s weight was measured,
and BMI was calculated as weight/height2;
– educational level, low if a subject had completed full-time education
before the age of 16 [EC1q32: Are you a full time student?, EC1q32.1: At
what age did you complete full time education?];
– occupation, coded as manual job, non-manual job, or other [EC1q32.2:
Are you currently employed or self-employed? EC1q32.3: What is you current
or most recent job? Be as precise as possible, EC1q32.4: Are you or were you
(TICK ONE BOX ONLY): a manager working for an employer?, a foreman
or supervisor working for an employer?, working for an employer, but neither
a manager, supervisor or foreman?, self-employed?];
– occupational risk [EC1q32.7: Have you ever worked in a job which exposed
you to vapours, gas, dust or fumes?];
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– duration of asthma, estimated as the difference between the age of the
subject at the ECRHS I interview and the age when the first asthma
attack occurred;
– total IgE (kU/L), measured according to a standardized protocol119;
– sensitization to allergens; specific IgE against house dust mite, cat dan-
der, timothy grass, Cladosporium species, and a local allergen, were
measured.119 A subject was considered sensitized to any allergen if the
assay result for at least one allergen was higher than 0.35 kU/L, the
detection limit of the assay;
– hospitalizations and/or emergency department visits for breathing prob-
lems [EC1q69: Have you ever visited a hospital casualty department or emer-
gency room because of breathing problems? and/or EC1q70: Have you ever
been seen by a doctor because of breathing problems or because of shortness of
breath?];
– pack-years, calculated for the period before the ECRHS I interview89
[EC1q58: Have you ever smoked for as long as a year? YES means at least 20
packs of cigarettes or 12 oz (360 grams) of tobacco in a lifetime, or at least one
cigarette per day or one cigar a week for one year, EC1q58.1: How old were
you when you started smoking?, EC1q58.2: Do you smoke now, as of one
month ago? and all the nested questions asking detailed information
about the intensity of smoking, EC1q58.3: Have you stopped or cut down
smoking? and all the nested questions asking detailed information
about the intensity of smoking before cutting down or having stopped
smoking, and the age when the subject cut down or stopped smoking];
– environmental tobacco smoke (ETS) exposure, i.e. regular exposure to
other people’s smoke for 1 hour/day or more [EC1q59: Have you been
regularly exposed to tobacco smoke in the last 12 months? ’Regularly’ means
on most days or nights, EC1q59.3: How many hours per day are you exposed
to other people’s tobacco smoke?];
• family history of atopic diseases (evaluated at baseline); based on the ques-
tions EC1q25: Did your mother ever have asthma?, EC1q26: Did your mother
ever have eczema, skin or nasal allergy or hay fever?, EC1q27: Did your father ever
have asthma?, EC1q28: Did your father ever have eczema, skin or nasal allergy or
hay fever?, the following covariates were implemented:
– family history of asthma (mother and/or father with asthma);
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– family history of allergy (mother and/or father with eczema, skin or
nasal allergy or hay fever);
– mother with asthma and/or eczema, skin or nasal allergy or hay fever;
– father with asthma and/or eczema, skin or nasal allergy or hay fever;
• follow-up covariates:
– pack-years, calculated for the period between the ECRHS I and II89
[EC2q74: Have you ever smoked for as long as a year?, EC2q74.1: How old
were you when you started smoking?, EC2q74.2: Do you smoke now, as of
one month ago? and all the nested questions, EC2q74.3: Have you stopped
or cut down smoking? and all the nested questions];
– BMI gain (kg/(m2year)), or weight gain (kg/year), during the follow
up, computed as the difference between BMI/weight, measured in the
ECRHS II and I, divided by the duration of the follow-up;
– change in ETS exposure from the ECRH I, coded as unchanged, wors-
ened, improved;
• lifetime covariates:
– lifetime pack-years, calculated as the sum of the baseline and follow-up
covariates.
3.6 Subjects included in the analyses
In the ECRHS I, 1348 subjects with current asthma had their lung function mea-
sured according to the ATS criteria (700 from the random and 648 from the symp-
tomatic samples). While there were no differences in age, sex, smoking habits,
FEV1 and IgE levels at baseline (ECRHS I) in ”random” and ”symptomatic” sub-
jects, the former had a slightly longer duration of the disease (17.8 vs 16.2 years),
a lower percentage of manual workers (25% vs 35%) and of people reporting
exposure to vapors, gas, dust or fumes in the workplace (44% vs 50%), a lower
body mass index (BMI) (23 vs 24 kg/m2), and they included a smaller percentage
of individuals with a low educational level (9% vs 15%) (p <0.01).
Of these 1348 individuals, 860 (64%) attended the second study (1999-2002),
and were therefore eligible for the analyses. In the ECRHS II (1999-2002), some
eligible subjects did not repeat spirometry (135 subjects), or had their lung function
measured in a way that was not in conformity with the ATS criteria (32 subjects),
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and were excluded from the analysis. Among those who had performed the lung
function test, some had used inhaled long-acting β2-agonists in the 12 hours before
the test. As the bronchodilating effect of long-acting β2-agonists can persist for
8-12 hours after use, they were also excluded (26 patients).
Finally, 667 subjects were included in the analyses (311 from the random and
356 from the symptomatic samples) in paper I (Appendix F).
In paper II (Appendix G), the above subjects were divided into two distinct
asthma phenotypes:
• asthmatic subjects without airflow obstruction at baseline (milder asthma,
n=544);
• asthmatic subjects with airflow obstruction at baseline (more severe asthma,
n=94).
Accordingly, 29 subjects with baseline airflow obstruction who had FEV1/FVC≥0.70
at follow-up were excluded from the analyses.
On average, among the individuals included in the analyses, the follow-up
time was 9 years (range: 6-11 years).
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Chapter 4
Results
4.1 Inhaled steroid use and lung function decline
4.1.1 Comparison between included and excluded subjects
Non-participants in the ECRHS II, or participants whose FEV1 was unavailable,
not in agreement with the ATS criteria or measured within 12 hours after the
last administration of a long-acting β2-agonist were excluded from the analyses
(n=681). Subjects included in the analyses (n=667) were slightly older (mean,
SD: 33.9, 7.2 vs 32.3, 7.2, p=0.0001) and comprised a lower percentage of current
smokers (30% vs 39%, p=0.05) and of manual workers (29.1% vs 31.3%, p<0.0001)
than subjects who were excluded.
4.1.2 Use of inhaled steroids
The cumulative time of ICS use could be evaluated for 636 subjects. In detail,
297 (47%) had never been on ICSs, whereas 339 (53%) had used ICSs during the
follow-up. Among ICS users, the median cumulative time of treatment was 1.4
(interquartile range, IQR: 6.3) years, with no significant difference between men
and women (p=0.33). Among people who had used ICSs for≥4 years, the median
time of use was 8.2 (IQR: 2.0) years. The steroid that was most commonly used
during the year before the follow-up visit (ECRHS II) was budesonide (51%),
followed by beclomethasone (27%), and fluticasone (20%); and the majority of
subjects used dry-powder inhalers (65%), one third used metered-dose inhalers,
while only 1% used nebulizers.
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4.1.3 Characteristics of steroid users and non-steroid users
At baseline, on average, asthmatic subjects treated with ICSs during the follow-
up (table 4.1) had a worse lung function, higher levels of total IgE, a shorter
duration of asthma, a greater prevalence of family asthma and of hospitaliza-
tions/emergency department visits than non-steroid users. Steroid users were
more likely to be women and had a higher baseline BMI than non-steroid users,
and they also comprised a lower percentage of current smokers at baseline (24%
vs 36%).
Table 4.1: Baseline characteristics (and lifetime pack-years smoked) of the asth-
matic subjects, stratified according to the use of ICSs during the follow-up. Data
are provided as mean (standard deviation) or percentages (%), unless stated oth-
erwise*. Statistically significant (p<0.05) results are reported in bold.
Inhaled corticosteroids
Non-users Users p-value
No. of subjects 297 339
(%) (46.7) (53.3) –
Sex (% female) 45.4 63.7 <0.001
Age (years) 33.7 (7.1) 34.1 (7.3) 0.44
BMI (kg/m2) 23.6 (3.6) 24.5 (4.9) 0.001
Smoking habits
(lifetime pack-yrs)* 1.6 (15.6) 0 (10.0) 0.013
Occupation
(% non-manual) 47.5 49.0
(% manual) 28.0 30.4 0.48
(% other) 24.5 20.6
Occupational exposure (%) 47.6 48.4 0.85
Duration of asthma* (yrs) 18.7 (19.1) 13.5 (17.9) 0.001
Family asthma (%) 19.3 31.1 0.001
Total IgE‡
(log transformation) 1.84 (0.66) 1.96 (0.68) 0.033
Hospitalizations (%) 28.6 42.9 <0.0001
FEV1 (L) 3.7 (0.8) 3.2 (0.8) <0.0001
FEV1 % predicted† 101.6 (12.6) 95.0 (17.9) <0.0001
* median (IQR); p-values of non-parametric test reported;
‡ corresponding to a geometric mean of 69.6 kU/L in non-users and of 91.9 kU/L in users;
† predicted values of FEV1 were calculated on the basis of sex, age and height.
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4.1.4 Decline in lung function
In subjects with asthma, the average decline in FEV1 was 35 (95% CI: 29; 40)
mL/year for men and 24 (95% CI: 20; 28) mL/year for women (figure 4.1). FEV1
decline was positively associated with age (p trend=0.003), but not with baseline
BMI and with lifetime exposure to active smoking (pack-years). FEV1 decline
was 32 (95% CI: 27; 36) mL/year and 25 (95% CI: 21; 30) mL/year for individuals
exposed and not exposed to occupational risk, respectively. FEV1 decline was
unrelated to occupation, hospitalizations/emergency department visits, total IgE,
family asthma, and asthma duration at baseline.
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Figure 4.1: unadjusted mean annual decline in FEV1 (with 95% CIs and p-value
for trend) from 1991-1993 to 1999-2002, according to sex, age, and BMI at baseline,
and lifetime pack-years smoked. * Student t test.
FEV1 decline was lower in subjects who had used ICSs for a longer time (p
trend=0.025); it was 34 mL/year in non-users, 28 mL/year in subjects treated for
<8.7 months, 24 mL/year in subjects treated for ≥8.7 months but <48 months, and
20 mL/year in subjects treated for ≥48 months.
When all the variables were considered simultaneously (table 4.2), the use of
ICSs for ≥48 months was statistically significantly associated with a lower decline
(11 mL/year, 95% CI: 0.1; 21, compared with non-users). A shorter therapy with
steroids (<48 months) was also associated with a lower FEV1 decline (about 4
mL/year), but it was not statistically significant. FEV1 decline was greater for
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older subjects (0.8 mL/year, 95% CI: 0.2; 1.4 for every additional year in subject
age). None of the other covariates considered in the analysis was significantly
associated with FEV1 decline.
There was no statistically significant interaction between sex and ICS use,
nor between lifetime pack-years smoked and ICS use, but a significant (p=0.02)
interaction was found between having an elevated (>100 kU/L) level of total IgE
and ICS use (figure 4.2). After adjusting for all the potential confounders, in
subjects having total IgE >100 kU/L (47% of the subjects included in the analysis),
the use of ICSs for≥4 years was associated with a lower FEV1 decline (23 mL/year,
95% CI: 8; 38, compared with non-users). In ICS users with elevated total IgE,
the Pearson correlation coefficient between FEV1 decline and total IgE was 0.07
(95% CI: –0.09; 0.22). When the analysis was repeated adjusting for bronchial
hyperresponsiveness, coded as ”present” (if a subject had PD20 <1 mg), ”absent”,
or ”test not performed”, the results were fully consistent with those presented
(data not shown).
Table 4.2: multiple regression coefficients* with 95% confidence intervals (CIs),
and related p-values for the association between the mean decline in FEV1 and sex,
age and BMI at baseline and smoking habits and ICS use during the follow-up.
Statistically significant (p<0.05) results are reported in bold.
covariate coefficient 95% CI p-value
(mL/year)
Sex† (female) –9.5 –20.4; 1.4 0.09
Age‡ (years) 0.8 0.2; 1.4 0.005
BMI‡ (kg/m2) –0.4 –1.3; 0.5 0.40
Smoking habits‡
(lifetime pack-years) 0.04 –0.2; 0.3 0.76
Use of ICSs†
<8.7 months –3.9 –14.4; 6.5 0.46
8.7 months to 4 years –4.8 –15.5; 6.0 0.38
≥4 years –10.7 –21.3; –0.1 0.048
* adjusted for height, occupation, exposure to occupational risk, duration of asthma, familiarity
of asthma, total IgE, previous hospitalizations/emergency department visits; obtained through a
two-level random intercept regression model fitted on subjects with complete information (n=511);
† the coefficient represents the difference in the annual rate of FEV1 decline (mL/year) between
subjects with the characteristic and subjects belonging to the reference category (i.e.: ”male” for
variable sex and ”no ICSs” for variable ”use of ICSs”);
‡ the coefficient represents the change in FEV1 decline (mL/year) for a unit change in the covariate.
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Figure 4.2: unadjusted mean annual decline in FEV1 (with 95% CIs and p-value
for trend), according to the level of total IgE* and to the time of ICS use during
the follow-up (non-users, 1st, 2nd and 3rd tertile).
* Elevated (>100 kU/L) total IgE were present in 47% of the subjects included in the
analysis.
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4.2 Other determinants of lung function decline
4.2.1 Comparison between included and excluded subjects
Subjects excluded from the analyses (n=710) were younger (median age, IQR: 32,
12 vs. 34, 12 years, p<0.001), and they were more likely to be current smokers
(38% vs 30%, p=0.01) than subjects who were included (n=638). However, the
two groups were similar as regards all the other baseline covariates (including
BMI: median, 23 kg/m2 in both groups), as well as baseline FEV1 and FVC.
4.2.2 Characteristics and lung function of the subjects included
Subjects with airflow obstruction at baseline (n=94, 15%) were more likely to be
men (66% vs 41%, p<0.001), to be older (median age, IQR: 36, 13 vs 33, 12 years,
p=0.004) and to have had asthma for a longer time (median duration of asthma,
IQR: 22, 20 vs 15, 19, p<0.001) than subjects without airflow obstruction (n=544,
85%). Moreover, they had a lower BMI gain during the follow-up (median, IQR:
0.15, 0.24 vs 0.18, 0.31 kg/m2year, p=0.01). In subjects without baseline airflow
obstruction, a high baseline BMI was associated with a lower baseline FEV1, both
in men and in women (figure 4.3). Obese subjects (BMI range, 30 to 47 kg/m2)
had a lower median FEV1 than non-obese subjects (3.0 vs 3.5 L, p <0.001), a lower
median FVC (3.8 vs 4.2, p <0.001) and a lower FEV1/FVC (0.80 vs 0.82, p=0.10).
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Figure 4.3: Baseline FEV1 by categories of baseline BMI for men and women
without airflow obstruction at baseline*. Medians with IQRs are reported.
* The number of subjects in the BMI categories <20, 20-24.9, 25-30, and >30 kg/m2 are 12, 134, 71,
7 (men) and 51, 182, 52, 35 (women) respectively.
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4.2.3 Determinants of lung function decline
FEV1 decline and %FEV1/FVC decline were greater for subjects without airflow
obstruction than for subjects with airflow obstruction (table 4.3). In asthmatic
subjects without airflow obstruction at baseline, FEV1 decline was associated
with baseline BMI in a quadratic way (table 4.4, column 1). In other words, men
and women with an intermediate BMI had the greatest FEV1 decline (figure 4.4).
Subjects with a high educational level had a faster FEV1 decline than subjects with
a low educational level (p=0.003) (table 4.4, column 1). Independently of baseline
BMI, FEV1 decline was 28 mL/year greater for every BMI unit (1 kg/m2) gained
during 1 year of follow-up (p<0.001). Moreover, there was an interaction between
sex and BMI gain (p=0.003): FEV1 decline was 61.8 (95% CI: 32.0; 91.7, p<0.001)
mL/year greater per BMI unit gained during 1 year of follow-up in men, and
20.2 (95% CI: 7.9; 32.6, p=0.001) mL/year greater per BMI unit gained in women
(figure 4.5). This corresponds to a FEV1 decline of 20.0 (95% CI: 10.4; 29.5, p<0.001)
mL/year per kg gained during 1 year of follow-up in men, and to 6.9 (95% CI:
2.5; 11.4, p=0.002) mL/year per kg gained in women. In asthmatic subjects with
airflow obstruction at baseline, the absence of allergen sensitization (p=0.035) and
a lower BMI (p=0.008) at baseline were both associated with a faster FEV1 decline
(table 4.4, column 2). No significant association was found between exposure to
active or passive smoking and FEV1 decline, either in subjects with or in subjects
without airflow obstruction.
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Figure 4.4: Plot of FEV1 decline vs baseline BMI, and of the curve representing
the FEV1 decline predicted on the basis of a linear regression on BMI and BMI
squared, in men and women without airflow obstruction at baseline.
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Table 4.3: Baseline lung function and lung function decline of the asthmatic
subjects, stratified by the presence of airflow obstruction at baseline. Data are
provided as means (with 95% CIs). Statistically significant (p<0.05) results are
reported in bold.
Airflow obstruction at baseline
No Yes p-value
FEV1 % predicted (%) 102 (101; 103) 78 (75; 82) <0.001
FVC % predicted (%) 107 (106; 108) 106 (102; 110) 0.97
FEV1* (L) 3.6 (3.5; 3.6) 2.7 (2.6; 2.8) <0.001
FVC* (L) 4.4 (4.4; 4.5) 4.4 (4.3; 4.5) 0.65
FEV1/FVC† 0.82 0.63 –
FEV1 decline* (mL/year) 33 (28; 37) 23 (14; 32) 0.04
FVC decline* (mL/year) 22 (15; 29) 26 (15; 38) 0.43
%FEV1/FVC decline† (%/year) 0.35 (0.29; 0.41) 0.16 (0.03; 0.29) 0.008
* adjusted for sex, age and height;
† adjusted for sex and age.
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Figure 4.5: Mean FEV1 decline* by categories of BMI gain (according to tertiles)
for men and women without airflow obstruction at baseline. P-value for trend: p
<0.001 (men) and p=0.001 (women).
* adjusted for all the covariates considered in the multivariate analysis.
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Table 4.4: Multiple regression coefficients* with 95% confidence intervals (CIs) for
the association between FEV1 decline and the covariates indicated, in asthmatic
subjects stratified by the presence of airflow obstruction at baseline. Statistically
significant results (p<0.05) are reported in bold.
Airflow obstruction at baseline
No (n=371)† Yes (n=76)†
estimate†† (95% CI) estimate†† (95% CI)
(mL/year) (mL/year)
Baseline covariates
BMI (kg/m2) 11.8 (5.4; 18.2)‡ –4.6 (–8.1; –1.2)‡
BMI2 ((kg/m2)2) –0.2 (–0.3; –0.09)‡ –
Low educational level –18.7 (–30.8; –6.5)‡ 20.2 (–15.2; 55.6)
Pack-years (1-unit increase) –0.2 (–0.6; 0.3) –0.7 (–2.2; 0.8)
Exposure to ETS 5.9 (–4.4; 16.2) –29.3 (–62.2; 3.6)
Sensitization to any allergen –4.0 (–13.1; 5.0) –29.2 (–56.3; –2.1)
Duration of asthma (years) –0.3 (–0.7; 0.01) –0.4 (–1.5; 0.7)
Family asthma –0.8 (–9.1; 7.6) –21.4 (–47.8; 5.0)
Follow-up covariates
BMI gain (kg/(m2·year)) 28.1 (15.1; 41.1)‡ –7.4 (–51.4; 36.6)
Pack-years between surveys
(1-unit increase) –0.2 (–1.3; 1.0) 3.7 (–0.6; 8.0)
Change in ETS
worsened vs. unchanged –3.9 (–20.4; 12.6) 26.2 (–23.5; 75.8)
improved vs. unchanged –6.8 (–17.9; 4.2) 13.7 (–22.6; 50.0)
Intercept** 38.9 (27.2; 50.6)‡ 77.1 (44.9; 109.3)‡
* adjusted also for sex, age, height, and for the interaction between total IgE and ICS use;
† number of subjects with complete information;
‡ p<0.01;
** quantitative variables were centered around their mean to calculate the intercepts; the intercept
represents the value of FEV1 decline when all categorical variables are set to the reference category
(e.g. sex = ”male”) and all the quantitative variables are set to their mean;
†† the estimate for different variables represents the difference in the annual decline in FEV1 be-
tween those with and those without these characteristics (e.g. subjects without airflow obstruction
at baseline who gained 1 BMI unit per year of follow-up had an additional decline in FEV1 of 28.1
ml/year compared to those who did not gain weight).
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4.3 Family history of atopic diseases and lung func-
tion decline
There were no statistically significant differences in the distribution of the family
history of asthma and/or other allergic diseases in subjects without and with
airflow obstruction at baseline (Table 4.5). Approximately 25% of the subjects
included in the analysis had a family history of asthma, and 50% had a family
history of eczema, skin or nasal allergy or hay fever.
No association was found between a family history of asthma and/or allergic
diseases and the FEV1 decline, either in subjects with or in subjects without airflow
obstruction at baseline (Table 4.6).
Table 4.5: Family history of asthma and/or other allergic diseases, in asthmatic
subjects stratified by the presence of airflow obstruction at baseline.
Airflow obstruction at baseline
No Yes p-value
(n=544) (n=94)
one/both parents with asthma 132 (26.1%) 23 (25.6%) 0.92
one/both parents with allergy 243 (49.2%) 43 (51.8%) 0.66
mother with asthma/allergy 174 (35.2%) 32 (37.6%) 0.66
father with asthma/allergy 150 (31.3%) 25 (29.8%) 0.78
Table 4.6: Regression coefficients* with 95% confidence intervals (CIs) for the
association between FEV1 decline and family history of asthma and other allergic
diseases, in asthmatic subjects stratified by the presence of airflow obstruction at
baseline.
Airflow obstruction at baseline
No Yes
(n=544) (n=94)
estimate (95% CI) estimate (95% CI)
(mL/year) (mL/year)
one/both parents with asthma 5.6 (–2.1; 13.3) –13.3 (–38.3; 11.6)
one/both parents with allergy –1.5 (–8.5; 5.5) –4.4 (–25.4; 16.6)
mother with asthma/allergy –2.1 (–9.3; 5.1) –2.2 (–24.3; 19.9)
father with asthma/allergy 3.3 (–4.3; 10.9) –12.5 (–36.0; 10.9)
* adjusted for sex, age, and height.
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Chapter 5
Discussion
5.1 Inhaled steroid use and lung function decline
In a large community-based sample of subjects with asthma from the general
population, followed up for 9 years, we have shown that a lower decline in FEV1
was associated with a prolonged use of inhaled steroids. This association was
only observed in those with elevated total IgE levels. There was a dose-response
relationship, with lower decline in those who had used inhaled steroids for the
longest periods. The association was found in men and in women, as well as in
smokers and in nonsmokers.
In the whole cohort, the average FEV1 decline was 11 mL/y lower in subjects
with asthma who reported that they had used ICSs for 4 years or more during
the follow-up, compared with nonusers. The current finding is in line both with
clinical trials80,81,120–122, and with 2 recent observational studies.85,86 Our estimate
of the prevented FEV1 decline that was potentially attributable to ICSs (11 mL/y;
95% CI, 0.1; 21) is somewhat smaller than that reported in the study by Lange
et al85 (18 mL/y). This may be a result of the relatively young age of our cohort.
In fact, the rate of lung function decline increases with age, as supported by our
results (Table 4.2) and as previously reported106,123; accordingly, one could expect
a greater benefit from ICSs in patients whose FEV1 is declining more steeply.
5.1.1 Interaction between total IgE and ICS use
An intriguing and original finding of our analysis was that a lower decline in lung
function in long-term steroid users was observed only in subjects with asthma
with elevated (>100 kU/L) total serum IgE levels, whereas subjects with low IgE
seemed to be less responsive. There was no correlation between lung function
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decline and total IgE in ICS users with elevated total IgE, supporting the idea
that the association between lower FEV1 decline and ICS use was an all-or-none
association.
High serum total IgE levels are strongly associated with asthma, indepen-
dently of specific allergic sensitization,124 with disease severity,125 and are a major
contributing factor for the development of bronchial hyperresponsiveness in both
allergic and nonallergic asthma.124 Elevated total serum IgE levels reflect the na-
ture of the underlying airway inflammation, and are associated with a higher
eosinophil count and higher eosinophil cationic protein (a marker of eosinophil
activation) in the blood.126 Recently, anti-IgE treatment has been shown to be
associated with significant and profound reductions in tissue eosinophils and in
mast cells, as well as T cells and B cells, suggesting that blocking IgE may inhibit
more chronic aspects of allergic inflammation.127,128 Furthermore, total serum IgE
is an independent predictor of immediate treatment response to ICSs,129 and a
decrease in total serum IgE is significantly correlated with an improvement in
asthma symptom scores.130
We speculate that the lower decline of lung function in long-term ICS users
with asthma is mainly a result of the effect of steroids on the eosinophils. These
cells produce cytokines, chemokines, lipid mediators, and growth factors, and can
also cause an increase in mucus production, resulting in subepithelial fibrosis and
in an alteration of airway smooth muscle contractility.22 Eosinophils are thought
to be key effector cells contributing to both airway inflammation and remodeling
in asthma.22 Steroids are able to inhibit the mediator release from eosinophils, to
decrease the eosinophil count by inducing apoptosis,131,132 and to attenuate the
levels of eosinophil progenitors in peripheral blood and, to some extent, in bone
marrow.22,131,133–135
Furthermore, in subjects having low IgE levels, inflammation could be pre-
dominantly neutrophilic,134 and it has been shown that neutrophils are not sen-
sitive to the effect of steroids. Indeed, systemic steroids increase peripheral neu-
trophil counts, a fact that may reflect an increased survival time because of an
inhibitory action on neutrophil apoptosis.136
5.1.2 Sex and smoking habits
In agreement with Lange et al,85 but not with Dijkstra et al,86 we found no evidence
that the association between ICS use and lung function decline was different in
men and in women.
The lack of association between smoking and lung function deterioration was
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somewhat surprising. One possible explanation could be the young age of our
cohort. Also, one could speculate that this finding could reflect the healthy smoker
effect (only subjects with asthma with relatively good lung function at baseline
smoke or start smoking, whereas subjects with more severe asthma refrain from
smoking).
Previous studies have found that smoking interferes with the long-term bene-
ficial effects of steroids.86,122,137,138 The lack of interaction between smoking habits
and ICS use found in our study probably reflects that the group of subjects se-
lected for our analysis does not allow a full appreciation of the effect of smoking
on lung function decline, and hence on its potential modification on the effect of
ICSs.
5.1.3 Potential limitations
In evaluating the association between the long-term use of ICSs and the av-
erage decline in FEV1, we adjusted for different characteristics of the subjects
(age, height, BMI, different hazardous exposures), as well as for variables related
to asthma (duration and familiarity) and its severity (previous hospitalizations
and/or emergency department visits, total IgE levels). Nevertheless, our results
may be affected by some bias, given that the allocation of subjects to ICS treatment
was not based on randomization but rather on indication. ICS users may differ
from nonusers in some aspects that have not been measured. For example, sub-
jects who get access to and regularly take prescribed medications may be more
likely to adopt generally healthier lifestyles (such as healthy diet and exercise).
High dietary intake of antioxidants has been associated with lung function,139 but
we have no information on this for our sample. On the other hand, one might
expect subjects with more severe disease to be prescribed more medication. At
baseline, the treated group had poorer lung function, higher rates of hospitaliza-
tion for respiratory diseases, and higher prevalence of family asthma than the
untreated group. Therefore, we might expect them to have a steeper decrease
in lung function than subjects who did not receive treatment (the horse-racing
effect).140,141 If this is true, we have underestimated the association between ICS
use and FEV1 decline.
A potential limitation of the current study is that a self-reported doctor di-
agnosis of asthma was used to identify individuals with asthma. Although this
definition may be open to some degree of misclassification, it has been proven to
be highly specific,142 so that only milder or undiagnosed asthmatics would not
have been included in our study.
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5.1.4 Points of strength
Compared with other recent longitudinal studies investigating the association be-
tween ICSs and lung function decline,85,86 our study has some points of strength.
First, the ECRHS sample was selected from the general population in an inter-
national setting. Second, in the current study, a cumulative time of ICS use was
estimated for each individual in the follow-up period. Finally, the individuals
who had used inhaled long-acting β2-agonists in the 12 hours before lung func-
tion testing were excluded, thus reducing the risk of a bias because of the residual
bronchodilating effect of these drugs.
5.1.5 Conclusion
In conclusion, the longitudinal analysis of the decline of lung function in a large,
international, population based sample of subjects with asthma supports the
hypothesis that the long-term use of ICSs might prevent the deterioration of lung
function in individuals having elevated levels of total serum IgE, whereas lung
function could be less influenced by steroids in subjects with lower levels of IgE.
This finding is not to be interpreted as an advise to prescribe ICSs only in
subjects with asthma and elevated IgE levels. In fact, we investigated only the
effect of a prolonged use of ICSs on lung function deterioration, whereas ICSs have
been clearly shown to have favorable effects on several short-term outcomes.
Moreover, a long-term use of ICSs has been demonstrated to reduce the risk
of both asthma-related death82 and hospitalization.143 Our findings underline
the importance of total IgE as a feature of asthma, not only because it helps to
predict its severity125 and prognosis, but also because it might influence decisions
on longterm anti-inflammatory treatment. Further investigations are needed to
clarify whether calibrating the corticosteroid dose according to the level of IgE is
a feasible approach in asthma management.
5.2 Other determinants of lung function decline
In the group of individuals without airflow obstruction at baseline, a faster FEV1
decline was observed in subjects whose BMI was intermediate than for lean and
obese subjects. FEV1 decline was associated with BMI gain independently of
baseline BMI, and this association was stronger in men than in women. In the
group of individuals with airflow obstruction at baseline, weight gain was not
associated with decline.
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The analyses were stratified by the presence of airflow obstruction at baseline
to account for the heterogeneity of asthma phenotypes.144 As a bronchodilator
challenge test was not part of the ECRHS core protocol, we used the follow-up
spirometry to confirm baseline airflow obstruction. The stratification by airflow
obstruction at baseline seems to be supported a posteriori by our findings, as
the role played by BMI and weight gain in FEV1 decline was different in the 2
groups. Furthermore, a joint (subjects with + subjects without airflow obstruction
at baseline) post-hoc analysis showed a significant interaction between BMI gain
and the presence of airflow obstruction (p=0.001).
Compared to subjects with airflow obstruction, subjects without airflow ob-
struction had a faster FEV1 decline and %FEV1/FVC decline during the follow-up.
This may be due to the fact that a steep decline had already occurred before the
first visit in subjects with airflow obstruction, as suggested by their lower baseline
FEV1.
5.2.1 Baseline BMI and lung function decline in subjects without
airflow obstruction at baseline
A high baseline BMI was associated with a lower baseline FEV1, but not with
a faster FEV1 decline during the follow-up. Several studies have reported that
obesity decreases lung volumes. In fact, the adipose tissue increases chest wall
loading.90,91,145,146 This would also explain the concomitant FVC decline observed
in the obese (BMI>30 kg/m2). However, no evident restrictive pattern (defined
by BMI≥30 kg/m2 and FEV1/FVC>0.70 and FVC<80% predicted)98 was found at
baseline in any of the subjects.
In the absence of a weight reduction, there is no evident reason why the lung
function decline in obese subjects should be blunted with respect to non obese
subjects. However, asthma in the obese may be different from asthma in normal
weight subjects. Obesity causes lower than normal functional residual capacity,
with the consequence of unloading the airway smooth muscle and allowing it
to shorten excessively when activated,91,92 and a decrease in operational lung
volume.147 Moreover, breathing at lower tidal volumes inhibits the bronchodilat-
ing effect of tidal strain on the airway smooth muscle.91,93 These mechanical and
functional changes within the respiratory system may explain the observed link
between obesity and bronchial asthma.148 Our data support the hypothesis that
asthma in the obese is less determined by inflammation than in the non-obese,
in agreement with the reversible nature of lung function decline observed with
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weight loss.149 This hypothesis, if true, could lead to the implication that, in obese
subjects with uncontrolled asthma, weight loss should be primarily targeted, and
that it may be worth assessing the level of bronchial inflammation before increas-
ing inhaled steroid doses. However, the faster FEV1 decline seen in the non-obese
compared to the obese could be due to the fact that obese subjects had a lower
baseline FEV1, and that the process of decline may no longer be progressive after
the FEV1 had previously dropped to a considerable extent.
As subjects included and excluded from our analyses had a similar BMI, a
selection bias in the obese subgroup, i.e. a lower participation rate among obese
people with poor lung function, is not likely. Obese subjects tend to report doctor-
diagnosed asthma, as well as asthma-like symptoms and use of bronchodilators,
more frequently than non-obese subjects, even if they do not have an objec-
tive impairment of lung function.150 In view of our epidemiological definition of
asthma, one could hypothesize that asthma has been over-diagnosed in the obese
subgroup. However, for subjects with BMI<20, 20-24.9, 25-30 and >30 kg/m2, the
prevalences of family asthma were 15%, 26%, 29%, and 35% (p=0.11), respectively.
Thus, the above explanation seems unconvincing.
5.2.2 BMI gain and lung function decline in subjects without
airflow obstruction at baseline
In asthmatic subjects without airflow obstruction, we found that BMI gain during
the follow-up was associated with FEV1 decline, and this association was stronger
in men than in women. In men FEV1 dropped by 20 (95% CI: 10; 30) mL/year
for every kg gained during the follow-up, while in women FEV1 decreased by
7 (95% CI: 2; 11) mL/year for every kg gained. This might be explained by the
fact that men who gain weight tend to accumulate abdominal and visceral fat,
while women who gain weight tend to accumulate peripheral fat.151 Chinn et al89
found that the FEV1 decline in the general population of the ECRHS was about
40% lower than the decline we found in the asthmatic subjects. Therefore, one
could speculate that the negative effect of weight gain on lung function is greater
in subjects with asthma than in people from the general population.
The observed association between BMI gain and FEV1 decline was indepen-
dent of baseline BMI. This is also confirmed when we consider the group of
subjects who were obese at baseline (n=42). Among them, 31 individuals gained
weight during the follow-up (median BMI gain, [range]: 0.5, [0.04; 3.0] kg/m2) and
11 individuals decreased their weight (–0.2, [–2.2; –0.05] kg/m2). FEV1 decline was
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faster in the obese subjects who gained weight (median, IQR: 26, 48 mL/year) than
in the obese subjects who decreased their weight (median, IQR: 5, 72 mL/year)
(p=0.13).
5.2.3 Educational level and lung function decline in subjects
without airflow obstruction at baseline
In the non-asthmatic population, a low socio-economic level is almost universally
associated with worse health outcomes, including lung function.152 In our data,
asthmatic subjects without airflow obstruction who had a high educational level
had a faster FEV1 decline than those with a lower educational level. However, the
latter had a low FEV1 already at baseline (median FEV1: 3.1 vs 3.5 L). It is possible
that a low educational level was associated with an early drop of FEV1 and that,
subsequently, the process of FEV1 decline was no longer progressive.
5.2.4 Active smoking, passive smoking and lung function de-
cline in subjects with/without airflow obstruction at base-
line
Many,19,96,97 but not all,99 studies have found that asthmatic smokers have a steeper
decline in lung function than asthmatic non-smokers. Several factors could ex-
plain the lack of an association that was observed in our study. Firstly, our subjects
were relatively young, and the detrimental effect of smoking could be greater at
older ages.96 Secondly, the exposure to active smoking of our cohort was relatively
low. In the Copenhagen City Heart Study, about 70% of the asthmatic subjects
were smokers,19 and they had been exposed to smoking for more than 30 years
on average.153 In our study, only 30% were current smokers, and the exposure to
active smoking tended to diminish significantly during the follow-up.154 Finally,
our finding could reflect the healthy smoker effect.
Passive smoking was found to be associated with lung function in several
studies.102,103 However, passive smoking was not related to FEV1 decline in our
cohort.
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5.2.5 Determinants of lung function decline in subjects with air-
flow obstruction at baseline
Among asthmatic subjects with airflow obstruction at baseline, those who were
not sensitized to allergens had on average 29 mL/year more decline than those
who were sensitized to allergens. This is in line with the finding that the rate
of lung function decline is greater in subjects with intrinsic asthma than in those
with extrinsic asthma,99 and with the observation that inhaled steroids may be
more effective in contrasting FEV1 decline in asthmatic subjects with high levels
of total IgE than in those with lower total IgE (see Section 4.1).
A 1-unit decrease in baseline BMI was associated with a 5 mL/year decrease
in FEV1 during the follow-up. In this group of subjects with airflow obstruction
at baseline, leanness itself may be a marker of an early form of COPD.155 No
association was found between FEV1 decline and BMI gain, probably because
mechanisms that are typical of milder asthma (including the effect of weight gain)
could be less important in severe asthma, while a serious long-lasting inflamma-
tion may play a crucial role. Moreover, subjects with airflow obstruction gained
on average less weight than those without.
5.2.6 Conclusion
In European asthmatic subjects without airflow obstruction at baseline, individu-
als with a high BMI had the lowest FEV1 at baseline. Weight gain was positively
associated with FEV1 decline, independently of baseline BMI, and this associa-
tion was stronger in men than in women. The detrimental effect of BMI gain on
lung function might be greater for subjects with asthma than for subjects without
asthma, but studies are needed to clarify this. Among asthmatic subjects with
airflow obstruction at baseline, lean subjects without sensitization to allergens
had the greatest FEV1 decline, while weight gain was not associated with FEV1
decline.
5.3 Family history of allergic diseases and lung func-
tion decline
A family history of asthma is known to be a strong risk factor for asthma.25 Some
studies also found that a family history of atopic diseases other than asthma is a
predictor of asthma risk, but results are inconsistent.25
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The increased risk of developing asthma found in children whose parents have
asthma may be due to the fact that they share some susceptibility genes for the
disease. However, family history is also a proxy of a shared environment. In fact,
one would expect that many of the environmental exposures experienced during
childhood, and of potential importance for the occurrence of asthma, are shared by
siblings who grow up in the same family environment. Such exposures include,
for example, air pollution, number of siblings, parental smoking, mites, domestic
pets, indoor air exposures, and factors associated with parental socio-economic
status. However, the genetic resemblance of children to their parents seems to be
the more likely explanation for the increased risk of asthma. In fact, studies on
twins have shown that asthma risk to co-twins of affected twins is significantly
greater for monozygotic than for dizygotic pairs.156
In our study, there was no association between a family history of asthma or
other allergic diseases and lung function decline, neither in subjects with nor in
subjects without baseline airflow obstruction. To our knowledge, no studies have
investigated the association between a family history of asthma or allergy and
lung function decline. The most obvious reason for the lack of an association
is that parental asthma or allergy are not involved in the course of the disease.
The genes implied in asthma susceptibility may be different from those implied
in lung function decline. As an example, it is known that SNPs on the ADAM33
gene are also involved in accelerated lung function decline in the non-asthmatic
population.64 It may be argued that family asthma is too rough an indicator of
asthma susceptibility in our population. However, this explanation seems to
be unlikely, as the same indicator was confirmed to be a risk factor for asthma
incidence in the general population of the ECRHS.157
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LUNG FUNCTION PROTOCOL, DATA SHEETS AND QUESTIONNAIRE 
LUNG FUNCTION TESTS 
 
CRITERIA FOR TESTING 
 
Criteria for baseline spirometry  
 
The purpose of baseline spirometry is to record an accurate Forced Expiratory Volume in one second (FEV1) and 
Forced Vital Capacity (FVC) from every subject who attends the testing centre.  
 
ACCEPTANCE CRITERIA: 
 
Any subject who is able to attend the testing centre.  
 
EXCLUSION CRITERIA:  
 
If the subject smokes: Lung function testing should be carried out at least one hour after the last cigarette has been 
smoked.  
 
If the subject has used an inhaler: Lung function testing should be carried out at least one hour after the use of any 
inhaler.  
 
If the subject has used an inhaler that is not a beta-2-agonist or an anticholinergic inhaler in the last one to four 
hours: Lung function testing is carried out and the data recorded.  
 
If the subject has used an inhaler that is a long acting Beta-2-agonist in the last 8 hours: If the subject is willing to 
come back at another time when they have not taken their lay acting Beta-2-agonist, another appointment should be 
made. HOWEVER – this may be difficult for them to do, in which case, testing should proceed and medication used 
should be recorded. 
 
If the subject has used an inhaler that is a beta-2-agonist or an anticholinergic inhaler in the last one to four hours: 
If the subject is willing to come back another time for lung function testing, another appointment should be made. If 
the subject is unable or reluctant to return another time, testing should proceed and the medication used should be 
recorded.  
 
If the subject has taken an oral beta-2-agonist or an oral theophylline or an oral antimuscarinic within the last eight 
hours: If the subject is willing to come back another time for lung function testing, another appointment should be 
made. If the subject is unable or reluctant to return another time, testing should proceed and the medication used 
recorded.  
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If the subject has had a respiratory tract infection in the last three weeks: Another appointment should be made 
unless the subject is unwilling to come back, in which case testing should continue. The number of days elapsed 
since the end of the respiratory infection should be recorded.  
 
If, after a total of nine attempts, a subject is unable to produce a  technically satisfactory manoeuvre, no FEV1 or 
FVC will be recorded.  
 
 
Predicted FEV1 values  
 
Normal FEV1 values will be calculated using the following equations:  
 
Males:  4.30 H - 0.029 A - 2.49 
Females:  3.95 H - 0.025 A - 2.60  
 
where  
H = height in metres 
A = age in years (range 25-44). 
 
These equations are only valid for subjects over the age of 25. Subjects aged 20-24 should have their expected FEV1 
calculated as if their age is 25.  
 
 
Criteria for methacholine challenge  
 
The aim of methacholine challenge is for subjects to inhale increasing concentrations of methacholine solutions and 
to monitor any change in FEV1 by repeated spirometric testing.  
 
ACCEPTANCE CRITERIA: Any subject who fulfils all three of the following criteria is accepted:  
 
1)  has been able to perform at least 2 technically satisfactory manoeuvres during baseline spirometry  
2)  has signed a consent form for methacholine challenge, 
3)  is not in the categories for exclusion (see below).  
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EXCLUSION CRITERIA: Any subject who fulfils any one of the following criteria is excluded from methacholine 
challenge:  
 
1)  has had a heart attack in the last three months, 
2)  has any heart disease for which he/she is taking medication, 
3)  has epilepsy for which he/she is taking medication,  
4)  is pregnant, 
5)  is breast feeding,  
6)  is taking a beta-blocker for any reason (including eye drops). 
 
These criteria will be assessed by the Lung Function Questionnaire.  
 
In addition, any subject who fulfils either of the following is excluded:  
 
7)  has an FEV1 less than 70% of the  predicted value,  
8)  has an FEV1 less than 1.5 litres.  
FEV1 is the maximum assessed during the baseline spirometry.  
 
 
Criteria for bronchodilator challenge  
 
The FEV1 and FVC will be measured following the administration of  400ug salbutamol by metered dose inhaler 
(MDI) via a Volumatic spacer.  
 
ACCEPTANCE CRITERIA: Any subject who fulfils all of the following criteria is accepted: 
 
1)  has produced technically satisfactory FEV1 and FVC manoeuvres,  
2)  refuses to undergo or is excluded from methacholine challenge,  
3)  has signed a consent form for bronchodilator challenge,  
4)  is not excluded by the following exclusion criteria.  
 
EXCLUSION CRITERIA: Any subject who fulfils any one of the following criteria is excluded:  
 
1)  has had a heart attack in the last three months, 
2)  has any heart disease for which he/she is taking medication,  
3)  has epilepsy for which he/she is taking medication, 
4)  is pregnant,  
5)  is breast feeding,  
6)  is taking a beta-blocker for any reason (including eye drops).  
 
These conditions will be assessed by the Lung Function Questionnaire.  
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Making the appointment for testing 
 
Ideally, lung function testing should be performed:  
 
1)  more than four hours after the use of a beta-2-agonist or anticholinergic inhaler, 
2)  more than eight hours after inhaled long acting beta-2-agonist, oral beta-2-agonist or theophylline or oral 
antimuscarinic.  
 
When the appointment for lung function testing is made the fieldworker should determine if the subject is taking any 
of the following medications:  
 
1)  beta-2-agonist inhaler (short or long acting), 
2)  anticholinergic inhaler, 
3)  oral beta-2-agonist,  
4)  oral theophylline, 
5)  oral antimuscarinic.  
 
If the subject is taking any of these medications (or any other inhaler) an appointment time should be agreed that will 
cause the least disruption to the subject's normal dosing schedule.  
 
One simple way of ensuring compliance with these instructions is to:  
 
1)  avoid early morning appointments for those using inhalers,  
 
2)  fix a time for an appointment and then ask the subject to take their inhalers four hours before and oral medication 
eight hours before testing. Ask them to avoid taking their long acting beta-2-agonist if possible. 
 
The fieldworker should ensure that the subject has not had a respiratory tract infection in the three weeks prior to 
testing and should advise the subject not to smoke for one hour prior to coming to the testing centre. A letter should 
be sent to the subject explaining this.  
 
Subjects who have not followed guidelines  
 
Those who have had a cigarette in the last hour should have the lung function test delayed until one hour has elapsed. 
(Most subjects will be in the centre for at least one hour.)  
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Those who have had an inhaler in the last four hours or oral medication (or long acting beta-2-agonist) in the last 
eight hours may fall into one or more of the following categories:  
 
1)  misunderstood the instructions, 
2)  forgot the instructions,  
3)  ignored the instructions,  
4)  may have symptoms too severe to follow the instructions.  
 
Lung function testing may still be carried out unless the subject is excluded for other reasons, and recent medication 
should be noted in the Lung Function Questionnaire. 
 
THE FORCED EXPIRATORY MANOEUVRE 
 
General guidelines 
 
All forced expiratory manoeuvres will be performed:  
 
1)  sitting, legs uncrossed 
2)  with noseclip on,  
3)  using a plastic or cardboard mouthpiece without teethgrips, 
4)  tight clothing should be loosened.  
 
Two types of forced expiratory manoeuvre will be used in this protocol:  
 
1) During baseline spirometry and bronchodilator challenge FVC will be measured and all subjects must exhale 
fully.  
 
2) During methacholine challenge only the FEV1 needs to be recorded and the technician may interrupt the 
exhalation when this has been achieved.  
 
A technically unsatisfactory manoeuvre (FEV1 or FVC) is defined as:  
 
1) an unsatisfactory start of expiration characterised by excessive hesitation of false start 
2) coughing during the first second of the manoeuvre, thereby affecting the measured FEV1 value, or any cough 
that interferes with the accurate measurement of FVC 
3) Valsalva Manoeuvre (glottis closure) 
4) A leak in the system or around the mouthpiece 
5) An obstructed mouthpiece , e.g. the tongue in front of the mouthpiece. 
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Manoeuvres which have these faults are technically unsatisfactory and are rejected as failed attempts.  
 
Evidence of poor compliance is shown by:  
 
1) greater than 200ml (NB in ERCHS I this was 5%, this has been changed in line with current ATS criteria) 
variation in FEV1 between blows 
2) greater than 150 mL or 5% FVC back-extrapolated volume 
3) peak expiratory flow that is less than 85% of the best record 
4) expiratory time that is less than six seconds 
 
 
If these features are noted technicians should encourage the subject to produce a better reading but the blows should 
not be excluded as failed attempts on these criteria alone.  
 
A manoeuvre may only be rejected as a failed attempt if it is 'technically unsatisfactory'. Manoeuvres with evidence 
of 'poor compliance' only should not be rejected.  
 
The above protocol is consistent with current ATS guidelines (Am J Respir Crit Care Med 1995;152:1107-1136). These 
state that ‘The only criterion for unacceptable performance is fewer than two acceptable curves. No spirogram should 
be rejected solely on the basis of its poor reproducibility……elimination of data from subjects who fail to meet ATS 
reproducibility criteria may result in population bias by excluding subjects who have abnormal lung function’ 
 
Instructions to subjects 
 
Some of the subjects will never have used any form of lung function testing equipment before and others will be very 
familiar with it.  
 
Technicians should explain to the subject that the aim of the test is to find out how much air can be blown out of the 
lungs and how forcefully it can be blown out.  
 
This can be done by asking the subject to follow these steps:  
 
1) Take in as deep breath as possible when full- 
2) Place the mouthpiece in his/her mouth. 
3) Close his/her lips tightly around the mouthpiece. 
4) Blast or blow through the mouthpiece into the spirometer, blowing air out as hard, fast, smoothly and 
completely as possible. 
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The subject should continue to push out air actively for as long as possible (FVC manoeuvre) or until the technician 
tells him/her to stop (FEV1 manoeuvre). During this time the technician must offer positive encouragement to push 
or squeeze out more air.  
 
 
Baseline spirometry  
 
1) Ensure that it is appropriate to perform lung function testing. 
 
2) Demonstrate the manoeuvre to all subjects at least once (more often if he/she appears uncertain). 
 
3) Ask the subject to carry out five FVC manoeuvres. 
 
4) Record the FEV1 and FVC and Peak Expiratory Flow (in litres per second) from at least two and up to five 
technically satisfactory manoeuvres. 
 
5) If the subject has failed to produce two technically satisfactory manoeuvres after five attempts, the technician 
should show them again how to conduct the manoeuvre and allow them four more attempts. 
 
6) Any subject who is unable to produce two technically satisfactory manoeuvres after nine attempts should not be 
tested further and no FEV1 / FVC data should be recorded. 
 
7) The number of rejected attempts should be recorded as appropriate on the Lung Function Data Collection Sheet. 
 
Methacholine challenge  
 
During methacholine challenge the subject may need to perform 30 or more expiratory manoeuvres and, to minimise 
exhaustion, the forced expiration will be abandoned each time after one second when the FEV1 has been recorded.  
1) Two minutes after inhalation from the dosimeter up to five attempts should be made to record an FEV1 
2) As soon as two technically satisfactory manoeuvres have been achieved these readings are recorded. The next 
dose can be given as soon as possible after the completion of these measurements. 
3) Further testing should be abandoned if the subject is unable to produce to technically satisfactory manoeuvres 
within five attempts. 
 
If a reversal of bronchoconstriction needs to be carried out then the procedure is the same as the bronchodilator 
challenge.  
 
 
Bronchodilator challenge 
 7
LUNG FUNCTION PROTOCOL, DATA SHEETS AND QUESTIONNAIRE 
 
A bronchodilator challenge will be given to those who do not undergo methacholine challenge. Any subject who has 
more than a 10% fall in FEV1 from baseline during the methacholine challenge test should have their 
bronchoconstriction reversed at the end of the test and before leaving the test centre, by the same method.  
 
The salbutamol inhaler should be shaken and inserted into the volumatic. One puff should be activated and the 
subject asked to place their lips around the volumatic and to inhale and exhale five times. The salbutamol inhaler 
should be activated again and five inhalations/exhalations performed. This should be repeated two more times so that 
a total of 400ug of salbutamol has been delivered. Subjects who are known asthmatics and familiar with Volumatic 
usage can self-administer this dose.  
 
The FEV1 and FVC are measured 10 minutes after the administration of bronchodilator. During the bronchodilator 
challenge FVC manoeuvres will be used. Up to nine attempts may be made to obtain two technically satisfactory 
recordings after the inhalation of bronchodilator.  
 
THE METHACHOLINE SOLUTIONS 
 
Source and supply 
Methacholine (Provocholine) will be obtained from Methapharm. 
 
The Diluent 
 
Saline buffered with phosphate to obtain physiological pH can be used as a diluent. Phenol  must  not be used as a 
preservative because of concerns regarding its safety. Citric acid/citrate buffer must not be used. Preservatives should 
be avoided. 
 
Session number and order in session  
 
Each time the nebulisers are filled with fresh methacholine solution a new session of testing is said to have started. 
Each session should be sequentially numbered. Each challenge within each testing session should also be 
sequentially numbered and recorded on the Lung Function Data Collection Sheet.  
 
At the beginning of a session all nebulisers contain 3 mL methacholine. Six subjects are tested and their order in 
session is 1-6. After the 6th person has been tested the 12.5 mg/mL solution is discarded, the nebuliser is cleaned and 
dried, and 3 mL of fresh 12.5 mg/mL solution is added. Six more subjects are tested and they are numbered 7-12. 
After the 12th person has been tested all solutions are discarded and the nebulisers are cleaned. The next session 
begins when new solutions are added. A session may be extended over one night only by placing the nebulisers 
containing solutions upright in the fridge, covered with parafilm.   
THE MEFAR MB3 DOSIMETER 
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Quality control of Mefar dosimeter nebuliser output 
 
The methacholine challenge protocol has been written assuming that each single inhalation delivers approximately 
0.01 mL solution to the mouth.  
 
All Mefar nebulisers in the study will be calibrated in Melbourne prior to use in the study.  
 
Pressure control Mefar 
The driving pressure of the Mefar dosimeter should be checked before the study starts and every four weeks 
thereafter. The method for checking and adjusting the driving pressure is available at: 
‘http://www.med.monash.edu.au/medicine/alfred/research/respiratory_medicine/newpage.htm.’ 
 
Pressure control forms should be returned to the co-ordinating centre at completion of the study. 
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Pressure Control Check Form 
                                                         Centre Name:    
                                                            
     Centre Number:       
 
Date Peak Pressure  
1 
Peak Pressure 
2 
Peak Pressure
 3 
Peak Pressure
 4 
Peak Pressure 
 5 
Mean Action taken 
none/adjusted
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Each nebuliser should be colour coded for the solution it will contain as follows:  
 
1) BLACK  12.5mg/mL 
2) RED  6.25mg/mL 
3) YELLOW 1.56mg/mL 
4) BLUE  0.39mg/mL 
5) WHITE  Diluent 
 
Setting up the Mefar dosimeter  
 
3 mL of methacholine solution should be placed in the appropriate nebuliser. A dry sterile mouthpiece should be 
connected for each new subject.  
 
The Mefar should be set at:  
 
1) inhalation time: 1 second 
2) pause time: 6 seconds 
 
The standard inhalation  
 
The sequence of inhalation is:  
 
1) Slow expiration to functional residual capacity. 
2) Place lips around mouthpiece to produce airtight seal. 
3) Slow inspiration to total lung capacity. 
4) Hold breath for at least three seconds. 
5) Remove mouthpiece and exhale. 
 
The procedure is repeated after six seconds until sufficient inhalations for the dose have been performed. Inhalations 
may be performed on consecutive breaths if desired. Spirometric testing is carried out two minutes after the dose. As 
soon as two FEV1 manoeuvres have been recorded, the test is continued with the next dose.  
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The end of the testing session  
 
Solutions remaining in the nebulisers must be discarded and under no circumstances should they be returned to the 
storage containers. All nebulisers must be cleaned and dried. All mouthpieces must be cleaned, sterilised and 
thoroughly rinsed to ensure that there is no sterilising solution left on the surface.  
 
 
THE METHACHOLINE PROTOCOL 
 
Instructions for baseline spirometry  
 
Perform full FVC manoeuvres as described previously for 'Baseline spirometry' (The forced expiratory manoeuvre). 
Record INITIAL FEV1 and FVC. Calculate the BEST INITIAL FEV1 as a percentage of the total predicted.  
 
 
Measurement of control (post-diluent) FEV1  
 
The control FEV1 is the FEV1 measured following the inhalation of diluent. Four inhalations of diluent (WHITE 
nebuliser) are given, as described in 'The standard inhalation'.  
 
Perform FEV1 manoeuvres as described in 'Methacholine challenge' (The forced expiratory manoeuvre). Record 
CONTROL (POST-DILUENT) FEV1. Calculate BEST CONTROL FEV1 as a percentage of the BEST INITIAL 
FEV1.  
 
If the BEST CONTROL FEV1 is less than 90% of the BEST INITIAL FEV1 methacholine challenge is not carried 
out. Bronchoconstriction should be reversed by administering 400 µg salbutamol by MDI via a Volumatic and full 
FVC manoeuvres should be repeated.  
 
If the BEST CONTROL FEV1 is within 10% of the best initial FEV1. Calculate 80% of the BEST CONTROL FEV1. 
Calculate 90% of the BEST CONTROL FEV1. Methacholine challenge may now be conducted following either the 
short or long protocol.  
 
Dosing Schedule 
 
In ECRHS I centres were able to decide whether to use one of two dosing schedules for methacholine challenge. In 
ECRHS II only one method shall be used (Method 2 from ECRHS I protocol). 
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Choice of long or short protocol  
 
Each subject can be challenged on the short or long protocol. The long protocol will increase by doubling doses and 
the short by quadrupling doses. Subjects most likely to react to methacholine should be tested on the long protocol. 
Subjects who are unexpectedly reactive and have been allocated to the short protocol may switch to the long protocol 
during the challenge to avoid severe bronchoconstriction. The choice of protocol for each subject will be assessed by 
the Main Questionnaire. The questions to be used to direct subjects to the long protocol may be decided locally, but 
the following are recommended:  
 
Subjects who answered 'YES' to any one of Questions 1, 2, 3, 5, 11 or 14 in the Main Questionnaire, that is any 
subject who has:  
 
1) had wheezing or whistling in their chest in the last 12 months (Q1) 
2) woken with tightness of chest in the last 12 months (Q2) 
3) had an attack of shortness of breath during the day while at rest in the last 12 months (Q3) 
4) been woken by an attack of shortness of breath in the last 12 months (Q4) 
5) trouble with their breathing (Q11) 
6) ever had asthma (Q14) 
 
 
Methacholine challenge protocol  
 
  
CONC 
(mg/mL) 
No of inhalations: 
LONG       SHORT 
CUMULATIVE 
DOSE (mg) 
DOSE LEVEL  
(As per ECRHS I) 
0.39 
0.39 
2 
2 
 
4 
0.0078 
0.0156 
3 
4 
1.56 
1.56 
1 
2 
 
3 
0.0312 
0.0625 
5 
6 
6.25 
6.25 
1 
2 
 
3 
0.125 
0.25 
7 
8 
12.5 
12.5 
2 
4 
 
6 
0.5 
1.0 
9 
10 
12.5 8 8 2.0 11 
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Changing from Long to Short protocol 
 
If, during the short protocol, the FEV1 falls 10% or more from the best control FEV1, the subject should change 
protocol and receive the next dose level on the long protocol.  
 
For example: A subject following the short protocol shows a fall of 10% after Dose 4 (four inhalations of  
0.39 mg/mL). They should inhale Dose 5  (one inhalation of 1.56 mg/mL) next.  
 
 
Short protocol:  
 
Change to long protocol if FEV1 falls below 90% of the BEST CONTROL FEV1. Go to next dose level on long 
protocol.  
 
STOP challenge if FEV1 falls below 80% of the BEST CONTROL FEV1  
 
Long protocol:  
 
STOP challenge if FEV1 falls below 80% of the BEST CONTROL FEV1  
 
Completion of test  
 
The methacholine challenge is complete when a cumulative dose 2 mg of methacholine has been reached.  
 
It is stopped sooner if:  
 
1)  there is greater than 10% fall in FEV1 from the BEST BASELINE FEV1 following inhalation of diluent, 
 
2)  there is greater than 20% fall in FEV1 from the BEST CONTROL FEV1 following inhalation of any 
concentration of methacholine solution, 
 
3)  the subject is not able to perform two technically satisfactory manoeuvres in five attempts following any dose 
level, 
 
4)  the subject does not wish to carry on. 
 
Subjects may complain of mild chest tightness, coughing or wheezing but if lung function does not demonstrate a 
20% fall in FEV1 this is not an indication to stop the test.  
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Reversal of bronchoconstriction  
 
Four hundred micrograms of salbutamol will be given via a volumatic (see above for bronchodilator challenge) 
Perform full FVC manoeuvres as described in 'Methacholine challenge' 10 minutes after administration.  
 
Record the POST-BRONCHODILATOR FEV1 and FVC. 
 
Calculate the BEST POST-BRONCHODILATOR FEV1 as a PERCENTAGE of the BEST INITIAL FEV1.  
 
If the best post-bronchodilator FEV1 is more than 90% of the best initial FEV1 the test is over.  
 
EACH CENTRE SHOULD PREPARE PROTOCOLS TO BE FOLLOWED IN THE EVENT OF A SUBJECT NOT 
RETURNING TO WITHIN 10% OF THE BASELINE.  
 
 
BRONCHODILATOR CHALLENGE PROTOCOL 
 
Four hundred micrograms of salbutamol are administered by MDI as described in 'Bronchodilator challenge'. 
Perform full FVC manoeuvres as described in 'Baseline spirometry'. Record the POST-BRONCHODILATOR FEV1 
AND FVC.  
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Area Number    
Personal Number      
Sample  
Date         
          DAY           MONTH       YEAR 
    
BEFORE STARTING THIS QUESTIONNAIRE PLEASE ASK THE FOLLOWING 
QUESTIONS 
 
                   YES    NO 
Have you had a cigarette in the last hour?   
                                                                                                                                                      YES     NO
Have you used an inhaler (puffer) in the last hour?   
 
IF ‘YES’ DELAY LUNG FUNCTION TESTS UNTIL ONE HOUR AFTER THE LAST 
CIGARETTE OR INHALER USE (RESPONSES DO NOT HAVE TO BE INCLUDED IN 
DATA RECORDER) 
 
 
                                    NUMBER 
  1.     How many times have you been woken at night with shortness of breath in the 
        last two weeks?  
 
2.     During the last two weeks, has your breathing been                                                  TICK ONE 
                                                                                                                                                                           BOX ONLY
(a) worse than usual?  1  
(b) same as usual? 2  
(c) better than usual? 3  
 
                   NO     YES 
3.    Have you had wheezing or whistling in your chest in the last 3 days?   
   
4.     Have you woken up with a feeling of tightness in your chest    
in the last 3 days? 
 
  
5.     Have you been woken by an attack of shortness of breath in the last 3 days?   
   
6.     Have you been woken by an attack of coughing in the last 3 days?   
   
7.     Have you had an attack of asthma in the last 3 days?   
 
8.     Have you taken any medicine (including inhalers, aerosols or tablets)   
 For asthma in the last 3 days? 
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            NO         YES 
9.  Have you had any symptoms of hay fever or nasal allergy in the last 3 days?    
10. have you had a respiratory infection in the last 3 weeks?    
 
IF ‘NO’ GO TO QUESTION 11 
 
IF ‘YES’ AND THE SUBJECT IS WILLING TO COME BACK, STOP AND MAKE A 
NEW APPOINTMENT. IF NOT, PROCEDE WITH QUESTION 10.1 
 
                      DAYS 
10.1  How many days ago did it end?   
                  
                     NO   YES 
11.    Have you used an inhaler in the last 24 hours?   
            
IF ‘NO’ GO TO QUESTION 12, IF ‘YES’ - :        
 
11.1 What inhaler(s) did you use and for how many hours did you use it? 
              
            DRUG            HOURS 
       
       
       
 
       
 
 
IF THE SUBJECT HAS USED A BETA-2-AGOINST INHALER OR AN ANTI-
MUSCARINIC INHALER IN THE LAST FOUR HOURS, CONSIDER: - 
a) WAITING UNTIL FOUR HOURS SINCE LAST USE HAS ELASPED 
b) RESCHEDULING FOR ANOTHER DAY IF THE SUBJECT IS WILLING, IF 
NEITHER OF THESE IS POSSIBLE, PROCEED.     
  
 
12.    Have you used any other medicine (including pills, capsules or NO       YES
           suppositories) to help your breathing, or any oral anti-muscarinic     
           in the last 24 hours? 
IF ‘NO’ GO TO QUESTION 13, IF YES: -  
 
12.1  What medicine(s) did you take and how many hours ago did you take it?   
                                     DRUG             HOURS  
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IF THE SUBJECT HAS TAKEN AN ORAL BETA-2-AGOINST, AN ORAL 
THEOPHYLLINE OR AN ORAL ANTI-MUSCARINIC, CONSIDER 
RESCHEDULING FOR ANOTHER DAY IF THE SUBJECT IS WILLING, IF 
THIS IS NOT POSSIBLE, PROCEED.  
 
 
                 NO       YES 
13.    Have you had a heart attack in the last three months?     
    
14.    Are you currently taking any medicine(s) for your heart?    
    
15.    Are you currently taking any medicines for epilepsy?     
    
16.    Are you currently taking any medicine containing beta-blockers,    
         including eye-drops?    
 
IF ‘YES’ TO ANY QUESTIONS 13-16 MEASURE BASELINE SPIROMETRY ONLY, DO 
NOT CHALLENGE. 
 
For women only: 
                  NO       YES  
17.    Are you pregnant?    
   
18.    Are you breast feeding?    
 
IF ‘YES’ TO QUESTIONS 17 OR 18 MEASURE BASELINE SPIROMETRY ONLY, DO 
NOT CHALLENGE. 
 
For all subjects: 
                NO         YES 
19.    Would you like us to notify your GP of the results of any test?    
 
END 
 
FIELDWORKER NUMBER  
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Coding for lung function questionnaire 
 
The same general rules apply as for the main questionnaire. 
 
Questions with NO / YES 
1 NO 
2 YES 
 
Questions with ‘TICK ONE BOX ONLY’ instruction: 
The number of the box ticked is the code for that answer. 
 
QUESTION 11.1     Inhalers in the last 24 hours  
Drug grouping should be consistent with those used for main questionnaire. 
1 Beta-2-agoinst (short acting) 
2 Beta-2-agoinst (long acting) 
3 Non-specific adrenoreceptor agonists  
4 Anticholinergic inhalers 
5 Inhaled steroids 
6 Sodium cromoglycate 
7 Nedocromil 
8 Compound bronchodilators 
 
98 Not coded 
99 Not known 
 
QUESTION 12.1     Oral medications 
Drug grouping should be consistent with those used for main questionnaire. 
1 Beta-2-agoinst 
2 Non-specific adrenorecptor agonist 
3 Oral anticholinergics/antimuscarinics 
4 Oral methylxanthines 
5 Oral steriods 
6 Oral antihistamines 
7 Oral compound bronchodilators 
8 Oral-antileukotrienes 
 
98 not coded 
99 not known 
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Area Number    
Personal Number      
Sample  
Date         
                                                                                               DAY             MONTH          YEAR 
  
  
  
               DAY         MONTH      YEAR 
 
    
              METRES 
     1.     Subject’s Height                                                                                    METRES 
             
2.     Subject’s Weight                                                                           KILOGRAMS    
 
3.     Subject’s Age                                                                                         AGE   
                                                                                                                                               Male   Female
4.     Subjects sex    
 
                                                                                                                                  HOURS    MINUTES  
5.     Time of Day            ‘24 hrs’   ?   
  
6.   PREDICTED FEV1  ?   
Each subject now has five attempts to produce a technically satisfactory manoeuvre. If after 
five attempts there have not produced at least two manoeuvres – four more attempts are allowed     
MAXIMUM NUMBER OF ATTEMPTS ALLOWED IS NINE ATTEMPTS 
 
7.    INITITAL FEV1 and FVC  
   
 FFEV1                   FVC         PEFR (L/s) 
1             ?  
2             ?  
3            ?  
4          
 
  ?  
5             ?  
 
    
    
7.1  Number of rejected attempts  
 
8.    Best INITIAL FEV1 as % of predicted FEV1    
 
 
IF BEST INITITAL FEV1 IS a) less than 70% PREDICTED or 
  b) less than 1.5 LITRES 
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GO TO BRONCHODILATOR CHALLENGE – DO NOT DO METHACHOLINE 
CHALLENGE 
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METHACHOLINE CHALLENGE 
Give four inhalations of diluent. Two minutes later record FEV1 
 
9.   CONTROL FEV1 following inhalation of diluent. 
 
 
 
9.1  Record two technically satisfactory manoeuvres                                          1  ?   
                                                                                                                              2  ?   
     
9.2  Number of rejected attempts     
 
 
    
 
10.   BEST CONTROL (post-diluent) FEV1 as % of INITIAL FEV1                %    
 
IF BEST CONTROL FEV1 <90% OF BEST INITIAL FEV1 
 STOP METHACHOLINE CHALLENGE AND GO TO REVERSAL OF 
BRONCHOCONSTRICTION  
 
Choice of methacholine long or short protocol 
     NO         YES 
  
   DID THE SUJECT ANSWER ‘YES’ TO QUESTIONS 1,2,3,5,11 or 14 
OF THE MAIN QUESTIONNAIRE?    
 
IF ‘NO’ GO TO SHORT PROTOCOL 
IF ‘YES’ GO TO LONG PROTOCOL 
     LONG SHORT         
11.  Will the subject follow the short or long protocol?    
 CODING:  1   LONG, 2   SHORT 
 
 
SHORT PROTOCOL: 
CHANGE TO LONG PROTOCOL if FEV1 falls to < 90% of CONTROL FEV1  
STOP METHACHOLINE CHALLENGE if FEV1 fall to < 80% of CONTROL FEV1 
 
                          90% of CONTROL FEV1  ?   
 
LONG PROTOCOL: 
STOP METHACHOLINE CHALLENGE if FEV1 fall to <80% of CONTROL FEV1 
 
                          80% of CONTROL FEV1  ?   
THESE DATA NOT REQUIRED BY CO-ORDINATING CENTRES 
 
 
12.  METHACHOLINE BATCH NUMBER     
 
       NUMBER OF SESSIONS    
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       ORDER IN SESSIONS   
 
 
 
DOSE 
LEVEL 
  
 
CUMULATIVE 
CUM DOSE (mg) 
  
 
NEBULISER 
CONCN 
 
 
NO. 
INHALATIONS
 
SHORT   LONG
  
 
FEV1 
  
 
FEV1 
 
 
   
   
   
   
   
   
  
R
ej
ec
te
d 
   
   
 
at
te
m
pt
s 
3  0.0078  0.39 ...  2  ?    ?    
4  0.0156  0.39 4 2  ?    ?    
                
5  0.0312  1.56 ... 1  ?    ?    
6  0.0625  1.56 3 2  ?    ?    
                
7  0.125  6.25  1  ?    ?    
8  0.25  6.25 3 2  ?    ?    
                
9  0.5  12.5  2  ?    ?    
10  1.0  12.5 6 4  ?    ?    
                
11  2.0  12.5 8 8  ?    ?    
 
 
 
 
 
    
     TICK ONE  
    
     BOX ONLY 
13.  Why was methacholine challenge stopped  
     
        a)  end of test reached (2mg inhaled)                                                                               1  
        b)  >20% fall in FEV1 occurred                                                                                      2    
        c)  two satisfactory manoeuvres not achieved                                                                 3  
        d)  subject asked to stop                                                                                                   4  
        e)  other                                                                                                                            5  
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IF SUBJECTS FEV1 HAS FALLEN BY MORE THAN 10% 
 
Reversal of bronchoconstriction 
GIVE 400 µG SALBUTOMAL VIA VOLUMATIC AND 10 MINUTES LATER RECORD 
FEV1 
 
14.   FEV1 and FVC 
 
FEV1 FVC 
14.1 Record first two technically satisfactory manoeuvres         
        ( up to five attempts)         
         
14.2 Number of rejected attempts         
 
        
15    Best POST-BRONCHODILATOR FEV1 as % of initial FEV1    
 
    NO YES 
16  Has the subject’s FEV1 returned to within 10% of initial    
        FEV1 
    
 
 
IF ‘YES’ THE SUBJECT MAY LEAVE THE CENTRE 
IF ‘NO’ FURTHER ACTION MUST BE TAKEN TO RESTORE BASELINE LUNG 
FUNCTION 
 
BRONCHODILATOR CHALLENGE ONLY 
GIVE 400 µg SALBUTAMOL VIA VOLUMATIC AND 10 MINUTES LATER RECORD FEV1 
 
17.  FEV1  and FVC 
                                   FEV1                    FVC 
  
      17.1 Record first two technically satisfactory manoeuvres           
        up to 9 attempts)         
                                                                                                 
?
?   
 
 
?
 
?   
                                            
17.2 Number of rejected attempts  
 
END 
FIELDWORKER NUMBER  
 
 
 24
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ECRHS APPENDIX A 1  Screening Questionnaire 
 
 Area number    1-3 
 Personal number     4-8 
 Sample    9 
 
TO ANSWER THE QUESTIONS PLEASE CHOOSE THE APPROPRIATE BOX 
IF YOU ARE UNSURE OF THE ANSWER PLEASE CHOOSE 'NO'  
 
1. Have you had wheezing or whistling in your chest at any time   NO YES 
in the last 12 months?  10 
 
 IF 'NO' GO TO QUESTION 2, IF 'YES':  
 
 1.1. Have you been at all breathless when the wheezing noise        NO YES 
         was present?  11 
 
 1.2. Have you had this wheezing or whistling when you did   NO YES 
         not have a cold?  12 
 
2. Have you woken up with a feeling of tightness in your chest at   NO YES 
any time in the last 12 months?  13 
 
3. Have you been woken by an attack of shortness of breath at any        NO YES 
time in the last 12 months?  14 
 
4. Have you been woken by an attack of coughing at any time in   NO YES 
the last 12 months?  15 
 
      NO YES 
5. Have you had an attack of asthma in the last 12 months?  16 
 
6. Are you currently taking any medicine (including inhalers,   NO YES 
aerosols or tablets) for asthma?  17 
 
      NO YES 
7. Do you have any nasal allergies including hay fever?  18 
 
          DAY     MONTH      YEAR 
8. What is your date of birth?    19-24 
 
          DAY     MONTH      YEAR 
9. What is today's date?    25-30 
 
       MALE  FEMALE 
10. Are you male or female?  31 
                           
THANK YOU FOR YOUR HELP  32 
If you don't mind being telephoned at home or at work by one of the  33 
study team, please write your telephone number below:  34 
 
(DAY)...........................................................(EVE)....................................................... 
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ECRHS APPENDIX B 1  Main Questionnaire
1
Area number 1-3
Personal number 4-8
Sample 9
Date 10-15
       DAY           MONTH        YEAR
I AM GOING TO ASK YOU SOME QUESTIONS. AT FIRST THESE WILL BE MOSTLY ABOUT
YOUR BREATHING. WHEREVER POSSIBLE, I WOULD LIKE YOU TO ANSWER 'YES' OR 'NO'.
Wheeze and tightness in the chest      CARD 2
1. Have you had wheezing or whistling in your chest at any time in the last  NO YES
12 months? 16
IF 'NO' GO TO QUESTION 2, IF 'YES':
 NO YES
         1.1 Have you been at all breathless when the wheezing noise was present? 17
1.2. Have you had this wheezing or whistling when you did not have  NO YES
         a cold? 18
2. Have you woken up with a feeling of tightness in your chest at any time in  NO YES
the last 12 months? 19
Shortness of breath
3. Have you had an attack of shortness of breath that came on during the day   NO YES
when you were at rest at any time in the last 12 months? 20
4. Have you had an attack of shortness of breath that came on following  NO YES
strenuous activity at any time in the last 12 months? 21
5. Have you been woken by an attack of shortness of breath at any time in the   NO YES
last 12 months? 22
Cough and phlegm from the chest
6. Have you been woken by an attack of coughing at any time in the last 12    NO YES
months? 23
   NO YES
7. Do you usually cough first thing in the morning in the winter? 24
       [IF DOUBTFUL, USE QUESTION 8.1 TO CONFIRM]
   NO YES
8. Do you usually cough during the day, or at night, in the winter? 25
IF 'NO' GO TO QUESTION 9, IF 'YES':
8.1 Do you cough like this on most days for as much as three months  NO YES
         each year? 26
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9. Do you usually bring up any phlegm from your chest first thing in the  NO YES
morning in the winter? [IF DOUBTFUL, USE QUESTION 10.1 TO CONFIRM] 27
10. Do you usually bring up any phlegm from your chest during the day, or  NO YES
at night, in the winter? 28
IF 'NO' GO TO QUESTION 11, IF 'YES':
10.1 Do you bring up phlegm like this on most days for as much as three  NO YES
         months each year? 29
Breathing
 NO YES
11. Do you ever have trouble with your breathing? 30
IF 'NO' GO TO QUESTION 12, IF 'YES':
11.1 Do you have this trouble TICK ONE
BOX ONLY
         a) continuously so that your breathing is never quite right? 1
         b) repeatedly, but it always gets completely better? 2
         c) only rarely? 3 31
12. Are you disabled from walking by a condition other than heart or lung  NO YES
disease? 32
IF 'YES' STATE CONDITION ____________________  AND GO TO QUESTION 13,
IF 'NO':
12.1 Are you troubled by shortness of breath when hurrying on level  NO YES
         ground or walking up a slight hill? 33
IF 'NO' GO TO QUESTION 13, IF 'YES':
12.1.1 Do you get short of breath walking with other people of  NOYES
                     your own age on level ground? 34
IF 'NO' GO TO QUESTION 13, IF 'YES':
12.1.1.1 Do you have to stop for breath when walking at  NO YES
                                 your own pace on level ground? 35
Asthma
 NO YES
13. Have you ever had asthma? 36
IF 'NO' GO TO QUESTION 14, IF 'YES':
 NO YES
         13.1 Was this confirmed by a doctor? 37
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  YEARS
         13.2 How old were you when you had your first attack of asthma? 38-39
  YEARS
         13.3 How old were you when you had your most recent attack of asthma? 40-41
13.4.1-6 Which months of the year do you usually have attacks of asthma?
 NO YES
         13.4.1 January / February 42
         13.4.2 March / April 43
         13.4.3 May / June 44
         13.4.4 July / August 45
         13.4.5 September / October 46
         13.4.6 November / December 47
 NO YES
         13.5 Have you had an attack of asthma in the last 12 months? 48
IF 'NO' GO TO QUESTION 13.6,  IF 'YES':
13.5.1 How many attacks of asthma have you had in the last 12 NUMBER
                     months? 49-50
13.6 Are you currently taking any medicines, including inhalers, aerosols  NO YES
         or tablets, for asthma? 51
Other conditions
 NO YES
14. Do you have any nasal allergies, including hay fever? 52
 NO YES
15. Have you ever had eczema or any kind of skin allergy? 53
 NO YES
16. Are you allergic to any insect stings or bites? 54
IF 'NO' GO TO QUESTION 17, IF 'YES':
         16.1 Which insect? __________________________________________ 55-56
16.2.1-3 What kind of reaction do you have?
 NO YES
         16.2.1 breathing difficulty, feeling faint, nausea or fever 57
         16.2.2 redness, itching or swelling at the site of the sting 58
         16.2.3 other: _______________________________________________ 59
 NO YES
17. Have you ever had any difficulty with your breathing after taking medicines? 60
IF 'NO' GO TO QUESTION 18, IF 'YES':
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         17.1 Which medicines? ______________________________________ 1 61
2 62
Your parents' smoking DON'T
  NO YES   KNOW
18. Did your father ever smoke regularly during your childhood? 63
DON'T
19. Did your mother ever smoke regularly during your childhood, or   NO YES   KNOW
before you were born? 64
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 20, IF 'YES':
19.1 When your mother was pregnant, in particular with you, did she TICK ONE
BOX ONLY
         a) stop smoking before pregnancy? 1
         b) cut down or stop during pregnancy? 2
         c) smoke as usual during pregnancy? 3
         d) don't know 4 65
More about yourself
    DAY           MONTH       YEAR
20. When were you born? 66-71
21. What country were you born in? _______________________________ 72-74
     MALE  FEMALE
22. Are you male or female? 75
NUMBER
23. How many brothers do or did you have? 76-77
INTERVIEW TYPE? TICK ONE
BOX ONLY
At centre face to face 1
At home face to face 2
By telephone 3 78
23. continued...                                                                              CARD NUMBER 79-80
   CARD 3
IF 'NONE' GO TO QUESTION 24, IF 'YES':  DUPLICATE 1-9
NUMBER
         23.1 How many older brothers? 10-11
         23.2 How many younger brothers? 12-13
         23.3 How many of your brothers ever had asthma? 14-15
23.4 How many of your other brothers ever had eczema, skin or nasal          NUMBER
         allergy or hay fever? 16-17
NUMBER
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24. How many sisters do or did you have? 18-19
IF 'NONE' GO TO QUESTION 25, IF 'YES': 
NUMBER
         24.1 How many older sisters? 20-21
         24.2 How many younger sisters? 22-23
         24.3 How many of your sisters ever had asthma? 24-25
24.4 How many of your other sisters ever had eczema, skin or nasal             NUMBER
         allergy or hay fever? 26-27
DON'T
  NO YES   KNOW
25. Did your mother ever have asthma? 28
DON'T
   NO YES   KNOW
26. Did your mother ever have eczema, skin or nasal allergy or hay fever? 29
DON'T
  NO YES   KNOW
27. Did your father ever have asthma? 30
DON'T
  NO YES   KNOW
28. Did your father ever have eczema, skin or nasal allergy or hay fever? 31
DON'T
29. Did you regularly share your bedroom with any older children     NO YES   KNOW
before the age of five years? 32
DON'T
30. Did you go to a school, play-school or nursery with older children   NO YES   KNOW
before the age of five years? 33
DON'T
31. Did you have a serious respiratory infection before the age of five   NO YES   KNOW
years? 34
 NO YES
32. Are you a full time student? 35
IF 'YES' GO TO QUESTION 32.7, IF 'NO':
 YEARS
         32.1 At what age did you complete full time education? 36-37
  NO YES
         32.2 Are you currently employed or self-employed? 38
IF 'YES' GO TO QUESTION 32.3, IF 'NO':
 NO YES
                     32.2.1 Are you currently looking for a job? 39
32.3 What is you current or most recent job? [Be as precise as possible]
                  _________________________________________________ 40-42
32.4 Are you or were you TICK ONE
BOX ONLY
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         a) a manager working for an employer? 1
         b) a foreman or supervisor working for an employer? 2
         c) working for an employer, but neither a manager, supervisor or foreman? 3
         d) self-employed? 4 43
  NO YES
         32.5 Does being at work ever make your chest tight or wheezy? 44
32.6 Have you ever had to change or leave your job because it affected  NO YES
         your breathing? 45
IF 'NO' GO TO QUESTION 32.7 IF 'YES':
32.6.1 What was this job? [Be as precise as possible]
                    ________________________________________________ 46-48
32.7 Have you ever worked in a job which exposed you to vapours, gas,  NO YES
         dust or fumes? 49
IF 'NO' GO TO QUESTION 33, IF 'YES':
32.7.1 What was or is this job? [Be as precise as possible]
If current job write 'current job'
                    ________________________________________________ 50-52
Your home
 YEARS
33. How many years have you lived in your present home? 53-54
 YEARS
34. How many years have you lived in __________________? [Insert area name] 55-56
35. When was your present home built? TICK ONE
BOX ONLY
a) before 1960? 1
b) 1961-1970? 2
c) 1971-1980? 3
d) 1981 or later? 4
e) don't know 5 57
36. Which best describes the building in which you live? TICK ONE
BOX ONLY
a) a mobile home or trailer? 1
b) a one family house detached from any other house? 2
c) a one family house attached to one or more houses? 3
d) a building for two families? 4
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e) a building for three or four families? 5
f) a building for five or more families? 6
g) a boat, tent or van 7
e) other: _______________________________________________________ 8 58
37.1-3 Does your home have any of the following?
 NO YES
37.1 central heating 59
37.2 ducted air heating 60
37.3 air conditioning 61
38.1-7 Which of the following fuels do you use for heating or for hot water?
 NO YES
38.1 open coal, coke or wood fire 62
38.2 open gas fire 63
38.3 electric heater 64
38.4 paraffin heater 65
38.5 gas-fired boiler 66
38.6 oil-fired boiler 67
38.7 other: _____________________________________________________ 68
39. What kind of stove do you mostly use for cooking? TICK ONE
BOX ONLY
a) coal, coke or wood (solid fuel)? 1
b) gas? 2
c) electric? 3
d) paraffin? 4
e) other: _______________________________________________________ 5 69
DON'T
  NO YES   KNOW
40. Do you have an extractor fan over the cooker? 70
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 41, IF 'YES':
40.1 When cooking, do you use the fan TICK ONE
BOX ONLY
         a) all of the time? 1
         b) some of the time? 2
         c) none of the time? 3 71
DON'T
  NO YES   KNOW
         40.2 Does the fan take the fumes outside the house? 72
41.1-5 Does the room which you use most at home during the day
 NO YES
41.1 have fitted carpets covering the whole floor? 73
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41.2 contain rugs? 74
41.3 have double glazing? 75
41.4 have curtains? 76
41.5 have upholstered or soft furnishings? 77
           BLANK 78
                                                                                                     CARD NUMBER 79-80
  CARD 4
42.1-5 Does your bedroom      DUPLICATE 1-9
 NO YES
42.1 have fitted carpets covering the whole floor? 10
42.2 contain rugs? 11
42.3 have double glazing? 12
42. continued...
 NO YES
42.4 have curtains? 13
42.5 have upholstered or soft furnishings? 14
If 'NO' ask: Do you have a conventional mattress?
If 'YES': code 'YES'
 NO YES
43. Do you sleep with the windows open at night during winter? 15
IF 'NO' GO TO QUESTION 44, IF 'YES':
43.1 Do you sleep with the windows open TICK ONE
BOX ONLY
         a) all of the time? 1
         b) sometimes? 2
         c) only occasionally? 3 16
DON'T
44. Has there ever been any water damage to the building or its contents,   NO YES   KNOW
for example, from broken pipes, leaks or floods? 17
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 45, IF 'YES': DON'T
   NO YES   KNOW
         44.1 Has there been any water damage in the last 12 months? 18
 NO YES
45. Do you have a basement or cellar? 19
IF 'NO' GO TO QUESTION 46, IF 'YES': DON'T
   NO YES   KNOW
         45.1 Does water ever collect on the basement floor? 20
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 46, IF 'YES':
 NO YES
                     45.1.1 Has this happened in the last 12 months? 21
DON'T
46. Has there ever been any mould or mildew on any surface, other than   NO YES   KNOW
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food, inside the home? 22
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 47, IF 'YES':
46.1.1-6 Which rooms have been affected?
 NO YES
         46.1.1 bathroom(s) 23
         46.1.2 bedroom(s) 24
         46.1.3 living area(s) 25
         46.1.4 kitchen 26
         46.1.5 basement or attic 27
         46.1.6 other: _______________________________________________ 28
46.2 Has there been mould or mildew on any surfaces inside the home  NO YES
         in the last 12 months? 29
DON'T
47. Do you use a humidifier, including any humidifier built into your   NO YES   KNOW
heating system? 30
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 48, IF 'YES':
47.1 What kind of humidifier do you use? TICK ONE
BOX ONLY
         a) humidifier built into heating system 1
         b) portable cold mist (ultrasonic or spinning disc) 2
         c) portable hot mist vaporiser 3
         d) other: ___________________________________________________ 4 31
47.2 Under what circumstances do you use your humidifier? TICK
ONE
BOX ONLY
         a) only when someone is ill - in their room 1
         b) to humidify the house 2
         d) other: ___________________________________________________ 3 32
Animals, dust and feathers
 NO YES
48. Do you keep a cat? 33
IF 'NO' GO TO QUESTION 49, IF 'YES': 
 NO YES
         48.1 Is your cat ever allowed into your bedroom? 34
         48.2 Do all your cats stay outside the house? 35
 NO YES
49. Do you keep a dog? 36
IF 'NO' GO TO QUESTION 50, IF 'YES': 
 NO YES
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         49.1 Is your dog ever allowed into your bedroom? 37
         49.2 Do all your dogs stay outside the house? 38
 NO YES
50. Do you keep any birds? 39
IF 'NO' GO TO QUESTION 51, IF 'YES': 
 NO YES
         50.1 Are any of these birds kept inside the house? 40
51.1-12 When you were a child did anyone in your household keep any of the
following pets?
 NO YES
51.1 cats 41
51.2 dogs 42
51.3 horses 43
51.4 birds 44
51.5 guinea pigs 45
51.6 hamsters 46
51. continued...
 NO YES
51.7 mice 47
51.8 rats 48
51.9 rabbits 49
51.10 gerbils 50
51.11 ferrets 51
51.12 other: ____________________________________________________ 52
52.1-6 When you are near animals, such as cats, dogs or horses, near feathers,
including pillows, quilts or duvets, or in a dusty part of the house, do you ever
 NO YES
52.1 start to cough? 53
52.2 start to wheeze? 54
52.3 get a feeling of tightness in your chest? 55
52.4 start to feel short of breath? 56
52.5 get a runny or stuffy nose or start to sneeze? 57
52.6 get itchy or watering eyes? 58
Trees, grass, plants, flowers and pollen
53.1-6 When you are near trees, grass or flowers, or when there is a lot of pollen
about, do you ever
 NO YES
53.1 start to cough? 59
53.2 start to wheeze? 60
53.3 get a feeling of tightness in your chest? 61
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53.4 start to feel short of breath? 62
53.5 get a runny or stuffy nose or start to sneeze? 63
53.6 get itchy or watering eyes? 64
IF 'YES' TO ANY OF THE ABOVE:
53.1.1-4 Which time of year does this happen?
 NO YES
         53.1.1 winter 65
         53.1.2 spring 66
         53.1.3 summer 67
         53.1.4 autumn 68
Diet
54. How often do you eat pre-packaged food, such as tinned food or pre-prepared
frozen meals? TICK ONE
BOX ONLY
a) every day or most days 1
b) at least once a week 2
c) less than once a week 3 69
55. How often do you drink sweet fizzy drinks? TICK ONE
BOX ONLY
a) every day or most days 1
b) at least once a week 2
c) less than once a week 3 70
 NO YES
56. Do you take snacks between meals? 71
IF 'NO' GO TO QUESTION 57, IF 'YES': 
56.1-3 Which of the following would you have as a snack at least
once a week?
 NO YES
         56.1 savoury biscuits or crisps 72
         56.2 sweets, chocolates or sweet biscuits 73
         56.3 fruit or vegetables 74
57. Have you ever had an illness or trouble caused by eating a particular  NO YES
food or foods? 75
IF 'NO' GO TO QUESTION 58, IF 'YES': 
57.1 Have you nearly always had the same illness or trouble after eating  NO YES
         this type of food? 76
           BLANK 77-78
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                                                                                                     CARD NUMBER 79-80
IF 'NO' GO TO QUESTION 58, IF 'YES': CARD 5
     DUPLICATE 1-9
57.1.1 What type of food was this? [List up to 3]
                                  ______________________________________________ 10-11
                                  ______________________________________________ 12-13
                                  ______________________________________________ 14-15
57.1.2.1-6 Did this illness or trouble include
 NO YES
                     57.1.2.1 a rash or itchy skin? 16
                     57.1.2.2 diarrhoea or vomiting? 17
                     57.1.2.3 runny or stuffy nose? 18
                     57.1.2.4 severe headaches? 19
                     57.1.2.5 breathlessness? 20
                     57.1.2.6 other: _______________________________________ 21
Smoking
 NO YES
58. Have you ever smoked for as long as a year? 22
['YES' means at least 20 packs of cigarettes or 12 oz (360 grams) of tobacco
in a lifetime, or at least one cigarette per day or one cigar a week for one year]
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IF 'NO' GO TO QUESTION 59, IF 'YES': 
 YEARS
         58.1 How old were you when you started smoking? 23-24
 NO YES
         58.2 Do you now smoke, as of one month ago? 25
IF 'NO' GO TO QUESTION 58.3.1, IF 'YES': 
58.2.1-4 How much do you now smoke on average
    NUMBER  
                     58.2.1 number of cigarettes per day 26-27
                     58.2.2 number of cigarillos per day 28-29
                     58.2.3 number of cigars a week 30-31
                     58.2.4 pipe tobacco in a) ounces / week 32-33
                                                         b) grams / week 34-36
 NO YES
         58.3 Have you stopped or cut down smoking? 37
IF 'NO' GO TO QUESTION 58.4, IF 'YES': 
 YEARS
                     58.3.1 How old were you when you stopped or cut down smoking? 38-39
58.3.2.1-4 On average of the entire time you smoked, before you
stopped or cut down, how much did you smoke?
    NUMBER  
                     58.3.2.1 number of cigarettes per day 40-41
                     58.3.2.2 number of cigarillos per day 42-43
                     58.3.2.3 number of cigars a week 44-45
                     58.3.2.4 pipe tobacco in a) ounces / week 46-47
                                                            b) grams / week 48-50
 NO YES
         58.4 Do you or did you inhale the smoke? 51
59. Have you been regularly exposed to tobacco smoke in the last 12  NO YES
months? ['Regularly' means on most days or nights] 52
IF 'NO' GO TO QUESTION 60, IF 'YES': 
59.1 Not counting yourself, how many people in your household smoke NUMBER
         regularly? 53-54
 NO YES
         59.2 Do people smoke regularly in the room where you work? 55
59.3 How many hours per day are you exposed to other people's  HOURS
         tobacco smoke? 56-57
Medicines and inhalers
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60. Have you used any inhaled medicines to help your breathing at any time  NO YES
in the last 12 months? 58
IF 'NO' GO TO QUESTION 61, IF 'YES':
60.1-6 Which of the following have you used in the last 12 months?
 NO YES
         60.1 beta-2-agonist inhalers 59
                  60.1.1 If used, which one? ________________________________ 60-61
 NO YES
         60.2 non-specific adrenoreceptor agonist inhalers 62
                  60.2.1 If used, which one? ________________________________ 63
 NO YES
         60.3 anti-muscarinic inhalers 64
                  60.3.1 If used, which one? ________________________________ 65
 NO YES
         60.4 inhaled steroids 66
                  60.4.1 If used, which one? ________________________________ 67
 NO YES
         60.5 other inhalers (non-steroid, single drug) 68
                  60.5.1 If used, which one? ________________________________ 69
 NO YES
         60.6 inhaled compound inhalers 70
                  60.6.1 If used, which one? ________________________________ 71
61. Have you used any pills, capsules, tablets or medicines, other than   NO YES
inhaled medicines, to help your breathing at any time in the last 12 months? 72
IF 'NO' GO TO QUESTION 62, IF 'YES':
61.1-6 Which of the following have you used in the last 12 months?
 NO YES
         61.1 oral specific beta-2-agonists 73
                  61.1.1 If used, which one? ________________________________ 74
 NO YES
         61.2 oral non-specific adrenoreceptor agonists 75
                  61.2.1 If used, which one? ________________________________ 76
 NO YES
         61.3 oral anti-muscarinic drugs 77
                  61.3.1 If used, which one? ________________________________ 78
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                                                                                                     CARD NUMBER 79-80
CARD 6
     DUPLICATE 1-9
 NO YES
         61.4 oral methylxanthines 10
                  60.4.1 If used, which one? ________________________________ 11
 NO YES
         61.5 oral steroids 12
                  61.5.1 If used, which one? ________________________________ 13-14
 NO YES
         61.6 oral antihistamines 15
                  61.6.1 If used, which one? ________________________________ 16
 NO YES
         61.7 oral compound bronchodilators (no sedatives) 17
                  61.7.1 If used, which one? ________________________________ 18
 NO YES
         61.8 oral compound bronchodilators with sedatives 19
                  61.8.1 If used, which one? ________________________________ 20
 NO YES
         61.9 other oral medications 21
                  61.9.1 If used, which one? ________________________________ 22
DON'T
  NO YES   KNOW
62. Have you ever been vaccinated for allergy at any time in your life? 23
IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 63, IF 'YES':
 NO YES
         62.1 Have you been vaccinated for allergy in the last 12 months? 24
63. Have you had any other injections to help your breathing at any time in  NOYES
the last 12 months? 25
IF 'NO' GO TO QUESTION 64, IF 'YES':
         63.1 What injections? _________________________________________ 26
                                            _________________________________________ 27
64. Have you had any suppositories to help your breathing at any time in the   NOYES
last 12 months? 28
IF 'NO' GO TO QUESTION 65, IF 'YES':
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         64.1 What suppositories? ______________________________________ 29
                                                  ______________________________________ 30
65. Have you used any other remedies to help your breathing at any time in  NO YES
the last 12 months? 31
IF 'NO' GO TO QUESTION 66, IF 'YES':
         65.1 What remedies?  _________________________________________ 32
                                            _________________________________________ 33
                                            _________________________________________ 34
66. Do you take drugs every day to help your breathing even if you don't feel  NO YES
short of breath? 35
IF 'NO' GO TO QUESTION 67, IF 'YES':
         66.1 Which drugs? __________________________________________ 36-37
                                        __________________________________________ 38-39
                                        __________________________________________ 40-41
                                        __________________________________________ 42-43
                                        __________________________________________ 44-45
                                        __________________________________________ 46-47
                                        __________________________________________ 48-49
                                        __________________________________________ 50-51
  NO YES
67. Do you take any drugs only for attacks of breathlessness? 52
IF 'NO' GO TO QUESTION 68, IF 'YES':
         67.1 Which drugs? __________________________________________ 53-54
                                        __________________________________________ 55-56
                                        __________________________________________ 57-58
                                        __________________________________________ 59-60
                                        __________________________________________ 61-62
                                        __________________________________________ 63-64
67.2 Do you take these drugs TICK ONE
BOX ONLY
         a) at the onset of the attack? 1
         b) only when the attack becomes more severe? 2 65
68. Has your doctor ever prescribed medicines, including inhalers, for your   NO YES
breathing? 66
IF 'NO' GO TO QUESTION 69, IF 'YES':
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68.1 If you are prescribed medicines for your breathing, do you normally
take TICK ONE
BOX ONLY
         a) all of the medicine? 1
         b) most of the medicine? 2
         c) some of the medicine? 3
         d) none of the medicine? 4 67
68.2 When your breathing gets worse, and you are prescribed
medicines for your breathing, do you normally take TICK ONE
BOX ONLY
         a) all of the medicine? 1
         b) most of the medicine? 2
         c) some of the medicine? 3
         d) none of the medicine? 4 68
68.3 Do you think it is bad for you to take medicines all the time to help  NO YES
         your breathing? 69
68.4 Do you think you should take as much medicine as you need to get  NO YES
         rid of all your breathing problems? 70
69. Have you ever visited a hospital casualty department or emergency room  NO YES
because of breathing problems? 71
 NO YES
70. Have you ever spent a night in hospital because of breathing problems? 72
IF 'NO' GO TO QUESTION 71, IF 'YES': 
NUMBER
         70.1 How many times in the last 12 months? 73-74
71. Have you ever been seen by a doctor because of breathing problems or   NO YES
because of shortness of breath? 75
IF 'NO' GO TO END, IF 'YES':
71.1 When was the last time you were seen by a doctor because of
breathing problems or because of shortness of breath? TICK ONE
BOX ONLY
         a) within the last seven days 1
         b) more than seven days ago but within the last four weeks 2
         c) more than four weeks ago but within the last 12 months 3
         d) more than a year ago 4 76
71.2 Where were you seen? TICK ONE
BOX ONLY
ECRHS APPENDIX B 1  Main Questionnaire
18
         a) by a GP at home 1
         b) by a GP in his office or surgery 2
         c) by a specialist at home 3
         d) by a specialist in his office or hospital outpatients department 4
         e) in a casualty department or emergency room 5
         f) admitted to a hospital ward 6 77
END                                                                                        FIELDWORKER NUMBER 78
                                                                                                                                 CARD NUMBER 79-80
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ECRHS II Screening Questionnaire 
 
 Area number    1-3 
 Personal number     4-8 
 Sample    9 
 
TO ANSWER THE QUESTIONS PLEASE CHOOSE THE APPROPRIATE BOX 
IF YOU ARE UNSURE OF THE ANSWER PLEASE CHOOSE 'NO'  
 
1. Have you had wheezing or whistling in your chest at any time    NO YES 
in the last 12 months?  10 
 
 IF 'NO' GO TO QUESTION 2, IF 'YES':  
 
 1.1. Have you been at all breathless when the wheezing noise        NO YES 
         was present?  11 
 
 1.2. Have you had this wheezing or whistling when you did    NO YES 
         not have a cold?  12 
 
2. Have you woken up with a feeling of tightness in your chest at    NO YES 
any time in the last 12 months?  13 
 
3. Have you been woken by an attack of shortness of breath at any        NO YES 
time in the last 12 months?  14 
 
4. Have you been woken by an attack of coughing at any time in    NO YES 
the last 12 months?  15 
 
      NO YES 
5. Have you had an attack of asthma in the last 12 months?  16 
 
6. Are you currently taking any medicine (including inhalers,   NO YES 
aerosols or tablets) for asthma?  17 
 
      NO YES 
7. Do you have any nasal allergies including hay fever?  18 
 
          DAY     MONTH      YEAR 
8. What is your date of birth?    19-24 
 
          DAY     MONTH      YEAR 
9. What is today's date?    25-30 
 
       MALE  FEMALE 
10. Are you male or female?  31 
                           
THANK YOU FOR YOUR HELP  32 
If you don't mind being telephoned at home or at work by one of the  33 
study team, please write your telephone number below:  34 
 
(DAY)...........................................................(EVE)....................................................... 
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 Centre number      
 Personal number     
 Sample      
 Date    
         DAY       MONTH   YEAR 
 
I AM GOING TO ASK YOU SOME QUESTIONS. AT FIRST THESE WILL BE MOSTLY ABOUT  
YOUR BREATHING. WHEREVER POSSIBLE, I WOULD LIKE YOU TO ANSWER 'YES' OR 'NO'.  
      
1.  Have you had wheezing or whistling in your chest at any time in the last  NO YES 
12 months?    
 
IF 'NO' GO TO QUESTION 2, IF 'YES':  
      NO YES 
1.1  Have you been at all breathless when the wheezing noise was present?    
 
1.2.  Have you had this wheezing or whistling when you did not have    NO YES 
        a cold?  
 
2.  Have you woken up with a feeling of tightness in your chest at any time in  NO YES 
 the last 12 months?    
 
3.  Have you had an attack of shortness of breath that came on during the day     NO YES 
 when you were at rest at any time in the last 12 months?    
 
4. Have you had an attack of shortness of breath that came on following   NO YES 
 strenuous activity at any time in the last 12 months?    
 
5.  Have you been woken by an attack of shortness of breath at any time in the    NO YES 
 last 12 months?    
 IF NO GO TO Q6, IF YES  
 5.1  Have you been woken by an attack of shortness of breath in the                NO YES 
             last 3 months?     
 IF NO GO TO Q6, IF YES  
 5.1.1  On average have you been woken by an attack of shortness of           NO YES 
             breath at least once a week in the last 3 months?     
 IF NO GO TO Q6, IF YES  
 5.1.1.1 How many times a week on average have you been   TIMES 
             woken by shortness of  breath in the last 3 months?    
 
6. Have you been woken by an attack of coughing at any time in the last 12      NO YES 
 months?    
        NO YES 
7. Do you usually cough first thing in the morning in the winter?    
       [IF DOUBTFUL, USE QUESTION 8.1 TO CONFIRM] 
         
     NO YES 
8. Do you usually cough during the day, or at night, in the winter?    
 
 2
  IF 'NO' GO TO QUESTION 9, IF 'YES':  
 8.1  Do you cough like this on most days for as much as three months    NO YES 
           each year?    
 
   9.  Do you usually bring up any phlegm from your chest first thing in the   NO YES 
 morning in the winter?     
[IF DOUBTFUL, USE QUESTION 10.1 TO CONFIRM] 
10. Do you usually bring up any phlegm from your chest during the day, or   NO  YES 
 at night, in the winter?    
 
 IF 'NO' GO TO QUESTION 11, IF 'YES':  
 10.1 Do you bring up phlegm like this on most days for as much as three        NO YES 
         months each year?    
      NO YES 
11. Do you ever have trouble with your breathing?    
 
 IF 'NO' GO TO QUESTION 12, IF 'YES':  
 11.1 Do you have this trouble                                                                   TICK ONE BOX ONLY 
         a) continuously so that your breathing is never quite right? 1   
         b) repeatedly, but it always gets completely better? 2   
         c) only rarely? 3   
 
12. Are you disabled from walking by a condition other than heart or lung    NO YES 
disease?    
 
 IF 'YES' STATE CONDITION ____________________  AND GO TO QUESTION 13,  
 IF 'NO':  
 12.1 Are you troubled by shortness of breath when hurrying on level    NO YES 
         ground or walking up a slight hill?    
  
 IF 'NO' GO TO QUESTION 13, IF 'YES':  
  12.1.1 Do you get short of breath walking with other people of        NO YES 
                     your own age on level ground?    
 
   IF 'NO' GO TO QUESTION 13, IF 'YES':  
   12.1.1.1 Do you have to stop for breath when walking at  NO   YES 
                                 your own pace on level ground?    
 
13. FOR WOMEN ONLY - MEN GO TO Q14  
Have you ever noticed that you had respiratory symptoms (such as wheeze,    
   tightness in your chest or shortness of breath) at a particular time of your  
   monthly cycle?       TICK ONE BOX ONLY 
 yes, in the week before my period 1   
 yes, during my period 2   
 yes, in the week after my period 3   
 yes, another time of the month 4   
 does not apply to me (i.e.,  amenorrhoeal) 5   
 No 6   
 
     NO YES 
 3
 14. Have you ever had asthma?    
 IF 'NO' GO TO QUESTION 15, IF 'YES':    
 
    NO YES 
         14.1 Was this confirmed by a doctor?    
         YEARS 
         14.2 How old were you when you had your first attack of asthma?    
         YEARS 
         14.3 How old were you when you had your most recent attack of asthma?    
 
         
14.4.1-6 Which months of the year do you usually have attacks of asthma? 
      NO YES 
         14.4.1 January / February    
         14.4.2 March / April    
         14.4.3 May / June    
         14.4.4 July / August    
         14.4.5 September / October    
         14.4.6 November / December    
      NO   YES 
            14.5 Have you had an attack of asthma in the last 12 months?    
                IF NO GO TO 14.8, IF YES           ATTACKS 
          14.6 How many attacks of asthma have you had in the last 12 months?    
           ATTACKS 
         14.7 How many attacks of asthma have you had in the last 3 months?    
 
         14.8 How many times have you woken up because of your asthma in the 
          last 3 months?      TICK ONE BOX ONLY 
 every night or almost every night 1   
 more than once a week, but not most nights 2   
 at least twice a month, but not more than once a week   3   
 less than twice a month 4   
 not at all 5   
 
          14.9. How often have you had trouble with your breathing because of your asthma  
               in the last 3 months?                       TICK ONE BOX ONLY 
 continuously 1   
 about once a day 2   
 at least once a week, but less than once a day 3   
 less than once a week 4   
 not at all 6   
 
    NO YES 
         14.10 Are you currently taking any medicines including inhalers,    
  aerosols or tablets for asthma? 
    NO YES 
         14.11 Do you have a peak flow meter of your own?     
 IF 'NO' GO TO QUESTION 14.12 , IF 'YES':  
   
  14.11.1 How often have you used it over the last 3 months? TICK ONE BOX ONLY 
 4
  never 1   
 some of the days 2   
 most of the days 3   
 
 14.12 Do you have written instructions from your doctor on    NO YES 
                 how to manage your asthma if it gets worse or if you have an attack?    
 
 14.13. FOR WOMEN ONLY - MEN GO TO Q15 
Have you ever noticed that your asthma got worse with your monthly  
cycle? TICK ONE BOX ONLY 
 Yes, in the week before my period 1   
 Yes, during my period 2   
 Yes, in the week after my period 3   
 Yes, another time of the month 4   
 Does not apply to me (i.e., amenorrhoeal) 5   
 No 6   
 
           
      NO   YES 
    14.14 Have you been pregnant (at least 25 weeks) since your asthma started?    
  IF NO GO TO Q15, IF YES  
14.14.1.What happened to your asthma during your pregnancies?  
      TICK ONE BOX ONLY 
 got better 1   
 got worse 2   
 stayed the same 3   
 not the same for all pregnancies 4   
 don’t know 5   
                       
                                                                                                                                    NO  YES 
15. Do you have any nasal allergies, including hay fever?    
 IF NO GO TO Q16, IF YES         YEARS 
15.1 How old were you when you first had hay fever or nasal allergy?    
 
16. Have you ever had a problem with sneezing, or a runny or a blocked   NO YES 
 nose when you did not have a cold or the flu?    
 IF NO GO TO Q17, IF YES 
 16.1.Have you had a problem with sneezing or a runny or blocked   NO   YES 
   nose when you did not have a cold or the flu in the last 12 months?    
  IF NO GO TO Q17, IF YES 
  16.1.1. Has this nose problem been accompanied by itchy or     NO   YES 
                         watery eyes?     
  16.1.2. In which months of the year did this nose problem occur?   NO YES 
January    
February    
March    
April    
May    
June    
July    
 5
 August    
September    
October    
November    
December    
 
17. Since the last survey have you used any medication to treat nasal disorders? NO   YES 
    
 IF NO GO TO Q18, IF YES 
  17.1 Have you used any of the following nasal sprays for the treatment  
     of your nasal disorder?    NO  YES 
{SHOW LIST OF STEROID NASAL SPRAYS} 
   IF NO GO TO Q17.2, IF YES 
   17.1.1 How many years have you been taking  YEARS 
                                                 this sort of nasal spray? 
   17.1.2 Have you used any of these nasal sprays  NO YES 
                                                in the last 12 months? 
  17.2 Have you used any of the following pills, capsules, or tablets for  
     the treatment of your nasal disorder?                  NO  YES 
{SHOW LIST OF ANTIHISTAMINES} 
   IF NO GO TO Q18, IF YES 
    
               17.2.1 How many years have you been taking these sort of pills,   YEARS 
                                 capsules or tablets?                      
   17.2.2 Have you used any of these pills, capsules  NO YES 
                                                 or tablets in the last 12 months? 
      NO YES 
  18. Have you ever had eczema or any kind of skin allergy?    
 
19. Have you ever had an itchy rash that was coming and going for at   NO YES 
least 6 months?    
 IF 'NO' GO TO QUESTION 20, IF 'YES':    NO YES 
19.1.. Have you had this itchy rash in the last 12 months?    
 IF 'NO' GO TO QUESTION 20, IF 'YES':  
19.1.1. Has this itchy rash at any time affected any of the following places: 
the folds of the elbows, behind the knees, in front of the ankles     NO YES 
under the buttocks or around the neck, ears or eyes  
 
      NO YES 
20. Have you ever had any difficulty with your breathing after taking medicines?    
 IF 'NO' GO TO QUESTION 21, IF 'YES':  
         20.1-2 Which medicines? ___________________________________   
    
          YEARS 
20.1.
20.1.2 
21. How old was your mother when you were born?    
 
 
 
 
22. How many times did you move house during the first five           
 6
    years of your life?      TICK ONE BOX ONLY 
         None 1   
         Once 2   
         more than once 3   
 
       NO YES 
23. Were you hospitalised before the age of two years for lung disease?    
                 YEARS 
24. At what age did you first attend a school, play school, day care or nursery?    
 
25. How many other children regularly slept in your bedroom before         CHILDREN 
you were five years old?    
 
I would now like to ask you some questions on the type of jobs that you have done.  
I am interested in each one of the jobs that you have done for more than 3 consecutive months since the 
time we last contacted you (in 1991/2). These jobs may be outside the house or at home, full time or part 
time, paid or not paid, including self employment, for example in a family business. Please include part 
time jobs only if you had been doing them for more than 8 hours per week. 
 
Q26. Are you currently 
                           TICK ONE BOX ONLY 
 Employed (including military service) 1  
 Self employed 2  
 Unemployed, looking for work 3  
 Not working because of  poor health 4  
 Full-time house-person 5  
 Full time student 6  
 Retired 7  
 Other 8  
  
IF EMPLOYED OR SELF EMPLOYED OR A FULL TIME HOURSEPERSON GO TO Q28 
  
27. Have you been employed in any job for three continuous NO      YES 
months or longer since the last survey?    
 
IF YES NOW GO TO OCCUPATIONAL MATRIX 
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 Centre number      
 Personal number      
 Sample      
 Date     
                            DAY     MONTH  YEAR 
 
Q 28. If you had more than one job in the same company, or if you were doing more than one job at the same time, we would like to talk about them 
separately.   Please start with your current or last job. 
 
 
JOB 
 
 
Q28.1. What is (was) the title of your 
current (last) job? 
 
OCCUPATION 
Q28.2. What did the firm, 
company or organisation do or 
what services did it provide? 
INDUSTRY 
Q28.3. In what month and 
year did you start working in 
this job? 
 
MONTH             YEAR 
Q28.4. In what month and 
year did you stop working in 
this job? 
 
MONTH                  YEAR 
JOB 1                 
JOB 2                 
JOB 3                 
JOB 4                 
JOB 5                 
JOB 6                 
JOB 7                 
JOB 8                 
JOB 9                 
JOB 10                 
 8 
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                       NO      YES 
29. Have any of these jobs ever made your chest tight or wheezy?     
 
 
IF YES, (tick no or yes for each job)  
 
                           NO      YES 
Job 1?    
Job 2?    
Job 3?    
Job 4?    
Job 5?    
Job 6?    
Job 7?    
Job 8?    
Job 9?    
Job 10?    
 
30. Have you had to leave any of these jobs because they                                      NO    YES 
affected your breathing?     
 
IF YES, (tick no or yes for each job) 
                             NO     YES 
Job 1?    
Job 2?    
Job 3?    
Job 4?    
Job 5?    
Job 6?    
Job 7?    
Job 8?    
Job 9?    
Job 10?    
 
31.Since the last survey have you been involved in an accident at home, work or elsewhere that exposed 
you to high levels of vapours, gas, dust or fumes?       NO    YES 
     
        IF YES, 
      31.1 Did you experience respiratory symptoms immediately following this   
exposure? NO 
 
YES 
 
  
 
IF YES 
31.1.1 Could you describe to me what it was?    _____________________________________ 
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Centres performing the extra occupational modules should at this point introduce the modular 
introductory questionnaire and complete modules as appropriate. 
        YEARS 
32. At what age did you complete full time education?    
   If full time student enter 88 
 
 
 
33. How often do you usually exercise so much that you get out of breath  
or sweat?     TICK ONE BOX ONLY 
every day 1   
4-6 times a week 2   
2-3 times a week 3   
once a week 4   
once a month 5   
less than once a month 6   
never 7   
  
 
   34. How many hours a week do you usually exercise so much that you  
get out of breath or sweat? TICK ONE BOX ONLY 
none 1   
about ½ hr 2   
about 1 hour 3   
about 2-3 hours 4   
about 4-6 hours 5   
7 hours or more 6   
     NO YES 
35. Do you avoid taking vigorous exercise because of wheezing or asthma?    
 
      YEAR 
36. When was your present home built?    
     NO YES 
37. Do you live in the same home as when you were last surveyed?    
 IF YES  GO TO QUESTION 38, IF NO    TIMES 
37.1. How many times have you moved since you were     
`   last surveyed?   YEARS 
37.2. How many years have you lived in your current home?     
 
37.3 Where do you currently live?       TICK ONE BOX ONLY 
a different home, but still in the study sampling area 1   
outside the sampling area  but still in the same country 2   
a different country 3   
   
37.3.1. IF A DIFFERENT COUNTRY Which country?     
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37.4 Which best describes the building in which you live?     TICK ONE BOX ONLY 
a) a mobile home or trailer? 1   
b) a one family house detached from any other house? 2   
c) a one family house attached to one or more houses? 3   
d) a building for two families? 4   
e) a building for three or four families? 5   
f) a building for five or more families? 6   
g) a boat, tent or van 7   
e) other: __________________________ 8   
 
38. Does your home have any of the following?    NO YES 
38.1 central heating    
38.2 ducted air heating (forced air heating)    
38.3 air conditioning    
 
39. Which of the following appliances do you use for heating or for hot water? 
       NO YES 
39.1 open coal, coke or wood fire    
39.2 open gas fire    
39.3 electric heater    
39.4 paraffin heater    
39.5 gas-fired boiler    
39.6 oil-fired boiler    
39.7 portable gas heater    
39.8 other: _____________________________________________________    
 
40. What kind of stove do you mostly use for cooking?           TICK ONE BOX ONLY 
a) coal, coke or wood (solid fuel)? 1   
b) gas (gas from the mains)? 2   
c) electric? 3   
d) paraffin (kerosene)? 4   
e) microwave 5   
f) gas (gas from bottles or other non-mains source) 6   
g) other: _______________________________________________________ 7   
 
 40.1 IF YOU USE GAS FOR COOKING   Which of the following do you have? 
       NO YES 
         40.1.1 gas hob    
         40.1 2.gas oven    
 
41. What kind of stove was mostly used for cooking in the home you lived  
in when you were five years old?           TICK ONE BOX ONLY 
a) coal, coke or wood (solid fuel)? 1   
b) gas (gas from the mains)? 2   
c) electric? 3   
d) paraffin? 4   
e) gas (gas from bottles or other non-mains source) 5   
f) don’t know 6   
g) other: _______________________________________________________ 7   
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         MINUTES 
42. On average how long have you spent cooking with your stove each day     
over the last four weeks? 
 
43. Over the last four weeks when you were cooking did you have a door or window to the  
outside air open           TICK ONE BOX ONLY 
a) most of the time 1   
b) some of  time 2   
c) rarely (or only occasionally) 3   
d) I do not have a door or window that opens to the outside in my kitchen 4   
                      
          NO   YES    DK 
44. Do you have an extractor fan over the cooker?    
  IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 45, IF 'YES':  
  44.1 When cooking, do you use the fan       TICK ONE BOX ONLY 
         a) all of the time? 1   
         b) some of the time? 2   
         c) none of the time? 3   
         
         NO  YES  DK 
           44.2  Does the fan take the fumes outside the house?    
 
45. Does the room which you use most at home during the day   NO YES 
                     45.1 have fitted carpets covering the whole floor?    
                     45.2 contain rugs?    
                     45.3 have double glazing?    
 
 
46 How old is the oldest carpet or rug in the room which you use most at home  
during the day? ,                                                                                    TICK ONE BOX ONLY 
a) less than one year 1   
b) 1-5 years old 2   
c) more than 5 years old 3   
  
47 On what floor is the room which you use most at home during the day?   
 
(The lowest floor of a building is 00) 
         
48. Does your bedroom    NO YES 
48.1 have fitted carpets covering the whole floor?    
48.2 contain rugs?    
48.3 have double glazing?    
 
49 How old is the oldest carpet or rug in your bedroom  
 
TICK ONE BOX ONLY 
a) less than one year    
b) 1-5 years old    
c) more than 5 years old    
 12
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50 How old is your mattress 
 
TICK ONE BOX ONLY 
a) less than one year   
b) 1-5 years old   
c) more than 5 years old   
 
    
51 What floor of the building is your bedroom on? (lowest=00)    
      NO YES 
52. Do you sleep with the windows open at night during winter?    
  
IF 'NO' GO TO QUESTION 53, IF 'YES':  
 
 52.1 Do you sleep with the windows open         TICK ONE BOX ONLY 
                         a) all of the time? 1   
                         b) sometimes? 2   
                         c) only occasionally? 3    
     
53. Has there been any water damage to the building or its contents,    NO      YES      DK 
for example, from broken pipes, leaks or floods?     
 IF YES         NO     YES      DK 
        53.1 Has there been any water damage in the last 12 months     
 
54. Within the last 12 months have you had wet or damp spots on surfaces  
inside your home other than in the basement (for example on walls, wall paper, NO YES 
ceilings or carpets)?     
        
55. Has there ever been any mould or mildew on any surface, other than     NO   YES   DK 
food, inside the home?    
 IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 56, IF 'YES':  
  
55.1.1-6 Which rooms have been affected?         NO YES 
         55.1.1 bathroom(s)    
         55.1.2 bedroom(s)    
         55.1.3 living area(s)    
         55.1.4 kitchen    
         55.1.5 basement or attic    
         55.1.6 other: _______________________________________________    
 
 55.2 Has there been mould or mildew on any surfaces inside the home NO   YES 
         in the last 12 months?    
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‘This scale looks like a thermometer; it allows you to rate your personal 
opinion regarding the following question on annoyance from air pollution. You 
can indicate your level of annoyance on this scale between 0 and 10 where 
0 mean does not annoy at all' and 10 means intolerable annoyance.' 
 
56 . How much are you annoyed by outdoor air pollution (from traffic, industry, etc.)  
if you keep the windows open?  
 
 
    10  intolerable annoyance 
     
9 
  
     
8 
  
     
7 
  
     
6 
  
     
5 
  
     
4 
  
     
3 
  
     
2 
  
     
1 
  
     
0 
  
doesn’t annoy at all 
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THOSE WHO HAVE NOT MOVED HOME SINCE  LAST SURVEY (Check with response to 
question 37) 
 GO TO QUESTION 58 
 
THOSE WHO HAVE MOVED SINCE LAST SURVEY – answer 57  
 
57. How much were you annoyed by outdoor air pollution (from 
traffic, industry, etc.) in your previous home, if you kept the windows open? 
 
.  
 
 
 
    10  intolerable annoyance 
     
9 
  
     
8 
  
     
7 
  
     
6 
  
     
5 
  
     
4 
  
     
3 
  
     
2 
  
     
1 
  
     
0 
  
doesn’t annoy at all 
       
       
       
       
 
 
       
 
58. How often do cars pass your house? TICK ONE BOX ONLY 
a)  constantly 1   
b)  frequently 2   
c)  seldom 3   
d)  never 4   
 
 
 15
Appendix B 1 – ECRHS II Main Questionnaire   
 
 
59. How often do heavy vehicles (e.g. trucks/buses) pass your house? TICK ONE BOX ONLY 
a)   constantly   
b)   frequently   
c)   seldom   
d)   never   
  
60. Have you taken any of the following measures to reduce allergen or  
      exposure to allergen in your home since the last survey?   NO YES 
          60.1 changed from carpet to a wooden or other smooth surface on  
                 floor of the room you use most   
 60.2 changed from carpet to a wooden or to a smooth surface on floor of  
        your bedroom  
60.3 bought a new carpet for the room you use most  
60.4 bought a new carpet for your bedroom  
60.5 used antidust-mite sprays   
60.6 put an allergy-proof cover on your mattress  
60.7 sold, given away or destroyed a pet dog or cat  
 
61. Do you keep a cat?   
 IF 'NO' GO TO QUESTION 62, IF 'YES'   NO  YES 
         61.1 Is your cat (are your cats) allowed inside the house?    
         61.2 Is your cat (are your cats) allowed in the bedroom?   
62. Do you keep a dog?   
 IF 'NO' GO TO QUESTION 63, IF 'YES':    NO YES 
         62.1 Is your dog (are your dogs) allowed inside the house?    
         62.2 Is your dog (are your dogs) allowed in your bedroom?   
63. Do you keep any birds?   
1 
2 
3 
4 
 
 
 
 
 
 
 
 
 
     NO YES 
 
 
      NO YES 
 
 
      NO YES 
 
 IF 'NO' GO TO QUESTION 64, IF 'YES':    NO YES 
         63.1 Are any of these birds kept inside the house?    
           
64. Was there a cat in your home?    NO YES   DK 
64.1 during your first year of life    
64.2 when you were aged 1 to 4 years    
64.3 when you were aged 5-15 years     
        
65. Was there a dog in your home?    NO YES   DK 
65.1 during your first year of life    
65.2 when you were aged 1 to 4 years    
65.3 when you were aged 5-15 years     
        
66. Was there a bird in your home?    NO YES   DK 
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66.2 when you were aged 1 to 4 years    
66.3 when you were aged 5-15 years     
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67. What term best describes the place you lived most of the time 
when you were under the age of five years? TICK ONE BOX ONLY 
a)  farm  1   
b)  village in a rural area  2   
c)  small town  3   
d)  suburb of a city  4   
e)  inner city  5    
 
68. When you are near animals, such as cats, dogs or horses, do you ever 
      NO YES 
68.1 start to cough?    
68.2 start to wheeze?    
68.3 get a feeling of tightness in your chest?    
68.4 start to feel short of breath?    
68.5 get a runny or stuffy nose or start to sneeze?    
68.6 get itchy or watering eyes?    
 
69. When you are in a dusty part of the house, or near pillows or duvets do you ever 
      NO YES 
69.1 start to cough?    
69.2 start to wheeze?    
69.3 get a feeling of tightness in your chest?    
69.4 start to feel short of breath?    
69.5 get a runny or stuffy nose or start to sneeze?    
69.6 get itchy or watering eyes?    
 
70. When you are near trees, grass or flowers, or when there is a lot of pollen 
about, do you ever 
      NO YES 
70.1 start to cough?    
70.2 start to wheeze?    
70.3 get a feeling of tightness in your chest?    
70.4 start to feel short of breath?    
70.5 get a runny or stuffy nose or start to sneeze?    
70.6 get itchy or watering eyes?    
 IF 'YES' TO ANY OF THE ABOVE:   
 70.7.1-4 Which time of year does this happen?    NO YES 
         70.7.1 winter    
         70.7.2 spring    
         70.7.3 summer    
         70.7.4 autumn    
 
71. How often do you eat pre-packaged food, such as tinned food or pre-prepared 
frozen meals?  TICK ONE BOX ONLY 
a) every day or most days 1   
b) at least once a week 2   
c) less than once a week 3   
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      NO YES 
72 Do you take snacks between meals?    
 IF 'NO' GO TO QUESTION 73, IF 'YES':    
 72.1.1-3 Which of the following would you have as a snack at least  
 once a week?    NO YES 
         72.1.1 savoury biscuits or crisps    
         72.1.2 sweets, chocolates or sweet biscuits    
         72.1.3 fruit or vegetables    
 
73. Have you ever had an illness or trouble caused by eating a particular    NO YES 
food or foods?    
 IF 'NO' GO TO QUESTION 74, IF 'YES':    
 73.1 Have you nearly always had the same illness or trouble after eating  NO YES 
         this type of food?    
 IF 'NO' GO TO QUESTION 74, IF 'YES':      
  73.1.1 What type of food was this? [List up to 3] 
                                  ______________________________________________    
                                  ______________________________________________    
                                  ______________________________________________    
   
73.1.2.1-6 Did this illness or trouble include   NO YES 
                    73.1.2.1 a rash or itchy skin?    
                    73.1.2.2 diarrhoea or vomiting?    
                    73.1.2.3 runny or stuffy nose?    
                    73.1.2.4 severe headaches?    
                    73.1.2.5 breathlessness?    
                    73.1.2.6 other: _______________________________________    
      NO YES 
74. Have you ever smoked for as long as a year?    
 ['YES' means at least 20 packs of cigarettes or 12 oz (360 grams) of tobacco 
 in a lifetime, or at least one cigarette per day or one cigar a week for one year] 
 
IF 'NO' GO TO QUESTION 75, IF 'YES':    
       YEARS 
         74.1 How old were you when you started smoking?    
      NO YES 
        74.2 Do you now smoke, as of one month ago?    
  IF 'NO' GO TO QUESTION 74.3, IF 'YES':     
        74.2.1-4 How much do you now smoke on average?  NUMBER     
                    74.2.1 number of cigarettes per day    
                    74.2.2 number of cigarillos per day    
                    74.2.3 number of cigars a week    
                    74.2.4 pipe tobacco in a) ounces / week    
                                                         b) grams / week     
      NO YES 
         74.3 Have you stopped or cut down smoking?    
 
   
 
 
 18
Appendix B 1 – ECRHS II Main Questionnaire   
 IF 'NO' GO TO QUESTION 74.4, IF 'YES':      YEARS 
                     74.3.1 how old were you when you stopped or cut down smoking?    
            74.3.2.1-4 on average of the entire time you smoked, before you  
           stopped or cut down, how much did you smoke?  NUMBER     
                     74.3.2.1 number of cigarettes per day    
                     74.3.2.2 number of cigarillos per day    
                     74.3.2.3 number of cigars a week    
                     74.3.2.4 pipe tobacco in a) ounces / week    
                                                            b) grams / week     
      NO YES 
         74.4 Do you or did you inhale the smoke?    
 
75. Have you been regularly exposed to tobacco smoke in the last 12     NO YES 
months? ['Regularly' means on most days or nights]    
  IF 'NO' GO TO QUESTION 76, IF 'YES':    
       75.1.  Not counting yourself, how many people in your household smoke  NUMBER 
         regularly?    
 
      NO YES 
       75.2   Do people smoke regularly in the room where you work?    
       
75.3   How many hours per day are you exposed to other people's    HOURS 
         tobacco smoke?    
75.4 Please provide more information.  
    How many hours per day, are you exposed to other peoples tobacco  
            smoke in the following locations? 
 
HOURS 
   at home    
  at workplace    
  in bars, restaurants, cinemas or similar social settings    
  elsewhere    
  
76. Have you used any inhaled medicines to help your breathing at any time   NO  YES 
in the last 12 months?    
 IF NO' GO TO QUESTION 77, IF 'YES':  
 Which of the following have you used in the last 12 months?       NO      YES 
76.1 short acting beta-2-agonist inhalers     
(Please include combinations that include beta 2 and steroids in section 76.5)  
76.1.1 If used, which one? ________________________________      
76.1.2 What type of inhaler do you use?      
 NUMBER  
76.1.3. What is the dose per puff (in micrograms)?      
 
76.1.4. In the last 3 months, how have you used them:                          TICK ONE BOX ONLY 
  a) when needed   1  
  b) in short courses 2  
  c) continuously 3  
  d) not at all 4  
 
If answer to  76.1.4 is when needed:   NUMBER 
76.1.5 Number of puffs per month   
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If answer to 76.1.4 is in short courses     NUMBER 
 76.1.6 number of courses   
 76.1.7 number of puffs per day   
 76.1.8 average number of days per month    
If answer to 76.1.4 is continuously          NUMBER 
 76.1.9 number of puffs per day   
 
      
    NO YES 
                76.2 long acting beta-2-agonist inhalers 
(Please include combinations that include beta 2 and steroids in section 76.5) 
 
76.2.1 If used, which one? ________________________________ 
76.2.2 What type of inhaler do you use? 
 NUMBER 
76.2.3. What is the dose per puff (in micrograms)? 
   
76.2.4. In the last 3 months, how have you used them:                       TICK ONE BOX ONLY 
  a) when needed 1  
  b) in short courses 2  
  c) continuously 3  
  d) not at all 4  
 
 If answer to  76.2.4 is when needed:    NUMBER 
76.2.5 Number of puffs per month   
If answer to 76.2.4 is in short courses     NUMBER 
76.2.6 number of courses   
76.2.7 number of puffs per day   
76.2.8 average number of days per month    
If answer to 76.2.4 is continuously         NUMBER 
76.2.9 number of puffs per day   
  
           NO   YES 
            76.3 non-specific adrenoreceptor agonist inhalers    
 
76.3.1 If used, which one? ________________________________     
  
        NO   YES 
         76.4 anti-muscarinic inhalers    
 
76.4.1 If used, which one? _______________________________     
76.4.2 What type of inhaler do you use?     
 NUMBER 
76.4.3. What is the dose per puff (in micrograms)?     
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  76.4.4. In the last 3 months, how have you used them:       TICK ONE BOX ONLY 
   a) when needed  1  
   b) in short courses 2  
   c) continuously 3  
   d) not at all 4  
 
  If answer to 76.4 .4 is when needed:   NUMBER 
                                                76.4.5 Number of puffs per month      
  If answer to 76.4.4 is in short courses    NUMBER 
       76.4.6 number of courses 
       76.4.7 number of puffs per day     
       76.4.8 average number of days per month      
  If answer to 76.4.4 is continuously         NUMBER 
                                                76.4.9 number of puffs per day      
  
     NO YES 
         76.5 inhaled steroids    
(if combined B2 and steroid please insert inhaled steroid dose) 
76.5.1 If used, which one? ________________________________     
76.5.2 What type of inhaler do you use?     
  NUMBER  
76.5.3. What is the dose per puff (in micrograms)?      
   
  76.5.4. In the last 3 months, how have you used them:       TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
d) not at all 4   
 
  
If answer to 76.5.4 is when needed:    NUMBER 
                                                76.5.5 Number of puffs per month         
  If answer to 76.5.4 is in short courses    NUMBER 
      76.5.6 number of courses 
      76.5.7 number of puffs per day     
      76.5.8 average number of days per month      
  If answer to 76.5.4 is continuously         NUMBER 
                                               76.5.9 number of puffs per day         
      NO YES 
         76.6 inhaled cromoglycate/nedocromil    
 
76.6.1 If used, which one? _______________________________      
 NUMBER  
76.6.2. What is the dose per puff (in milligrams)?      
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  76.6.3. In the last 3 months, how have you used them:       TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
 d) not at all 4   
 
  If answer to 76.6.3 is when needed:   NUMBER 
                                                76.6.4 Number of puffs per month         
  If answer to 76.6.3 is in short courses    NUMBER 
       76.6.5 number of courses 
       76.6.6 number of puffs per day     
       76.6.7 average number of days per month      
  If answer to 76.6.3 is continuously         NUMBER 
                                                 76.6.8 number of puffs per day         
  
           NO  YES 
         76.7 inhaled compounds    
 
76.7.1 If used, which one? _______________________________      
76.7.2 What type of inhaler do you use?      
 NUMBER  
76.7.3. What is the dose per puff (in micrograms)?      
   
 
77. Have you used any pills, capsules, tablets or medicines, other than   NO YES 
inhaled medicines, to help your breathing at any time in the last 12 months?    
 IF 'NO' GO TO QUESTION 78, IF 'YES':  
 Which of the following have you used in the last 12 months?  
     NO YES 
         77.1 oral beta-2-agonists    
 
77.1.1 If used, which one? ________________________________     
77.1.2 what dose of tablet     
   
  77.1.3. In the last 3 months, how have you used them:       TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
d) not at all 4   
 
  If answer to 77.1.3 is when needed:   NUMBER 
                                                77.1.4 number of tablets per month         
  If answer to 77.1.3 is in short courses     NUMBER 
        77.1.5 number of courses 
        77.1.6 tablets per day     
        77.1.7 average number of days per month      
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If answer to 77.1.3 is continuously         NUMBER 
                                                 77.1.8 tablets per day         
     NO YES 
         77.2 oral methylxanthines    
 
77.2.1 if used, which one? _______________________________     
77.2.2 what dose of tablet     
 
77.2.3. In the last 3 months, how have you used them:           TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
d) not at all 4   
   
  If answer to 77.2.3 is when needed:    NUMBER 
                                                77.2.4 number of tablets per month         
  If answer to 77.2.3 is in short courses    NUMBER 
      77.2.5 number of courses 
      77.2.6 tablets per day     
      77.2.7 average number of days per month      
  If answer to 77.2.3 is continuously         NUMBER 
                                               77.2.8 tablets per day         
 
     NO YES 
         77.3 oral steroids    
   
77.3.1 If used, which one? _____________________________   
 
77.3.2 what dose of tablet   .  
 
  77.3.3. In the last 12 months, how have you used them:         TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
   
  If answer to  77.3.3 is when needed:    NUMBER  
                                                77.3.4 number of tablets per month         
  If answer to 77.3 3 is in short courses    NUMBER 
     77.3.5 number of courses 
     77.3.6 tablets per day     
     77.3.7 average number of days per month      
  If answer to 77.3.3 is continuously         NUMBER 
                                              77.3.8 tablets per day         
 
                          NO  YES 
 77.3.9. Have you used them in the last 3 months?    
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     NO YES 
         77.4 oral anti-leukotrienes    
 
77.4.1 If used, which one? ____________________________     
77.4.2 what dose of tablet     
 
77.4.3. In the last 3 months, how have you used them:         TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
d) not at all 4   
  If answer to 77.4.3 is when needed:    NUMBER 
                                                77.4.4 number of tablets per month         
  If answer to 77.4.3 is in short courses    NUMBER 
     77.4.5 number of courses 
     77.4.6 tablets per day     
     77.4 .7 average number of days per month      
  If answer to 77.4.3 is continuously         NUMBER 
       NO YES 
 
   
                                              77.4.8 tablets per day         
 
         77.5 ketotifen    
77.5.1 If used, which one? ________________________________     
77.5.2 what dose of tablet     
77.5.3. In the last 3 months, how have you used them:            TICK ONE BOX ONLY 
a) when needed 1   
b) in short courses 2   
c) continuously 3   
 d) not at all 4   
   
  If answer to 77.5.3 is when needed:    NUMBER 
                                                77.5.4 number of tablets per month         
  If answer to  77.5.3 is in short courses    NUMBER 
      77.5.5 number of courses 
      77.5.6 tablets per day     
      77.5.7 average number of days per month      
  If answer to 77.5.3 is continuously         NUMBER 
   
                          NO YES 
IF NO GO TO QUESTION 79      YEARS 
                                               77.5.8 tablets per day         
78. Since the last survey have you ever used inhaled steroids (show list)?     
78.1. How old were you when you first started to use inhaled steroids?  
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     NO  YES 
78.2. Have you used inhaled steroids every year since the last survey?  
 IF NO GO TO QUESTION 78.3, IF YES    MONTHS 
  78.2.1. On average how many months each year have you taken them?  
NOW GO TO Q79 
78.3 How many of the years since the last survey have you taken 
inhaled steroids?   YEARS 
  
78.4. On average how many months of each of these years have you taken  
them?    MONTHS 
  
  
                     NO  YES   DK 
       NO YES 
 
80. Have you had any other injections to help your breathing at any time in   NO YES 
 IF 'NO' GO TO QUESTION 81, IF 'YES':  
79. Have you been vaccinated for allergy since the last survey?      
 IF 'NO' OR 'DON'T KNOW' GO TO QUESTION 80, IF 'YES':  
         79.1 Have you been vaccinated for allergy in the last 12 months?     
the last 12 months?     
 
         80.1 What injections? _________________________________________     
                                            _________________________________________     
 
81. Have you had any suppositories to help your breathing at any time in the   NO YES 
last 12 months?    
 IF 'NO' GO TO QUESTION 82, IF 'YES':  
82 . Have you used any other remedies to help your breathing at any time in    NO YES 
 IF 'NO' GO TO QUESTION 83 IF 'YES':  
         81.1 What suppositories? ______________________________________    
                                                  ______________________________________    
 
the last 12 months?    
         82.1. What remedies?  _________________________________________    
                                            _________________________________________    
                                            _________________________________________    
 
83. Has your doctor ever prescribed medicines, including inhalers, for your    NO YES 
breathing?    
 
 IF 'NO' GO TO QUESTION 84, IF 'YES':  
83.1 If you are prescribed medicines for your breathing, do you normally  
 take  TICK ONE BOX ONLY 
         a) all of the medicine? 1   
         b) most of the medicine? 2   
         c) some of the medicine? 3   
         d) none of the medicine? 4   
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83.2 When your breathing gets worse, and you are prescribed  
 medicines for your breathing, do you normally take     TICK ONE BOX ONLY 
 
         a) all of the medicine? 1   
         b) most of the medicine? 2   
         c) some of the medicine? 3   
         d) none of the medicine? 4   
 83.3 Do you think it is bad for you to take medicines all the time to help   NO YES 
         your breathing?    
 
 83.4 Do you think you should take as much medicine as you need to get   NO YES 
         rid of all your breathing problems?    
 
84. Since the last survey have you visited a hospital casualty department             NO YES 
 IF NO GO TO Q85, IF YES 
84.1  Have you visited a hospital casualty department or     NO YES 
 IF NO GO TO 85, IF YES         NO YES 
           
      TIMES 
or emergency room because of breathing problems?    
emergency room because of breathing problems in the last 12 months?  
84.1.1  Was this due to asthma, shortness of breath or wheezing?  
  84.1.2 How many times in the last 12 months? 
 
85. Since the last survey have you spent a night in hospital because of  NO  YES 
breathing problems?    
 IF NO GO TO Q86  IF YES 
85.1 Have you spent a night in hospital because of breathing problems  NO YES 
in the last 12 months?  
 IF NO GO TO Q86, IF YES         NO YES 
85.1.1 Was this due to asthma, shortness of breath or wheezing?  
  
 85.1.2 How many nights have you spent on each of the following  
types of ward in the last 12 months?    NUMBER   
General    
Chest medicine    
Rehabilitation    
Intensive care unit    
Other    
 
86. Since the last survey have you been seen by a doctor because of     NO YES 
breathing problems or because of shortness of breath?    
 IF NO GO TO Q87, IF YES    
86.1 Have you been seen by a general practitioner because of    NO YES 
breathing problems or shortness of breath in the last 12 months?  
IF NO GO TO Q86.4, IF YES NO YES 
86.2.Was this due to asthma, shortness of breath or wheezing?  
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86.3  How many times have you been seen by your general practitioner because  
   of breathing problems or shortness of breath in each of these locations  
              over the last 12 months?                                                   NUMBER   
at home (excluding emergency visits)    
in his surgery    
at home in an emergency    
at another location    
 
86.4  Have you seen a specialist (chest physician, allergy  
specialist, internal medicine specialist, ENT doctor) because of your          NO   YES 
 breathing problems or shortness of breath in the last 12 months?  
 IF NO GO TO Q87 IF YES       NUMBER 
 86.4.1 How many times?    
 
87. Are you given regular appointments to be seen by a doctor (or nurse)     NO   YES 
 IF NO GO TO Q88  IF YES       NO  YES 
NO  YES 
for your asthma, wheezing or shortness of breath?    
87.1.Are you given regular appointments with a hospital doctor?  
87.2 Are you given regular appointments with your general practitioner?  
NO  YES 
87.3. Are you given regular appointments with a nurse?  
 
 
88. How many times have you visited the following because of  
breathing problems or shortness of breath in the last 12 months? 
      NUMBER 
88.1 nurse    
88.2 physiotherapist    
88.3 practitioner of ‘alternative’ medicine    
 
89. Have you had any clinical or laboratory tests because of asthma    NO YES 
wheezing or shortness of breath in the last 12 months?     
IF NO GOT Q90 ,IF YES 
 89.1. How many times have you had the following in the last 12 months?  
                                 NUMBER   
Breathing test in a laboratory specially for lung function measures    
Skin test for allergy    
Blood test for allergy    
x-rays    
 
       NO YES 
90. Are you currently working?    
IF NO GO TO Q90.2  IF YES  
90.1. How many days of work have you lost because of asthma,          NUMBER 
              shortness of  breath or wheezing in the last 12 months?  
 
  90.2.  Were you forced to give up working because of asthma,            NO    YES 
              wheezing or shortness of breath in the last 12 months? 
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IF NO GO TO 91.  IF YES DAY     MONTH  YEAR 
91.2.1. When?  
    
91. Have there been any days when you have had to give up activities other than work 
     (e.g. looking after children, the house, studying) because of your asthma, NO  YES 
   wheezing or shortness of breath in the last 12 months?    
IF NO YOU HAVE FINISHED THE QUESTIONNAIRE IF YES   
91.2. How many days on average each month?     
 
                       M        F 
Subjects Gender   
          DAY        MONTH   YEAR 
Subjects Date of Birth   
 
 
INTERVIEW TYPE? TICK ONE BOX ONLY 
a) At centre face to face 1   
b) At home face to face 2   
c) By telephone 3   
d) Self completed at home 4   
 
 
END                                                                                FIELDWORKER NUMBER   
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Inhaled steroids are associated with reduced
lung function decline in subjects with asthma
with elevated total IgE
Roberto de Marco, PhD,a Alessandro Marcon, MSc,a Deborah Jarvis, FFPHM,b Simone
Accordini, MSc,a Massimiliano Bugiani, MD,c Lucia Cazzoletti, MSc,a Isa Cerveri, MD,d
Angelo Corsico, MD, PhD,d David Gislason, MD,e Amund Gulsvik, MD, PhD,f Rain Jo˜gi,
PhD,g Jesu´s Martı´nez-Moratalla, MD,h Isabelle Pin, MD,i and Christer Janson, MD,j
on behalf of the ECRHS Therapy Group Verona, Turin, and Pavia, Italy, London, United
Kingdom, Reykjavik, Iceland, Bergen, Norway, Tartu, Estonia, Albacete, Spain, Grenoble, France,
and Uppsala, Sweden
Background: Few studies have investigated the long-term
association between inhaled corticosteroids (ICSs) and lung
function decline in asthma.
Objective: To evaluate whether prolonged treatment with ICSs
is associated with FEV1 decline in adults with asthma.
Methods: An international cohort of 667 subjects with asthma
(20-44 years old) was identified in the European Community
Respiratory Health Survey (1991-1993) and followed up from
1999 to 2002. Spirometry was performed on both occasions.
FEV1 decline was analyzed according to age, sex, height, body
mass index, total IgE, time of ICS use, and smoking, while
adjusting for potential confounders.
Results: As ICS use increased, the decline in FEV1 was lower
(P trend 5 .025): on average, decline passed from 34 mL/y in
nonusers (half of the sample) to 20 mL/y in subjects treated for
48 months or more (18%). When adjusting for all covariates,
there was an interaction (P 5 .02) between ICS use and total
IgE: in subjects with high (>100 kU/L) IgE, ICS use for 4 years
or more was associated with a lower FEV1 decline (23 mL/y;
95% CI, 8-38 compared with nonusers). This association
was not seen in those with lower IgE.
Conclusion: Although confirming a beneficial long-term
association between ICSs and lung function in asthma, our
study suggests that subjects with high IgE could maximally
benefit from a prolonged ICS treatment.
Clinical implications: This study adds further evidence to the
beneficial effect of inhaled steroids on lung function in asthma;
future studies will clarify whether calibrating the corticosteroid
dose according to the level of total IgE is a feasible approach
in asthma management. (J Allergy Clin Immunol
2007;119:611-7.)
Key words: Asthma, lung function decline, inhaled corticosteroids,
total IgE, eosinophils, prospective cohort study, FEV1 decline,
European Community Respiratory Health Survey, ECRHS
In patients with asthma, the decline in lung function is
accelerated compared with subjects without asthma1 and,
in more severe asthma, it may result in an irreversible air-
flow obstruction.2,3 The rapid decline in lung function and
the airflow obstruction may stem from structural changes
(airway remodeling) or functional changes that may or
may not be associated with the underlying chronic inflam-
mation.4-8
Inhaled corticosteroids (ICSs) are the mainstay of
asthma treatment,9 and many short-term clinical trials
have demonstrated their efficacy in decreasing airway in-
flammation, improving lung function, and reducing symp-
toms and airway hyperresponsiveness.10-13 However,
there is limited evidence that ICSs are able to slow
down the progressive loss of lung function over time in
asthma, and also that ICSs can prevent or revert structural
changes in the lungs.14-16 This is mainly because of the
difficulty in following up patients in clinical trials over
many years. Therefore, observational studies make an
important contribution to assess the effectiveness of the
long-term use of ICSs.
Recently, 2 observational follow-up studies have been
published,17,18 both reporting a beneficial effect of the
long-term use of ICSs on lung function decline. Lange
et al18 reported that treatment with ICSs was associated
with an 18 mL/y reduction in the rate of decline in FEV1
compared with no use of ICSs, and Dijkstra et al17 found
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Abbreviations used
ATS: American Thoracic Society
BMI: Body mass index
ECRHS: European Community Respiratory Health Survey
ED: Emergency department
ICS: Inhaled corticosteroid
IQR: Interquartile range
LABA: Long-acting b2-agonist
a similar effect only in nonsmoking men. However, both
surveys investigated relatively small samples of selected
individuals.
The aim of this study was to evaluate whether
prolonged use of ICSs is associated with a reduced long-
term decline in lung function in a large, international,
population-based cohort of subjects with asthma, followed
up for 9 years in the European Community Respiratory
Health Survey (ECRHS).
METHODS
Study design
The ECRHS is an international multicenter study of asthma. The
first survey19 was performed from 1991 to 1993 on random commu-
nity-based samples of adults age 20 to 44 years. Each participant was
sent a brief questionnaire (stage 1) and, from those who responded, a
20% random sample was invited to undergo a more detailed clinical
examination (stage 2). In addition, a symptomatic sample consisting
of those who reported symptoms of waking with shortness of breath
or asthma attacks in the last 12 months or who were using asthma
medication in stage 1 was also studied. The ECRHS II20 was a fol-
low-up study of all participants in stage 2 of the ECRHS I, performed
from 1999 to 2002 (the full protocol can be found at www.ecrhs.org).
Subjects answered a standardized questionnaire administered by
trained interviewers and underwent lung function and blood tests.
Quality control procedures are fully described in the study proto-
cols.19,20 The current study includes data from 26 centers that took
part in the ECRHS II. Ethical approval was obtained for each center
from the appropriate institutional or regional ethics committee, and
written consent was obtained for each participant.
Subjects and definitions
All individuals with current asthma identified in the ECRHS I
(1991-1993) who had performed spirometry according to the
American Thoracic Society (ATS) criteria for reproducibility21 and
who participated in the ECRHS II were eligible for this analysis.
Current asthma was defined as having reported, in the ECRHS I,
asthma confirmed by a doctor and having had asthmalike symptoms
(wheeze; nocturnal chest tightness; attacks of breathlessness after
activity, at rest, or at nighttime; asthma attacks), and/or having
used inhaled/oral medicines because of breathing problems during
the last 12 months.
In the ECRHS I, 1348 subjects with current asthma had their lung
function measured according to the ATS criteria (700 from the
random and 648 from the symptomatic sample). Although there were
no differences in age, sex, smoking habits, FEV1, and IgE levels at
baseline (ECRHS I) in random and symptomatic subjects, the former
had a slightly longer duration of the disease (17.8 vs 16.2 years) and a
lower percentage of manual workers (25% vs 35%) and of people re-
porting exposure to vapors, gas, dust, or fumes in the workplace (44%
vs 50%). Of these 1348 individuals, 860 (64%) attended the second
study (1999-2002) and were therefore eligible for the analysis.
In the ECRHS II (1999-2002), some eligible subjects did not
repeat spirometry (135 subjects) or had their lung function measured
in disagreement with the ATS criteria (32 subjects) and were
excluded from the analysis. Among those who had performed the
lung function test, some had used inhaled long-acting b2-agonists
(LABAs) in the 12 hours before the test. Because the bronchodilating
effect of LABAs can persist for 8 to 12 hours after use, these subjects
were also excluded (26 subjects). Finally, 667 subjects were included
in the analysis (311 from the random and 356 from the symptomatic
sample).
Decline in lung function
Themaximum FEV1 of as many as 5 technically acceptable blows
was recorded, both at baseline and at the end of the follow-up, accord-
ing to the ATS criteria for reproducibility.21 The predicted value
of FEV1 was calculated on the basis of sex, age, and height,
22 and
the FEV1 % predicted was obtained (100 * measured FEV1/predicted
FEV1).
For each subject, the average change in lung function during the
follow-up (in mL/y) was computed as the difference between FEV1
measured in the ECRHS I and II, divided by the individual duration
of the follow-up (ie, a positive value represents decline).
Clinical and questionnaire data
In both surveys, the height, weight, and serum total IgE level of the
participants were measured. For each subject, detailed information
was collected by questionnaire about sex, age, smoking habits
(smoking status, number of cigarettes smoked per day, age at which
they started, age at which they gave up if they did), occupation,
exposure to occupational risk (if a subject had ever been exposed to
vapors, dust, gas, or fumes in the working environment), age at first
asthma attack, family asthma (if a subject reported that his/her mother
or father had ever had asthma), and hospitalizations and/or emer-
gency department (ED) visits (if a subject had ever spent 1 night in the
hospital, and/or visited a casualty department or ED) because of
breathing problems.
Asthma duration was estimated as the difference between the age
of the subject at the ECRHS I interview and the age when the first
asthma attack occurred. Body mass index (BMI) was computed
dividing weight by height squared (kg/m2). Lifetime pack-years were
calculated combining information on smoking habits obtained in the
ECRHS I and II.23
At baseline, subjects performed a methacholine challenge test24;
however, bronchial hyperresponsiveness was not considered in the
main analysis because about 20% of the subjects had not performed
the challenge test, and the exclusion criteria for the test were associ-
ated with baseline FEV1 (eg, FEV1 < 70% predicted, FEV1 < 1.5 L).
Use of inhaled steroids
In both surveys, the participants were askedwhether they had used
ICSs in the last 12 months, and the type/brand of steroid and the type
of inhaler employed over the last year were recorded. In the ECRHS
II, quantitative information was collected about ICS use during the
follow-up (howmany months per year, howmany years since the last
survey a subject had been on ICSs). The data on ICSs were combined
to calculate the cumulative time of treatment during the follow-up.
Subjects with asthma were stratified according to the time of steroid
use into (1) nonusers, (2) people who had used ICSs for <8.7 months
(1st tertile of time of ICS use distribution among users), (3) 8.7
months but <48 months (2nd tertile), and (4) 48 months.
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Statistics
Data were summarized as percentages or means (with SDs), with
95% CIs. Median with interquartile range (IQR) was used for
asymmetrical variables. x2 Test, Student t test, ANOVA, and Wil-
coxon test were used to test differences, where appropriate, using a
significance level of .05.
To assess the association between FEV1 decline (dependent vari-
able) and the cumulative time of ICS use, a 2-level random intercept
regression model was fitted to the data, with level 1 units (subjects)
nested into level 2 units (centers crossed by type of sample: random
or symptomatic). The independent variables included in the model
were sex, age, height, baseline BMI, and smoking habits (lifetime
pack-years); themodel also adjusted for a set of potential confounders
measured at baseline—that is, occupation (in a manual job, nonman-
ual job, or other), occupational risk, duration of asthma, family
asthma, total IgE, and previous hospitalizations/ED visits for breath-
ing problems. When evaluating the interaction between time of ICS
use and total IgE, the latter was used as a dichotomous variable
(100 kU/L; >100 kU/L).25
The statistical analysis was performed using STATA software,
release 8.2 (Stata Corp, College Station, Tex).
RESULTS
Comparison between included
and excluded subjects
Table I describes the main baseline features of the sub-
jects included and not included in the analysis. The latter
are either nonparticipants in the ECRHS II, or participants
whose FEV1 was unavailable, not in agreement with the
ATS criteria, or measured within 12 hours after the last ad-
ministration of a LABA. Subjects included in the analysis
were slightly older and had a lower percentage of current
smokers (30% vs 39%) and of manual workers than sub-
jects who were excluded. On average, among the individ-
uals included in the analysis, the follow-up time was 9
years (range, 6-11 years).
Use of inhaled steroids
The cumulative time of ICS use could not be evaluated
for 31 individuals (<5%) because some data were missing.
Out of the remaining 636 subjects, 297 (47%) had never
been on ICSs, whereas 339 (53%) had used ICSs during
the follow-up. Among ICS users, the median cumulative
time of treatment was 1.4 (IQR, 6.3) years, with no
significant difference between men and women (P5 .33).
Among people who had used ICSs for 4 years, the
median time of use was 8.2 (IQR, 2.0) years.
The steroid that was most commonly used during
the year before the follow-up visit (ECRHS II) was bude-
sonide (51%), followed by beclomethasone (27%), and
fluticasone (20%); the majority of subjects used dry-
powder inhalers (65%), 1/3 used metered-dose inhalers,
and only 1% used nebulizers.
Characteristics of steroid users
and nonsteroid users
At baseline, on average, subjects with asthma treated
with ICSs during the follow-up (Table II) had a worse lung
function, higher levels of total IgE, a shorter duration of
asthma, and a greater prevalence of family asthma and
of hospitalizations/ED visits than nonsteroid users.
Steroid users were more likely to be women and had a
higher baseline BMI than nonsteroid users, and they also
TABLE I. Baseline (ECRHS I) characteristics of excluded
and included subjects; data provided as means (SDs)
or percentages (%) unless stated otherwise*
Excluded Included P value
Subjects (N) 681 667 —
Sex (% female) 54.6 55.0 .88
Age (y) 32.3 (7.2) 33.9 (7.2) .0001
BMI (kg/m2) 23.9 (4.3) 24.2 (4.5) .31
Smoking habits* (pack-years) 2.0 (10.0) 0.5 (9.0) .046
Occupation
(% nonmanual) 36.4 48.0 <.0001
(% manual) 31.3 29.1
(% other) 32.3 22.9
Occupational exposure (%) 46.6 47.6 .71
Duration of asthma* (y) 16.2 (16.5) 15.6 (19.1) .60
Family asthma (%) 28.5 26.2 .36
Total IgE (log transformation) 1.98 (0.71) 1.91 (0.68) .053
Hospitalizations/ED visits (%) 36.3 35.9 .88
ICS (% users) 41.6 43.4 .60
FEV1 (L) 3.4 (0.9) 3.4 (0.8) .50
*Median (interquartile range); P values of nonparametric test reported.
Over the period of the last 12 months.
TABLE II. Baseline (ECRHS I) characteristics (and lifetime
pack-years smoked) of the subjects with asthma, stratified
according to the use of inhaled corticosteroids during the
follow-up; data provided asmeans (SDs) or percentages (%)
unless stated otherwise*
ICSs
Nonusers Users P value
Subjects, N (%) 297 (46.7) 339 (53.3) —
Sex (% female) 45.4 63.7 <.001
Age (y) 33.7 (7.1) 34.1 (7.3) .44
BMI (kg/m2) 23.6 (3.6) 24.5 (4.9) .001
Smoking habits* (lifetime
pack-years)
1.6 (15.6) 0 (10.0) .013
Occupation
(% nonmanual) 47.5 49.0 .48
(% manual) 28.0 30.4
(% other) 24.5 20.6
Occupational exposure (%) 47.6 48.4 .85
Duration of asthma* (y) 18.7 (19.1) 13.5 (17.9) .001
Family asthma (%) 19.3 31.1 .001
Total IgE (log
transformation)
1.84 (0.66) 1.96 (0.68) .033
Hospitalizations/ED
visits (%)
28.6 42.9 <.0001
FEV1 (L) 3.7 (0.8) 3.2 (0.8) <.0001
FEV1 % predicted 101.6 (12.6) 95.0 (17.9) <.0001
*Median (interquartile range); P values of nonparametric test reported.
Predicted values of FEV1 were calculated on the basis of sex, age,
and height.
Corresponding to a geometric mean of 69.6 kU/L in nonusers and of
91.9 kU/L in users.
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had a lower percentage of current smokers at baseline
(24% vs 36%).
Decline in lung function
In subjects with asthma, the average decline in FEV1
was 35 (95% CI, 29-40) mL/y for men and 24 (95% CI,
20-28) mL/y for women (Fig 1). FEV1 decline was posi-
tively associated with age (P trend 5 .003), but not with
baseline BMI and with lifetime exposure to active smok-
ing (pack-years). FEV1 decline was 32 (95% CI, 27-36)
mL/y and 25 (95% CI, 21-30) mL/y for individuals ex-
posed and not exposed to occupational risk, respectively.
FEV1 decline was unrelated to occupation, hospitaliza-
tions/ED visits, total IgE, family asthma, and asthma dura-
tion at baseline.
FEV1 decline was lower in subjects who had used ICSs
for a longer time (P trend5 .025); it was 34 mL/y in non-
users, 28 mL/year in subjects treated for <8.7 months, 24
mL/y in subjects treated for8.7 months but<48 months,
and 20 mL/y in subjects treated for 48 months.
When all the variables were considered simultaneously
(Table III), the use of ICSs for 48 months was statisti-
cally significantly associated with a lower decline (11
mL/y; 95%CI, 0.1-21 compared with nonusers). A shorter
therapy with steroids (<48 months) was also associated
with a lower decline (about 4 mL/y), but it was not statis-
tically significant. FEV1 decline was greater for older sub-
jects (0.8 mL/y; 95% CI, 0.2-1.4 for every additional year
in subject age). None of the other covariates considered in
the analysis was significantly associated with FEV1 de-
cline. There was no statistically significant interaction be-
tween sex and ICS use, nor between lifetime pack-years
smoked and ICS use, but a significant (P5 .02) interaction
was found between having an elevated (>100 kU/L) level
of total IgE and ICS use (Fig 2). After adjusting for all the
potential confounders, in subjects having total IgE > 100
FIG 1. Unadjusted mean annual decline in FEV1 (with 95% CIs and P value for trend) from 1991-1993 to 1999-
2002, according to sex, age, and BMI at baseline, and lifetime pack-years smoked. *Student t test.
TABLE III. Multiple regression coefficients* with 95% CIs
and related P values for the association between the mean
decline in FEV1 and sex, age, and BMI at baseline and
smoking habits and ICS use during the follow-up
Covariate
Coefficient
(mL/y) 95% CI P value
Sex (female) 29.5 220.4; 1.4 .09
Age (y) 0.8 0.2; 1.4 .005
BMI (kg/m2) 20.4 21.3; 0.5 .40
Smoking habits
(lifetime pack-years)
0.04 20.2; 0.3 .76
Use of ICSs
<8.7 months 23.9 214.4; 6.5 .46
8.7 months to 4 years 24.8 215.5; 6.0 .38
>4 years 210.7 221.3;20.1 .048
*Adjusted for height, occupation, exposure to occupational risk, duration of
asthma, familiarity of asthma, total IgE, previous hospitalizations/ED visits;
obtained through a 2-level random intercept regression model fitted on
subjects with complete information (n 5 511).
The coefficient represents the difference in the mean decline in FEV1
decline (mL/y) between subjects with the characteristic and subjects
belonging to the reference category (ie, ‘‘male’’ for variable ‘‘sex’’ and
‘‘no ICSs’’ for variable ‘‘use of ICSs’’).
The coefficient represents the change in FEV1 decline (mL/y) for a
unit change in the covariate.
FIG 2.Unadjusted mean annual decline in FEV1 (with 95% CIs and P
value for trend), according to the level of total IgE and to the time of
ICS use during the follow-up (nonusers, 1st, 2nd, and 3rd tertile).
Elevated (>100 kU/L) total IgE levels were present in 47% of the
subjects included in the analysis.
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kU/L (47% of the subjects included in the analysis), the
use of ICSs for 4 years was associated with a lower
FEV1 decline (23 mL/y; 95% CI, 8-38 compared with
nonusers). In ICS users with elevated total IgE, the
Pearson correlation coefficient between FEV1 decline
and total IgE was 0.07 (95% CI, 20.09 to 0.22).
When the analysis was repeated adjusting for bronchial
hyperresponsiveness, coded as present (if a subject had
PD20 < 1000 mg), absent, or test not performed, the results
were fully consistentwith those presented (data not shown).
DISCUSSION
In a large community-based sample of subjects with
asthma from the general population, followed up for 9
years, we have shown that a lower decline in FEV1 was as-
sociated with a prolonged use of inhaled steroids. This as-
sociation was only observed in those with elevated total
IgE levels. There was a dose-response relationship, with
lower decline in those who had used inhaled steroids for
the longest periods. The association was found in men
and in women, as well as in smokers and in nonsmokers.
In the whole cohort, the average FEV1 decline was 11
mL/y lower in subjects with asthma who reported that
they had used ICSs for 4 years or more during the fol-
low-up, compared with nonusers. The current finding is
in line both with clinical trials,12,13,26-28 and with 2 recent
observational studies.17,18 Our estimate of the prevented
FEV1 decline that was potentially attributable to ICSs
(11 mL/y; 95% CI, 0.1-21) is somewhat smaller than
that reported in the study by Lange et al18 (18 mL/y).
This may be a result of the relatively young age of our co-
hort. In fact, the rate of lung function decline increases
with age, as supported by our results (Table III) and as
previously reported29,30; accordingly, one could expect a
greater benefit from ICSs in patients whose FEV1 is
declining more steeply.
An intriguing and original finding of our analysis was
that a lower decline in lung function in long-term steroid
users was observed only in subjects with asthma with
elevated (>100 kU/L) total serum IgE levels, whereas
subjects with low IgE seemed to be less responsive. There
was no correlation between lung function decline and total
IgE in ICS users with elevated total IgE, supporting the
idea that the association between lower FEV1 decline and
ICS use was an all-or-none association.
High serum total IgE levels are strongly associated with
asthma, independently of specific allergic sensitization,31
with disease severity,32 and are a major contributing factor
for the development of bronchial hyperresponsiveness in
both allergic and nonallergic asthma.31 Elevated total se-
rum IgE levels reflect the nature of the underlying airway
inflammation, and are associated with a higher eosinophil
count and higher eosinophil cationic protein (a marker of
eosinophil activation) in the blood.33 Recently, anti-IgE
treatment has been shown to be associated with significant
and profound reductions in tissue eosinophils and in mast
cells, as well as T cells and B cells, suggesting that
blocking IgE may inhibit more chronic aspects of allergic
inflammation.34,35 Furthermore, total serum IgE is an in-
dependent predictor of immediate treatment response to
ICSs,36 and a decrease in total serum IgE is significantly cor-
related with an improvement in asthma symptom scores.37
We speculate that the lower decline of lung function in
long-term ICS users with asthma is mainly a result of the
effect of steroids on the eosinophils. These cells produce
cytokines, chemokines, lipid mediators, and growth fac-
tors, and can also cause an increase in mucus production,
resulting in subepithelial fibrosis and in an alteration of
airway smooth muscle contractility.38 Eosinophils are
thought to be key effector cells contributing to both airway
inflammation and remodeling in asthma.38 Steroids are
able to inhibit the mediator release from eosinophils, to
decrease the eosinophil count by inducing apoptosis,39,40
and to attenuate the levels of eosinophil progenitors in
peripheral blood and, to some extent, in bone mar-
row.38,39,41-43
Furthermore, in subjects having low IgE levels, inflam-
mation could be predominantly neutrophilic,42 and it has
been shown that neutrophils are not sensitive to the effect
of steroids. Indeed, systemic steroids increase peripheral
neutrophil counts, a fact that may reflect an increased sur-
vival time because of an inhibitory action on neutrophil
apoptosis.44
In agreement with Lange et al,18 but not with Dijkstra
et al,17 we found no evidence that the association between
ICS use and lung function decline was different in men
and in women.
The lack of association between smoking and lung
function deterioration was somewhat surprising. One
possible explanation could be the young age of our cohort.
Also, one could speculate that this finding could reflect the
healthy smoker effect (only subjects with asthma with
relatively good lung function at baseline smoke or start
smoking, whereas subjects with more severe asthma
refrain from smoking).
Previous studies have found that smoking interferes
with the long-term beneficial effects of steroids.17,26,45,46
The lack of interaction between smoking habits and ICS
use found in our study probably reflects that the group
of subjects selected for our analysis does not allow a full
appreciation of the effect of smoking on lung function
decline, and hence on its potential modification on the
effect of ICSs.
In evaluating the association between the long-term use
of ICSs and the average decline in FEV1, we adjusted for
different characteristics of the subjects (age, height, BMI,
different hazardous exposures), as well as for variables
related to asthma (duration and familiarity) and its sev-
erity (previous hospitalizations and/or ED visits, total
IgE levels). Nevertheless, our results may be affected by
some bias, given that the allocation of subjects to ICS
treatment was not based on randomization but rather on in-
dication. ICS users may differ from nonusers in some as-
pects that have not been measured. For example, subjects
who get access to and regularly take prescribed medica-
tions may be more likely to adopt generally healthier
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lifestyles (such as healthy diet and exercise). High dietary
intake of antioxidants has been associated with lung func-
tion,47 but we have no information on this for our sample.
On the other hand, one might expect subjects with more
severe disease to be prescribed more medication. At base-
line, the treated group had poorer lung function, higher
rates of hospitalization for respiratory diseases, and higher
prevalence of family asthma than the untreated group.
Therefore, we might expect them to have a steeper de-
crease in lung function than subjects who did not receive
treatment (the horse-racing effect).48,49 If this is true, we
have underestimated the association between ICS use
and FEV1 decline.
A potential limitation of the current study is that a self-
reported doctor diagnosis of asthma was used to identify
individuals with asthma. Although this definition may be
open to some degree of misclassification, it has been
proven to be highly specific,50 so that only milder or undi-
agnosed asthmatics would not have been included in our
study.
Compared with other recent longitudinal studies inves-
tigating the association between ICSs and lung function
decline,17,18 our study has some points of strength. First,
the ECRHS sample was selected from the general pop-
ulation in an international setting. Second, in the current
study, a cumulative time of ICS use was estimated for
each individual in the follow-up period. Finally, the indi-
viduals who had used inhaled LABAs in the 12 hours be-
fore lung function testingwere excluded, thus reducing the
risk of a bias because of the residual bronchodilating effect
of these drugs.
In conclusion, the longitudinal analysis of the decline
of lung function in a large, international, population-
based sample of subjects with asthma supports the
hypothesis that the long-term use of ICSs might prevent
the deterioration of lung function in individuals having
elevated levels of total serum IgE, whereas lung function
could be less influenced by steroids in subjects with
lower levels of IgE. This finding is not to be interpreted
as an advise to prescribe ICSs only in subjects with
asthma and elevated IgE levels. In fact, we investigated
only the effect of a prolonged use of ICSs on lung
function deterioration, whereas ICSs have been clearly
shown to have favorable effects on several short-term
outcomes. Moreover, a long-term use of ICSs has been
demonstrated to reduce the risk of both asthma-related
death51 and hospitalization.52 Our findings underline the
importance of total IgE as a feature of asthma, not only
because it helps to predict its severity32 and prognosis,
but also because it might influence decisions on long-
term anti-inflammatory treatment. Further investigations
are needed to clarify whether calibrating the corticoste-
roid dose according to the level of IgE is a feasible ap-
proach in asthma management.
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Original article
Body mass index, weight gain, and other determinants of
lung function decline in adult asthma
Alessandro Marcon, MSc,a Angelo Corsico, MD, PhD,b Lucia Cazzoletti, MSc,a Massimiliano Bugiani, MD,c
Simone Accordini, MSc,a Enrique Almar, MD,d Isa Cerveri, MD,b David Gislason, MD,e Amund Gulsvik, MD, PhD,f
Christer Janson, MD,g Deborah Jarvis, MD,h Jesu´s Martı´nez-Moratalla, MD,i Isabelle Pin, MD,j and Roberto de Marco,
PhD,a and the Therapy and Health Economics Group of the European Community Respiratory Health Survey Verona, Pavia,
and Turin, Italy, Albacete, Spain, Reykjavik, Iceland, Bergen, Norway, Uppsala, Sweden, London, United Kingdom, and Grenoble, France
Background: Little is known about factors associated with lung
function decline in asthma.
Objective: To identify the determinants of FEV1 decline in
adults with asthma with and without airflow obstruction at
baseline.
Methods: An international cohort of 638 subjects with asthma
(20-44 years old) was identified in the European Community
Respiratory Health Survey (1991-1993) and followed up from
1998 to 2002. Spirometry was performed on both occasions.
FEV1 decline was related to potential determinants evaluated at
baseline and during the follow-up by random intercept linear
regression models. The analyses were stratified by the presence
of airflow obstruction (FEV1/forced vital capacity < 0.70) at
baseline.
Results: In the group of individuals without airflow obstruction
(n 5 544), a faster FEV1 decline was observed for subjects with
intermediate body mass index (BMI) than for lean and obese
subjects. FEV1 decline was associated with weight gain
independently of baseline BMI, and this association was
stronger in men (20; 95% CI, 10-30, mL/y/kg gained) than in
women (6; 95% CI, 1-11, mL/y). In the group of individuals with
airflow obstruction (n 5 94), the absence of allergen
sensitization and a low BMI at baseline were associated with a
faster FEV1 decline, whereas weight gain was not associated
with decline.
Conclusions: The detrimental effect of weight gain on FEV1
decline is particularly relevant in subjects with asthma who still
do not have an established airflow obstruction. Our findings
support the importance of weight management in asthma and
recommend weight loss in overweight or obese individuals with
asthma. (J Allergy Clin Immunol nnnn;nnn:nnn-nnn.)
Key words: Asthma, lung function decline, airflow obstruction, body
mass index, weight gain, obesity, FEV1, allergen sensitization, pro-
spective cohort study, predictors
Impaired pulmonary function, as measured by a low FEV1, is a
predictor of mortality in the general1 as well as in the asthmatic
population.2 Subjects with asthma have a faster FEV1 decline
than subjects without asthma,3 and FEV1 decline leads to persis-
tent airflow obstruction for some individuals with asthma. Com-
pared with subjects without obstruction, subjects with airflow
obstruction have a more severe form of asthma, they may be on
an inadequate asthma treatment, and their airways may already
have been remodeled by chronic inflammation.4 Subjects in the
2 groups may have different individual characteristics and past
exposures, a different history of asthma, and different determi-
nants of lung function change over time. Some recent articles
have suggested that long-term treatment with inhaled steroids
may slow down the decline in FEV1,
5-7 particularly in subjects
with elevated total IgE levels.7 However, little is known about
other factors associated with rapid FEV1 decline in adult asthma.
We aimed at investigating the determinants of FEV1 decline in a
large, international, population-based cohort of subjects with
asthma with or without airflow obstruction at baseline, who
were followed up for 9 years in the European Community Respi-
ratory Health Survey (ECRHS).
METHODS
Study design
The ECRHS is an international multicentre study of asthma. The first
survey (ECRHS I)8 was carried out from 1991 to 1993 on random community-
based samples of adults age 20 to 44 years. Each participant was sent a brief
questionnaire (stage 1), and from thosewho responded, a 20% random sample
was invited to undergo a more detailed clinical examination (stage 2). In ad-
dition, a sample (called ‘‘symptomatic sample’’ in the article) consisting of
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Abbreviations used
ATS: American Thoracic Society
BMI: Body mass index
ECRHS: European Community Respiratory Health Survey
ETS: Environmental tobacco smoke
FVC: Forced vital capacity
Q1: 1st quartile
Q3: 3rd quartile
subjects not already included in the random sample who reported asthmalike
symptoms in the last 12months, or whowere using asthmamedication in stage
1, was also studied. Subjects from the random and from the symptomatic
samples were examined at the same time and with the same methods and
accuracy. The ECRHS II9 was a follow-up study of all the participants in stage
2 of the ECRHS I, performed between 1999 and 2002 (the full protocol can be
found at http://www.ecrhs.org). In both studies, subjects answered a standard-
ized questionnaire administered by trained interviewers and they underwent
lung function and blood tests. The current study includes data from 26 centers
that took part in the ECRHS II. Ethical approval was obtained for each center
from the appropriate institutional or regional ethics committee, and written
consent was obtained from each participant.
Subjects and definitions
All individuals with current asthma identified in the ECRHS I (1991-1993)
who had performed spirometry complying with the American Thoracic
Society (ATS) criteria for reproducibility10 and who had participated in the
ECRHS II were eligible for these analyses. Current asthma was defined as
having reported, in the ECRHS I, asthma confirmed by a doctor, and having
had asthmalike symptoms (wheeze; nocturnal chest tightness; attacks of
breathlessness after activity, at rest, or at night time; asthma attacks), and/
or having used inhaled/oral medicines because of breathing problems during
the last 12 months. In the ECRHS I, 1348 subjects with current asthma had
their lung function measured according to the ATS criteria. Compared with
subjects from the symptomatic sample (n 5 648), subjects from the random
sample (n 5 700) had a longer duration of the disease (median, 17 vs 15
years), had a lower body mass index (BMI; 23 vs 24 kg/m2) and included a
smaller percentage of individuals with a low educational level (9% vs 15%;
P < .01). Of these 1348 individuals, 860 (64%) participated in the second
study (1999-2002) and were therefore eligible for the analyses. In the ECRHS
II (1999-2002), some eligible subjects did not repeat spirometry (135 sub-
jects), or their lung function was not measured in compliance with the ATS
criteria (32 subjects), or they had used inhaled long-acting b2-agonists in
the 12 hours before the test (26 patients), and were therefore excluded
from the analyses.
Lung function
The maximum FEV1 and forced vital capacity (FVC) of at least 2 and as
many as 5 technically acceptable maneuvers were recorded, according to
the ATS criteria for reproducibility.10 FEV1% predicted and FVC%predicted
were calculated on the basis of the equations by Quanjer et al.11 The average
decline in FEV1 (or FVC) during the follow-upwas computed as the difference
between FEV1 (or FVC) measured in the ECRHS I and II, divided by the du-
ration of the follow-up (expressed in mL/y). %FEV1/FVC decline was also
computed as the difference between %FEV1/FVC in the ECRHS I and II, di-
vided by the duration of the follow-up (expressed in %/y). Baseline airflow
obstruction was defined as FEV1/FVC<0.70
12 at the first visit (ECRHS I). Be-
cause a bronchodilator challenge test was not part of the ECRHS core proto-
col, the follow-up spirometrywas used to confirm baseline airflow obstruction.
Accordingly, 29 subjects with baseline airflow obstruction, who had FEV1/
FVC 0.70 at the follow-up, were excluded from the analyses to reduce the
number of false-positives results.13 A sensitivity analysis was performed to
confirm that this did not affect our results (data not shown).
Clinical and questionnaire data
The clinical interview included questions on asthma and respiratory
symptoms, smoking habits (smoking status, number of cigarettes smoked
per day, age when subjects started smoking, age when they gave it up if they
did), environmental tobacco smoke (ETS; ie, regular exposure to other
people’s smoke for 1 h/d or more), educational level (low if a subject had
completed full-time education before the age of 16 years), age at first asthma
attack, family asthma (mother/father ever had asthma), and use of inhaled
steroids during the follow-up. Pack-years smoked were calculated for the
period before the ECRHS I and for the follow-up period.14 Asthma duration
was estimated as the difference between the age of the subject at the ECRHS
I interview and the age when the first asthma attack occurred. The subject’s
weight (kg) and height (m) were measured, and BMI was calculated
(weight/height2). BMI gain (kg/[m2y]) or weight gain (kg/y) during the fol-
low-up was computed as the difference between BMI/weight, measured in
the ECRHS II and I, divided by the duration of the follow-up.
At baseline (ECRHS I), total IgE and specific IgE against house dust mite,
cat dander, timothy grass, Cladosporium species, and a local allergen were
measured. A subject was considered sensitized to any allergen if the assay re-
sult for at least 1 allergen was higher than 0.35 kU/L. Subjects performed a
methacholine challenge test,15 but bronchial hyperresponsiveness was not
considered in the analyses because about 20% of the subjects had not per-
formed the challenge test, and the exclusion criteria for the test were associ-
ated with baseline FEV1 (eg, FEV1 < 70% predicted; FEV1 < 1.5 L).
Statistics
Overall, 638 subjects were included in the analyses. All the analyses were
stratified by the presence of airflow obstruction (FEV1/FVC < 0.70) at base-
line. Data were summarized as percentages, or medians with interquartile
ranges (1st quartile-3rd quartile [Q1-Q3]). The x
2 test, the Fisher exact test,
and the Wilcoxon test were used to test differences, where appropriate (a 5
0.05). To assess the association between FEV1 decline and the potential deter-
minants, 2-level (with level-1 units, subjects, nested into level-2 units, centers,
crossed by type of sample: random/symptomatic) random intercept multiple
linear regression models16 were fitted to the data. The independent variables
included in the models were BMI, educational level, pack-years, ETS expo-
sure, sensitization to allergens, asthma duration, and family asthma measured
at baseline; and BMI/weight gain, pack-years, and change in ETS exposure
measured during the follow-up. The models were also adjusted for sex, age,
height, and the interaction between inhaled steroid use during the follow-up
(<4 years vs 4 years) and baseline total IgE (100 kU/L vs >100 kU/L).7
In the group of subjects without airflow obstruction, BMI squared was also in-
cluded in the model, because it significantly (P5 .0009) improved the model
fitting. Statistical interactions were evaluated through likelihood ratio tests.
The statistical analyses were performed using STATA software, release 9.2
(Stata Corp, College Station, Tex).
RESULTS
Comparison between included and excluded
subjects
Subjects excluded from the analyses (n 5 710) were younger
(median age [Q1-Q3], 32 [26, 38] years vs 34 [28, 40] years; P <
.001), and they were more likely to be current smokers (38% vs
30%; P5 .01) than subjects who were included (n5 638). How-
ever, the 2 groups were similar in regard to all the other baseline
covariates (including BMI: median, 23 kg/m2 in both groups), as
well as baseline FEV1 and FVC.
Characteristics and lung function of the subjects
included in the analyses
Subjects in the random (n 5 299) and subjects in the symp-
tomatic (n 5 339) samples were similar for baseline FEV1
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(median [Q1-Q3], 3.4 [2.9, 4.0] L vs 3.3 [2.8, 4.1] L; P5 .15), as
well as for FEV1 decline during the follow-up (median [Q1-Q3],
29 [7, 50] mL/y vs 29 [10, 52] mL/y; P5 .75). As shown in Table
I½T1 , subjects with airflow obstruction at baseline (n5 94; 15%)were
more likely to be men, to be older, and to have had asthma for a
longer time than subjects without airflow obstruction (n 5 544;
85%). Moreover, they had a lower BMI gain during the follow-
up. In subjects without baseline airflow obstruction, a high base-
line BMI was associated with a lower baseline FEV1, both in men
and in women (Fig 1½F1 ). Obese subjects (BMI range, 30-47 kg/m2)
had a lower median FEV1 than nonobese subjects (3.0 vs 3.5 L;
P < .001), a lower median FVC (3.8 vs 4.2; P < .001) and
FEV1Q2 /FVC (0.80 vs 0.82; P 5 .10).
Determinants of lung function decline
FEV1 decline and %FEV1/FVC decline were greater for sub-
jects without airflow obstruction than for subjects with airflow
obstruction (Table II½T2 ).
In subjects with asthma without airflow obstruction at baseline
(also see univariate analyses in this article’s Table E1Q3 of the On-
line Repository at www.jacionline.org), FEV1 declinewas associ-
ated with baseline BMI in a quadratic way (Table III½T3 , column 1).
In other words, men andwomenwith an intermediate BMI had the
greatest FEV1 decline (Fig 2½F2 ). Subjects with a high educational
level had a faster FEV1 decline than subjects with a low educa-
tional level (P 5 .003; Table III, column 1). Independently of
baseline BMI, FEV1 decline was 28 mL/y greater for every
BMI unit (1 kg/m2) gained during 1 year of follow-up (P <
.001). Moreover, there was an interaction between sex and BMI
gain (P 5 .003): FEV1 decline was 61.8 (95% CI, 32.0-91.7;
P < .001) mL/y greater per BMI unit gained during 1 year of
follow-up in men, and 20.2 (95% CI, 7.9-32.6; P 5 .001) mL/y
greater per BMI unit gained in women (Fig 3 ½F3). This corresponds
to a FEV1 decline of 20.0 (95% CI, 10.4-29.5; P < .001) mL/y/kg
gained during 1 year of follow-up inmen, and to 6.9 (95%CI, 2.5-
11.4; P 5 .002) mL/y/kg gained in women.
In subjects with asthma with airflow obstruction at baseline
(see this article’s Table E2 of the Online Repository at www.ja-
cionline.org), the absence of allergen sensitization (P 5 .035)
and a lower BMI (P 5 .008) at baseline were both associated
with a faster FEV1 decline (Table III, column 2).
No significant association was found between exposure to
active or passive smoking and FEV1 decline, either in subjects
with or in subjects without airflow obstruction.
DISCUSSION
A large community-based sample of subjects with asthma was
surveyed in 1991 Q4/93 and again in 1999/2002 Q5. In the group of in-
dividuals without airflow obstruction at baseline, a faster FEV1
decline was observed in subjects whose BMI was intermediate
than for lean and obese subjects. FEV1 decline was associated
with BMI gain independently of baseline BMI, and this associa-
tion was stronger in men than in women. In the group of individ-
uals with airflow obstruction at baseline, weight gain was not
associated with decline.
The analyses were stratified by the presence of airflow
obstruction at baseline to account for the heterogeneity of asthma
phenotypes.4 Because a bronchodilator challenge test was not part
of the ECRHS core protocol, we used the follow-up spirometry to
confirm baseline airflow obstruction.
The stratification by airflow obstruction at baseline seems to be
supported a posteriori by our findings, because the role played by
BMI and weight gain in FEV1 decline was different in the 2
groups. Furthermore, a joint post hoc analysis (data not reported)
showed a significant interaction between BMI gain and the pres-
ence of airflow obstruction (P 5 .001).
Compared with subjects with airflow obstruction, subjects
without airflow obstruction had a faster FEV1 decline and
%FEV1/FVC decline during the follow-up. This may be because
a steep decline had already occurred before the first visit in sub-
jects with airflow obstruction, as suggested by their lower baseline
FEV1.
Baseline BMI and FEV1 decline in subjects with
asthma without airflow obstruction at baseline
A high baseline BMI was associated with a lower baseline
FEV1, but not with a faster FEV1 decline during the follow-up.
Several studies have reported that obesity decreases lung volumes.
In fact, the adipose tissue increases chest wall loading.17-19 This
would also explain the concomitant FVC decline observed in
the obese (BMI > 30kg/m2). However, no evident restrictive pat-
tern (defined by BMI30 kg/m2 and FEV1/FVC >0.70 and FVC
<80% predicted)20 was found at baseline in any of the subjects.
In the absence of a weight reduction, there is no evident reason
why the lung function decline in obese subjects should be blunted
with respect to nonobese subjects. However, asthma in the obese
may be different from asthma in normal-weight subjects. Obesity
causes lower than normal functional residual capacity, with the
TABLE I. Baseline and follow-up characteristics of the subjects
with asthma, stratified by the presence of airflow obstruction at
baseline
Airflow obstruction at baseline
No Yes P value
No. of subjects (%) 544 (85) 94 (15) —
Sex (% female) 59 34 <.001
Baseline covariates
Age (y) 33 (28-40) 36 (30-43) .004
BMI (kg/m2) 23 (21-26) 23 (21-26) .57
Low educational level (%) 11 14 .50
Smoking habits
Nonsmokers (%) 49 40 .25
Ex-smokers (%) 21 26
Current smokers (%) 30 34
Pack-years 0 (0-9) 2 (0-10) .16
ETS (%) 48 44 .45
Sensitization to any
allergen (%)
67 75 .12
Duration of asthma (y) 15 (6-25) 22 (9-29) <.001
Family asthma (%) 26 26 .92
Follow-up covariates
Weight gain (%) 80 73 .12
BMI gain (kg/[m2y]) 0.18 (0.04-0.35) 0.15 (0-0.24) .01
Pack-years between surveys 0 (0-2) 0 (0-4) .24
Change in ETS (%)
Unchanged 69 70 .74
Worsened 6 7
Improved 25 23
Data are provided as percentages or medians (Q1-Q3). Statistically significant results
(P < .05) are in boldface.
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consequence of unloading the airway smoothmuscle and allowing
it to shorten excessively when activated,19,21 and a decrease in op-
erational lung volume.22 Moreover, breathing at lower tidal vol-
umes inhibits the bronchodilating effect of tidal strain on the
airway smooth muscle.19,23 These mechanical and functional
changes within the respiratory system may explain the observed
link between obesity and bronchial asthma.24 Our data support
the hypothesis that asthma in the obese is less determined by in-
flammation than in the nonobese, in agreement with the reversible
nature of lung function decline observed with weight loss.25 This
hypothesis, if true, could lead to the implication that, in obese sub-
jects with uncontrolled asthma, weight loss should be primarily
targeted, and that it may be worth assessing the level of bronchial
inflammation before increasing inhaled steroid doses. However,
the faster FEV1 decline seen in the nonobese compared with the
obese could be a result of the fact that obese subjects had a lower
baseline FEV1, and that the process of decline may no longer be
progressive after the FEV1 had previously dropped to a consider-
able extent.
Obese subjects tend to report doctor-diagnosed asthma, as well
as asthmalike symptoms and use of bronchodilators, more
frequently than nonobese subjects, even if they do not have an
objective impairment of lung function.26 In view of our epidemi-
ologic definition of asthma, one could hypothesize that asthma
has been overdiagnosed in the obese subgroup. However, for sub-
jects with BMI <20, BMI 20 to 24.9, BMI 25 to 30, and BMI >30
kg/m2, the prevalences of family asthma were 15%, 26%, 29%,
and 35% (P 5 .11), respectively. Thus, this explanation seems
unconvincing.
BMI gain and FEV1 decline in subjects with asthma
without airflow obstruction at baseline
In subjects without airflow obstruction, we found that BMI gain
during the follow-up was associated with FEV1 decline, and this
FIG 1. Baseline FEV1 by categories of baseline BMI for men and womenwithout airflow obstruction at base-
line. Medians with Q1-Q3 are reported. The number of subjects in the BMI categories <20, 20-24.9, 25-30, and
>30 kg/m2 are 12, 134, 71, and 7 (men) and 51, 182, 52, and 35 (women), respectively.
TABLE II. Baseline lung function and lung function decline of the
subjects with asthma, stratified by the presence of airflow
obstruction at baseline
Airflow obstruction at baseline
No Yes P value
FEV1 % predicted (%) 102 (101-103) 78 (75-82) <.001
FVC % predicted (%) 107 (106-108) 106 (102-110) .97
FEV1 (L)* 3.6 (3.5-3.6) 2.7 (2.6-2.8) <.001
FVC (L)* 4.4 (4.4-4.5) 4.4 (4.3-4.5) .65
FEV1/FVC 0.82 0.63 —
FEV1 decline (mL/y)* 33 (28-37) 23 (14-32) .04
FVC decline (mL/y)* 22 (15-29) 26 (15-38) .43
%FEV1/FVC decline (%/y) 0.35 (0.29-0.41) 0.16 (0.03-0.29) .008
Data are provided as means (with 95% CIs). Statistically significant results (P < .05)
are in boldface.
*Adjusted for sex, age, and height.
Adjusted for sex and age.
TABLE III. Multiple regression coefficients* with 95% CIs for the
association between FEV1 decline and the covariates indicated in
subjects with asthma stratified by the presence of airflow
obstruction at baseline
Airflow obstruction at baseline
No (n 5 371)y Yes (n 5 76)y
Estimatek
(95% CI) (mL/y)
Estimatek
(95% CI) (mL/y)
Baseline covariates
BMI (kg/m2) 11.8 (5.4, 18.2) 24.6 (28.1, –1.2) 
BMI2 ([kg/m2]2) 20.2 (20.3, –0.09)  —
Low educational level 218.7 (230.8, –6.5)  20.2 (–15.2, 55.6)
Pack-years (1-U increase) 20.2 (–0.6, 0.3) 20.7 (–2.2, 0.8)
Exposure to ETS 5.9 (–4.4, 16.2) 229.3 (–62.2, 3.6)
Sensitization to any
allergen
24.0 (–13.1, 5.0) 229.2 (256.3, –2.1)
Duration of asthma (y) 20.3 (–0.7, 0.01) 20.4 (–1.5, 0.7)
Family asthma 20.8 (–9.1, 7.6) 221.4 (–47.8, 5.0)
Follow-up covariates
BMI gain(kg/[m2y]) 28.1 (15.1, 41.1) 27.4 (–51.4, 36.6)
Pack-years between
surveys (1-U increase)
20.2 (–1.3, 1.0) 3.7 (–0.6, 8.0)
Change in ETS
Worsened vs unchanged 23.9 (–20.4, 12.6) 26.2 (–23.5, 75.8)
Improved vs unchanged 26.8 (–17.9, 4.2) 13.7 (–22.6, 50.0)
Intercept§ 38.9 (27.2, 50.6) 77.1 (44.9, 109.3)
Statistically significant results (P < .05) are in boldface.
*Adjusted also for sex, age, height, and the interaction between total IgE and inhaled
steroid use.
Number of subjects with complete information.
P < .01.
§Quantitative variables were centered around their mean to calculate the intercepts;
the intercept represents the value of FEV1 decline when all categorical variables are
set to the reference category (eg, sex 5 male) and all the quantitative variables are set
to their mean.
kThe estimate for different variables represents the difference in the annual decline in
FEV1 between those with and those without these characteristics (eg, subjects without
airflow obstruction at baseline who gained 1 BMI unit per year of follow-up had an
additional decline in FEV1 of 28.1 mL/y compared with those who did not gain
weight).
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association was stronger in men than in women. In men, FEV1
dropped by 20 (95% CI, 10-30) mL/y for every kilogram gained
during the follow-up, whereas in women, FEV1 decreased by 6
(95%CI, 1-11)mL/y for every kilogram gained. Thismight be ex-
plained by the fact that men who gain weight tend to accumulate
abdominal and visceral fat, whereas womenwho gain weight tend
to accumulate peripheral fat.27 Chinn et al14 found that the FEV1
decline in the general population of the ECRHS was about 40%
lower than the decline we found in the subjects with asthma.
Therefore, one could speculate that the negative effect of weight
gain on lung function is greater in subjects with asthma than in
people from the general population.
The observed association between BMI gain and FEV1 decline
was independent of baseline BMI. This is also confirmedwhenwe
consider the group of subjects who were obese at baseline (n 5
42). Among them, 31 individuals gained weight during the fol-
low-up (median BMI gain [range], 0.5 [0.04, 3.0] kg/m2), and
11 individuals decreased their weight (median BMI gain [range],
–0.2 [–2.2, –0.05] kg/m2). FEV1 decline was faster in the obese
subjects who gained weight (median [Q1-Q3], 26 [–1, 47] mL/y)
than in the obese subjects who decreased their weight (median
[Q1-Q3], 5 [–38, 34] mL/y; P 5 .13).
Educational level and FEV1 decline in subjects with
asthma without airflow obstruction at baseline
In the population without asthma, a low socioeconomic level is
almost universally associated with worse health outcomes,
including lung function.28 In our data, subjects with asthma with-
out airflow obstruction who had a high educational level had a
faster FEV1 decline than those with a lower educational level.
However, the latter had a low FEV1 already at baseline (Table
E1). It is possible that a low educational level was associated
with an early drop of FEV1 and that, subsequently, the process
of FEV1 decline was no longer progressive.
Active smoking, passive smoking, and FEV1 decline
in subjects with or without airflow obstruction at
baseline
Many29-31 but not all32 studies have found that smokers with
asthma have a steeper decline in lung function than nonsmokers
with asthma. Several factors could explain the lack of an associ-
ation that was observed in our study. First, our subjects were rel-
atively young, and the detrimental effect of smoking could be
greater at older ages.30 Second, the exposure to active smoking
of our cohort was relatively low. In the Copenhagen City Heart
Study, about 70% of the subjects with asthma were smokers,29
and they had even Q6been exposed to smoking for more than 30
years on average.33 In our study, only 30% were current smokers,
and the exposure to active smoking tended to diminish signifi-
cantly during the follow-up.34 Finally, our finding could reflect
the healthy smoker effect.
Determinants of FEV1 decline in subjects with
asthma with airflow obstruction at baseline
Among subjects with airflow obstruction at baseline, thosewho
were not sensitized to allergens had on average 29 mL/y more
decline than those who were not. This is in line with the finding
that the rate of lung function decline is greater in subjects with
intrinsic asthma than in those with extrinsic asthma,32 and with
previous observations.7
A 1-U decrease in baseline BMI was associated with a 5 mL/y
decrease in FEV1 during the follow-up. In this group of subjects
with airflow obstruction at baseline, leanness itself may be a
marker of an early form of chronic obstructive pulmonary dis-
ease.35 No association was found between FEV1 decline and
BMIgain, probably becausemechanisms that are typical ofmilder
asthma (including the effect of weight gain) could be less impor-
tant in severe asthma,whereas a serious long-lasting inflammation
FIG 2. Plot of FEV1 decline vs baseline BMI, and of the curve representing the FEV1 decline predicted on the
basis of a linear regression on BMI and BMI squared, in men and women without airflow obstruction at
baseline.
FIG 3. Mean FEV1 decline (adjusted for all the covariates considered in the
multivariate analysis) by categories of BMI gain (according to tertiles) for
men and women without airflow obstruction at baseline. P value for trend:
P <.001 (men) and P 5.001 (women).
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may play a crucial role. Moreover, subjects with airflow obstruc-
tion gained on average less weight than those without.
Conclusion
In European subjects with asthma without airflow obstruction
at baseline, individuals with a high BMI had the lowest FEV1 at
baseline. Weight gain was positively associated with FEV1 de-
cline, independently of baseline BMI, and this association was
stronger in men than in women. The detrimental effect of BMI
gain on lung function might be greater for subjects with asthma
than for subjects without asthma, but studies are needed to clarify
this. Among subjects with asthma with airflow obstruction at
baseline, lean subjects without sensitization to allergens had the
greatest FEV1 decline, whereas weight gain was not associated
with FEV1 decline.
We thank the ECRHS Coordinating Center (London), the Project Manage-
ment Group, and the Study Group for their assistance (for a list of principal
participants in ECRHS, see this article’s Online Repository at www.
jacionline.org).
Clinical implications: Weight management or weight loss
should be encouraged in patients with asthma. Asthma in the
obese may be different from asthma in the nonobese, possibly
because respiratory mechanical factors have a crucial role in
the obese.
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